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Mg2+ homeostasis
Magnesium (Mg2+) is the second most abundant intracellular cation and the fourth 
most abundant cation in the body. Approximately 50% of the total body Mg2+ is 
mineralized in bone, whereas almost the other half is localized intracellularly and 
only 1% of the total body Mg2+ is present extracellularly (1). Of the intracellular 
Mg2+, merely up to 10% exists as the metabolically active ionized form which plays 
an essential role as a co-factor in many biochemical and physiological processes 
such as activation of ATPases, regulation of many plasma membrane ion channel 
activities, and translational processes (2-4). In serum, 60% of the Mg2+ exists as the 
physiologically active ionized form, 30% is protein bound, mainly to albumin (5), and 
the remaining 10% forms complexes with serum anions such as phosphates and 
citrates (6). Disturbances of serum Mg2+ levels can result in serious symptoms such 
as seizures and coma (1, 7). Therefore, an adequate homeostasis of Mg2+ resulting 
in tightly regulated serum Mg2+ levels, within a narrow range of 0.7 to 1.1 mM, is 
essential (8). The extracellular Mg2+ concentration is controlled by the concerted 
action of renal Mg2+ reabsorption, intestinal absorption, and exchange of Mg2+ 
from bone.
Hypomagnesemia
Hypomagnesemia (serum Mg2+ < 0.7 mM),  is a common phenomenon occurring 
up to 15% in the general population (9), 12% in hospitalized patients (10) and as 
high as 65% in intensive care patients (11-13). This is of special interest in view of 
the association between hypomagnesemia and common chronic diseases such as 
diabetes mellitus type II, hypertension, coronary heart disease and asthma 
bronchiale (14-18). Importantly, aggravation of these disorders is observed with 
further Mg2+ depletion. Mg2+ deficiency has an effect on multiple body functions. 
Symptoms of Mg2+ deficiency are mostly related to muscle dysfunctioning, such as 
muscle weakness, tetany, prolonged QT interval and cardiac arrhythmias. Failure of 
early diagnosis or noncompliance with treatment can be fatal or result in permanent 
neurological damage. A long-term complication seen in many adult patients with 
chronic hypomagnesemia is chondrocalcinosis, which can lead to impairment of 
joint function (19). At present hypomagnesemia is treated with oral Mg2+ supplements 
(20). However, normalization of serum Mg2+ in patients with chronic hypomagnesemia 
is difficult to achieve because high doses of Mg2+ cause severe diarrhea. In general, 
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filtration rate of 125 ml/min, approximately 140 mmol/d Mg2+ is filtered, of which the 
majority is subsequently reabsorbed along the nephron (4, 28). Approximately 20% 
of Mg2+ is reabsorbed by the proximal tubule (PCT). However, the bulk amount of 
Mg2+ (70%) is reabsorbed by the thick ascending limb of Henle (TAL), which 
mediates Mg2+ reabsorption via passive paracellular transport. The distal convoluted 
tubule (DCT) actively reabsorbs 5 to 10% of the filtered Mg2+ and the reabsorption 
rate in this segment defines the final urinary Mg2+ concentration, as no reabsorption 
takes place beyond this segment (4). Finally, 3 to 5% of the filtered Mg2+ is excreted 
in the urine. In the presence of hypermagnesemia the fractional excretion of Mg2+ 
can raise to nearly 100%. In contrast, in the occurrence of hypomagnesemia or 
reduced Mg2+ intake, the kidney minimizes urinary losses by increased reabsorption 
and can lower the fractional excretion to less than 1% (1, 29).
reduced dietary intake, intestinal malabsorption or renal Mg2+ loss can result in 
secondary or primary hypomagnesemia. This can be the result of for instance the 
use of osmotic agents, diuretics, alcohol, and drugs such as foscarnet and cisplatin 
(1). Furthermore, primary and secondary Mg2+ deficiency is observed in several 
monogenic disorders, which will be discussed in more detail further on. 
Hypermagnesemia
Compared to hypomagnesemia, hypermagnesemia (serum Mg2+ > 1.1 mM) is rare, 
but frequently fatal. Symptoms of hypermagnesemia include lethargy, nausea, loss 
of deep tendon reflexes, paralysis and coma (1). The most common cause of 
hypermagnesemia is impaired renal excretion of Mg2+ which can be caused by 
progressive renal insufficiency, lithium therapy or hypocalciuric hypercalcemia (1). 
Dialysis is a rapid way to lower Mg2+ levels in patients with renal insufficiency.
Intestinal Mg2+ absorption 
Normal dietary intake of Mg2+ is 300 to 360 mg/d (12.5-15 mmol/d) of which 40-50% 
is absorbed. Dietary Mg2+ intake is the only source by which the body can replete 
Mg2+ stores and a Mg2+ intake of approximately 4.0 mg/kg/d is necessary to 
maintain body Mg2+ homeostasis (21, 22). The net intestinal Mg2+ absorption is 
dependent on the fractional Mg2+ absorption within a specific segment of the 
intestine, the length of that specific segment and the transit time of the food bolus. 
Considering these parameters, the ileum and colon absorb most of the ingested 
Mg2+ (23, 24). In the intestine Mg2+ is reabsorbed via an unsaturable passive 
paracellular pathway which is dependent on the electrochemical gradient and a 
saturable active transcellular pathway (24, 25). The total intestinal Mg2+ absorption 
can be described by a curvilinear function which is proposed to be the sum of 
passive and transcellular transport mechanisms. The paracellular passive transport 
mechanism linearly rises with elevated luminal Mg2+ concentrations whereas the 
active transcellular transport mechanism  saturates at high luminal Mg2+ concentrations 
and is of functional importance at low luminal Mg2+  concentrations (24, 25). 
Renal Mg2+ reabsorption
The principal organ responsible for the regulation of the body Mg2+ balance is the 
kidney, which tightly matches the intestinal absorption of Mg2+ (figure 1). About 
80% of the total plasma Mg2+ is filtered in the glomeruli (26, 27). With a glomerular 
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Figure 1. Mg2+ reabsorption along the nephron 
The percentages of the filtered Mg2+ that are being reabsorbed by the various nephron 
segments and the final urinary excretion of Mg2+ is indicated. PCT, proximal  convoluted 
tubule; TAL, thick ascending limb of Henle’s loop; DCT, distal convoluted tubule; CNT, 
 connecting tubule; CCD, cortical collecting duct.
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Paracellular Mg2+ transport
Passive paracellular Mg2+ reabsorption takes place in PCT and TAL. In PCT 
approximately 20% of the filtered Mg2+ is reabsorbed. Although Mg2+ reabsorption 
in this segment is not well understood it appears to be paracellular and dependent 
on the filtered load, and net salt and water reabsorption (30). The major site of 
paracellular Mg2+ transport is the TAL, where Mg2+ transport is driven by a 
favorable lumen-positive electrochemical gradient, which is generated by the 
transcellular reabsorption of NaCl. Transcellular NaCl reabsorption is dependent on 
the concerted activity of Na+, K+, 2Cl- cotransporter 2 (NKCC2), renal outer 
medullary K+ channel (ROMK), Na+,K+-ATPase and the renal Cl- channel CLC-Kb 
(figure 2A) (31). The lumen-positive electrochemical gradient allows Mg2+ to be 
transported into the blood compartment via the tight junction proteins claudin-16 
and -19 (figure 2A) (32, 33). Furthermore, plasma Mg2+ and Ca2+ levels are 
monitored by the Ca2+ sensing receptor (CaSR) which can also influence Mg2+ 
reabsorption in TAL (figure 2A) (34).
Transcellular Mg2+ transport
Hypothetically, the process of transcellular Mg2+ transport in kidney and intestine is 
envisaged by the following sequential steps (figure 2B). Driven by a favorable 
transmembrane potential, Mg2+ enters the epithelial cell through the apical epithelial 
Mg2+ channel transient receptor potential subfamily M, member 6 (TRPM6). Next, 
Mg2+ will diffuse through the cytosol to be extruded actively against an 
electrochemical negative gradient across the basolateral membrane (35). The key 
molecules that represent the cytosolic Mg2+-binding proteins (if present) and the 
basolateral Mg2+ extrusion mechanism in the process of transcellular Mg2+ 
transport are still elusive. Until now, specific Mg2+-binding proteins have not been 
identified, but it is interesting to mention that the Ca2+-binding proteins parvalbumin 
and calbindins, which are present in DCT, also bind Mg2+ (35, 36). For the 
basolateral Mg2+ extrusion mechanism most physiological studies favor a 
Na+-dependent exchange mechanism (3). Other candidate mechanisms include an 
ATP-dependent Mg2+ pump. Importantly, Mg2+ entry into the cells appears to be 
the rate-limiting step and the site of regulation. In kidney, the function of DCT in 
active ion transport is underlined by the fact that cells of this nephron segment have 
the highest energy consumption of the nephron (37). In addition to the proteins 
mentioned, the functioning of the Na+, Cl- cotransporter (NCC), which is exclusively 
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Figure 2. Paracellular and transcellular Mg2+ reabsorption in kidney
 
(A) Mg2+ reabsorption in TAL is driven by a favorable electrochemical gradient generated 
by the transcellular reabsorption of NaCl. Mg2+ is transported down this gradient through 
the tight-junction proteins claudin-16 and claudin-19 to the blood compartment. (B) Active 
Mg2+ reabsorption is presumably carried out as a 3-step-process in DCT. Following entry 
of Mg2+ in DCT through the epithelial Mg2+ channel, TRPM6, Mg2+ diffuses possibly bound 
by cytosolic proteins to the basolateral membrane. As the extrusion mechanisms, a 
 basolateral Na+/Mg2+ exchanger and/or ATP-dependent Mg2+ pump are postulated.  
The Na+,K+-ATPase complex including its g-subunit control this transepithelial Mg2+  
transport. In this way, net Mg2+ reabsorption from the luminal space to the extracellular 
compartment takes place. See text for details and abbreviations.
16 17
of this superfamily, TRPM6 and TRPM7 have been identified as key regulators of 
total body and cellular Mg2+ homeostasis, respectively. TRPM6 and TRPM7 are 
unique bifunctional proteins combining Mg2+-permeable cation channel properties 
with protein kinase activity (51, 54) and are therefore referred to as chanzymes (55). 
TRPM6
Investigations of families suffering from autosomal-recessive hypomagnesemia 
with secondary hypocalcemia (HSH), which will be described in the following 
paragraphs, identified mutations in TRPM6 (20, 56). Through these and other 
studies, TRPM6 was discovered as an essential molecular determinant in transcellular 
Mg2+ transport in renal and intestinal epithelia (20, 35, 56). TRPM6 is one of the 
eight members of the identified TRPM cation channel subfamily and is composed 
of 2022 amino acids encoded by a large gene that contains 39 exons (20, 51, 56). 
The TRPM6 protein shows 52% homology with its closest homologue TRPM7. 
TRPM6 displays a restricted expression pattern and is predominantly present in (re)
absorbing epithelia (20, 35, 56). Interestingly, three short alternative 5' exons, called 
present in DCT, the CaSR and CLC-Kb are also important for active Mg2+ 
reabsorption in DCT (34, 38-40) (figure 2B). The role of NCC, CLC-Kb and CaSR in 
Mg2+ homeostasis will be discussed in more detail in the following paragraphs.  
Hormonal regulation of Mg2+ reabsorption
Several hormones including, parathyroid hormone (PTH), calcitonin, 1,25-dihydroxy-
vitamin-D3 (1,25(OH)2D3), insulin, glucagon, vasopressin, aldosterone, and sex 
steroids (estrogens)  have been reported to influence Mg2+ transport in vitro (41-43). 
Moreover, it was demonstrated that Mg2+ transport in DCT is influenced by dietary 
Mg2+ restriction and various hormones and that PTH in vivo stimulates Mg2+ 
reabsorption in TAL and DCT (44-46). In addition, it was shown that Mg2+ transport 
in rat colon was not responsive to 1,25(OH)2D3 (47, 48). In spite of  the reports 
described above, hormonal regulation of active transcellular Mg2+ transport 
remains largely unknown (4, 30, 45, 49). Moreover, It has been suggested that the 
hormones influencing the Mg2+ balance are only indirect regulators of Mg2+ 
homeostasis, because Mg2+ lacks a specific endocrine control similar to what 
exists for Ca2+, Na+, and K+ (42). Thus far, there is no evidence of specific 
physiological hormonal control of Mg2+ (re)absorption. Apical Mg2+ influx is the 
initial step of transcellular Mg2+ transport. Therefore, this step is an ideal target for 
hormonal regulation of active Mg2+ (re)absorption. The following paragraphs will 
highlight the distinctive features and the physiologic relevance of the proteins that 
represent the gatekeepers of epithelial Mg2+ transport. 
The gatekeepers of epithelial Mg2+ transport 
The transient receptor potential (TRP) superfamily consists of many cation channels 
of which most permeate both monovalent and divalent cations. Thus far, 28 
mammalian TRP channels have been identified, which can be subdivided into six 
main subfamilies: the TRPC (canonical), TRPV (vanilloid), TRPM (melastatin), TRPP 
(polycystin), TRPML (mucolipin), and the TRPA (ankyrin) groups (50). TRP channels 
are expressed in almost every tissue and cell type, and play an important role in the 
regulation of various cell functions. Each of the proteins is a cation channel 
composed of six transmembrane-spanning domains and a conserved pore-forming 
region that assemble in a tetrameric configuration (figure 3) (51-53). Two members 
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Figure 3. The predicted structural organization of TRPM6 and TRPM7
 
(A) TRPM6 and TRPM7 belong to the largest TRP channels consisting of around 2000 
amino acids including very large cytosolic amino- and carboxyl-termini, and an atypical 
α-kinase domain. The gate and selectivity filter are formed by the four 2 transmembrane 
domains (TM5-pore loop-TM6) facing the centre of the channel. Cations are selected for 
permeation by the extracellularly facing pore loop, held in place by the TM5 and TM6 
α-helices. (B) Top view of a schematic representation of the tetrameric organization of the 
TRPM6/7 pore. The pore-forming regions of four TRPM6/7 monomers join to constitute a 
single pore. The individual transmembrane domains are indicated by numbers 1 to 6. 
A B
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but significant inward currents were observed in TRPM6-expressing HEK293 cells 
with all tested divalent cations as the sole charge carrier (35). However, mutations 
in TRPM6 are linked directly to HSH, emphasizing that this channel is an essential 
component of the epithelial Mg2+ uptake machinery. Interestingly, HEK293 cells 
transfected with the TRPM6 mutants identified in HSH patients (TRPM6-Ser590X 
and TRPM6-Arg736fsX737) displayed currents with similar amplitude and activation 
kinetics as nontransfected HEK293 cells, indicating that these mutant proteins are 
nonfunctional. This is in line with the postulated function of TRPM6 being the Mg2+ 
influx step in epithelial Mg2+ transport (35). The unique permeation rank order 
determined from the inward current amplitude at -80 mV was comparable to TRPM7 
(Ba2+ ≥ Ni2+ > Mg2+ > Ca2+) (35, 54). Micropuncture studies have demonstrated 
that the luminal concentration of Mg2+ in DCT ranges from 0.2 to 0.7 mM (4). 
Because the luminal Ca2+ concentration is also in the millimolar range, the apical 
Mg2+ influx pathway should exhibit a higher affinity for Mg2+ than for Ca2+. It is 
interesting that dose-response curves for the Na+ current block at -80 mV indicated 
a four times higher partition coefficient value for Ca2+ compared with Mg2+ (35). 
These data suggest that the pore of TRPM6 has a higher affinity for Mg2+ than for 
Ca2+. In this way, TRPM6 comprises a unique channel because all known 
Ca2+-permeable channels, including members of the TRP superfamily, generally 
display a 10 to 1000 times lower affinity for Mg2+ than for Ca2+ (35).
TRPM6 regulation
Chronic metabolic acidosis results in renal Mg2+ wasting, whereas chronic metabolic 
alkalosis is known to exert the reverse effect. It was hypothesized that these adaptations 
are mediated, at least in part, by the renal Mg2+ transport protein TRPM6. It was 
demonstrated that chronic metabolic acidosis decreased renal TRPM6 expression, 
increased Mg2+ excretion, and decreased serum Mg2+ concentration, whereas chronic 
metabolic alkalosis resulted in the exact opposite effects (67). Thus, these data suggest 
that regulation of TRPM6 significantly contributes to the effect of the acid-base status 
on renal Mg2+ handling. Interestingly, extracellular protons enhance TRPM6 and 
TRPM7 inward currents by decreasing the divalent affinity to the channels (68, 69). 
Recently, the amino acids determining the pH sensitivity of TRPM6 and TRPM7 have 
been identified (70). Moreover, it was shown that TRPM7, in response to the extracellular 
pH, may contribute to the regulation of neurotransmitter release (71). The sensitivity of 
TRPM6 and TRPM7 to pH represents a novel feature and implies that both channels 
1A, 1B, and 1C, were identified, suggesting that the TRPM6 gene harbors a 
promoter with alternative transcription start sites. The resulting transcripts have 
been named accordingly TRPM6a, TRPM6b, and TRPM6c. Functional measurements 
are needed to characterize these splice variants (57). In kidney, TRPM6 is localized 
along the apical membrane of DCT, known as the main site of active transcellular 
Mg2+ reabsorption along the nephron (35). This localization is in line with the 
expected function of being the gatekeeper of Mg2+ influx. In the small intestine, 
TRPM6 is detected along the brush-border membrane of the absorptive epithelial 
cells (20, 35). The renal and intestinal expression of TRPM6, in addition to the renal 
Mg2+ leak in patients with HSH, emphasizes the important role of TRPM6 in renal 
and intestinal Mg2+ (re)absorption. Moreover, the role of TRPM6 in total body Mg2+ 
homeostasis is underlined by the fact that TRPM6 and TRPM7 are not functionally 
redundant in humans, since the ubiquitously expressed TRPM7 can not rescue the 
severe phenotype of HSH patients (58). 
TRPM7
Prior to the discovery of TRPM6, the Mg2+ channel TRPM7 was cloned from mouse 
brain cDNA (54). TRPM7 is ubiquitously expressed and is essential for cell growth 
and viability rather than for total body Mg2+ balance (58-60). The ubiquitous 
expression of TRPM7 supports its role in cellular viability and cellular Mg2+ 
homeostasis. It was demonstrated that Mg2+ supplementation of cells that lack 
TRPM7 expression rescued growth arrest and cell lethality that was caused by 
TRPM7 inactivation (60). Although TRPM7 is permeable for Ca2+, as well as trace 
divalents such as Zn2+, Ni2+, Ba2+, and Co2+, supplementation with these cations 
was ineffective, indicating the specific effect of Mg2+ on these cellular processes. 
TRPM7 has also been implicated to play a role in anoxic neuronal death (59, 61, 62), 
cell adhesion and actomyosin contractility (63, 64), and bone generation (65). In 
addition, a TRPM7 gene variant has been implicated in the neurodegenerative 
disorder amyotrophic lateral sclerosis-parkinsonism/dementia complex of Guam (66).
Mg2+ permeability of TRPM6 
Electrophysiological characterization of TRPM6 demonstrated that TRPM6-
transfected HEK293 cells exhibited outwardly rectifying currents upon establishment 
of the whole-cell configuration as demonstrated for TRPM7 (35, 54, 59). It is 
intriguing that at physiologic membrane potentials of the DCT cell (-80 mV), small 
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The α-kinase domain
Unlike other members of the TRP channel family, TRPM6 and TRPM7 contain long 
carboxy-terminal domains including an active threonine/serine kinase, which 
belongs to the atypical family of eukaryotic α-kinases (54). Genomic studies 
identified six α-kinases in mammals, including the ones fused to TRPM6 and 
TRPM7. The α-kinases share no sequence homology with the conventional kinases 
(77). A key question concerns the nature of the mechanisms underlying the 
activation and regulation of TRPM6 and TRPM7. In particular, what is the function of 
the atypical protein α-kinase domain located in the carboxyl terminus? 
The TRPM7 kinase is able to undergo autophosphorylation and to phosphorylate 
substrates such as myelin basic protein and histone H3 on serine and threonine 
residues (78). The kinase is specific for ATP and Mg2+ or Mn2+ is required for 
optimal activity. It was demonstrated that TRPM6 can phosphorylate TRPM7, but 
not vice versa (58). Recently, annexin 1 and myosin II A have been identified as 
endogenous substrates of the TRPM7 kinase (63, 79). Although, the biological role 
of annexin 1 phosphorylation via TRPM7 is currently unknown, both proteins have 
been linked to processes of cell survival and growth (62, 80). Future studies should 
elucidate whether the kinase domains of TRPM6 and TRPM7 have specific cellular 
phosphorylation targets that modulate ion channel activity and, therefore, the Mg2+ 
balance. It has been suggested that TRPM7 could potentially serve both as a Mg2+ 
uptake mechanism and a Mg2+ sensor when the ion channel domain could 
modulate the phosphotransferase activity by increasing intracellular Mg2+ or 
directly via conformational changes induced by gating of the channel (81). This 
modification could result in the phosphorylation of yet unidentified substrates 
providing real time information on channel activity or cellular Mg2+ status. While 
there is general consensus that TRPM6 and TRPM7 are inhibited by free intracellular 
Mg2+, the functional role of intracellular levels of Mg2+·ATP and the kinase domain 
in regulating channel activity remain controversial. Several groups suggested that 
the kinase domain is essential for channel activity (54, 82), whereas others indicated 
that it is not involved (60, 83). Furthermore, the phosphotransferase activity of the 
TRPM7 kinase domain affected channel activity by regulating the sensitivity of the 
channel to inhibition by Mg2+ and Mg2+·ATP (60, 84, 85), but this finding was not 
generally confirmed (74, 82). Further experiments are needed to elucidate these 
inconsistent results and firmly establish the functional role of the kinase domain and 
intracellular levels of Mg2+·ATP in regulating TRPM6 and TRPM7 channel activity.
may play a role under acidic pathological conditions (68). In addition to the external pH, 
TRPM6 and TRPM7 are also regulated by intracellular Mg2+ levels. It was demonstrated 
that elevation of the intracellular Mg2+ concentration reduced the TRPM6-induced 
current, indicating that the channel is regulated by intracellular Mg2+ or Mg2+ bound to 
ATP (Mg2+·ATP) (35). These processes are called the Mg2+-inhibited cation current 
(MIC) or Mg2+ nucleotide-regulated metal ion current (MagNuM), respectively (59, 72). 
Previous studies reported that TRPM7 channel activity is strongly suppressed by 
Mg2+·ATP concentrations in the millimolar range (59, 73). Moreover, it was shown that 
intracellular Mg2+ rather than ATP inhibits TRPM7 channel activity (74). In addition to 
Mg2+ inhibition, TRPM7 is also inactivated by hydrolysis of the phosphoinositide lipid 
PIP2 (75). Interestingly, TRPM7 was discovered on the basis of binding to phospholipase 
C (PLC), which cleaves PIP2 (54). This raises the question whether there is a link 
between the two apparently dissimilar modes of channel inhibition: an increase in Mg2+ 
and hydrolysis of PIP2. It was postulated that Mg2+ could possibly activate PLC that 
associates with TRPM7 (55). This possibility is strengthened by a study in B lymphocytes 
that demonstrated the presence of phosphoinositide-specific PLC which is activated 
when the Mg2+ concentration is raised from 30 to 1000 µM (76). The role of PIP2 and 
PLC in the regulation of TRPM6 channel activity needs to be established.
TRPM6 and TRPM7 assembly
It was postulated that TRPM6 requires assembly with TRPM7 to form functional 
channel complexes in the plasma membrane and that disruption of multimer 
formation by a mutated TRPM6 variant, TRPM6-S141L, results in HSH (57). It was 
shown that, TRPM6-S141L was not directed to the cell surface by TRPM7 and failed 
to interact with the co-expressed TRPM7. Remarkably, in contrast to TRPM7, 
Gudermann and co-workers found that TRPM6 expression in Xenopus laevis 
oocytes and HEK293 cells did not entail significant ion currents (57). In addition, 
Schmitz et al. also supported the idea that TRPM6 and TRPM7 associate and that 
trafficking of TRPM6 to the cell surface is strongly dependent on TRPM7 
co-expression (58). In variance, Voets et al. measured significantly larger currents in 
TRPM6-transfected HEK293 cells compared to mock-transfected cells (35). 
Accordingly, Li and colleagues indicated that TRPM6, TRPM7 and TRPM6/TRPM7 
channels represent three different channels with unique functional characteristics 
(69). A plausible explanation for these discrepant findings is still elusive. 
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in misrouting of this protein (90). Although the Na+,K+-ATPase g-subunit is critical for 
active transcellular Mg2+ reabsorption in DCT, the molecular mechanism for renal 
Mg2+ loss in this autosomal dominant type of primary hypomagnesemia remains to 
be elucidated (90). Interestingly, individuals with an 11q23.3 deletion, including 
FXYD2, showed normal serum Mg2+ levels (90). Furthermore, ablation of the FXYD2 
gene in mice did not result in significantly lowered serum Mg2+ levels compared to 
wild-type littermates (94). Based on the fact that haploinsufficiency in humans and 
loss of Na+,K+-ATPase g-subunit expression in mouse are not determining factors in 
the development of IDHH, it is assumed that the G41R mutation has a dominant 
negative effect resulting in this disease.  
Isolated dominant hypomagnesemia (IDH)
Kantorovich et al. described another family with an autosomal dominant form of 
primary hypomagnesemia with an almost similar phenotype as patients with the 
mutation in FXYD2 (87). Patients displayed hypomagnesemia, lowered serum 
immunoreactive PTH levels and lowered bone mineral density at the lumbar spine 
and proximal femur. Although a trend was observed of decreased 24 hour urinary 
Ca2+ excretion in the affected individuals, no difference was detected when the 
urinary Ca2+ excretion was expressed as mg/100ml/GFR/1.73m2. Serum Ca2+, 
25-hydroxyvitamin D and 1,25(OH)2D3 were normal. The serum and urine values for 
Cl-, HCO3-, K+ and amino acids were all within the normal range. Although the 
phenotype is very similar to IDHH caused by a mutation in FXYD2, no linkage was 
found to the 11q23 locus where FXYD2 is situated indicating that another unknown 
autosomal gene causes this disease (87). However, inheritance via the mitochondrial 
genome can not be excluded in this family with IDH.  
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC)
Patients with FHHNC suffer from severe hypomagnesemia due to profound renal 
Mg2+ wasting, which cannot be corrected by oral or intravenous Mg2+ 
supplementation (32). In addition, patients with FHHNC display renal failure and 
renal Ca2+ wasting resulting in parenchymal calcification. Other symptoms include 
urinary tract infections, kidney stones, hyperuricemia and ocular findings. Renal salt 
wasting is not observed in these patients. A positional cloning strategy identified the 
gene CLDN16 (or PCLN-1) encoding the protein claudin-16 (or paracellin-1) that was 
found to be mutated in these patients. The tight junction protein claudin-16, related 
Inherited disorders with primary hypomagnesemia
The investigation of families with primary hereditary hypomagnesemia has greatly 
facilitated the identification of genes and proteins directly involved in renal Mg2+ 
handling. Our knowledge concerning the epithelial Mg2+ transport pathways has 
evolved from physiological studies concerning these diseases described below. In 
humans, several inherited renal tubular disorders are known in which disturbances 
of serum Mg2+ levels are a primary or a secondary phenomenon (table 1 and 2). 
So far, seven disorders have been described in which hypomagnesemia is a 
primary defect. Two disorders are inherited in the autosomal dominant form, four in 
an autosomal recessive form and one is maternally inherited via mitochondrial DNA 
(table 1). The gene defects of isolated recessive renal hypomagnesemia (IRH) and 
isolated dominant hypomagnesemia (IDH) remain to be identified (table 1) (86, 87). 
Isolated recessive renal hypomagnesemia (IRH)
In the literature a single family has been described thus far, which displays IRH (86). 
IRH is characterized by hypomagnesemia due to renal Mg2+ wasting, convulsions 
in the first year of live, psychomotor retardation during childhood and moderate 
mental retardation. Interestingly, in all disorders known with primary hypomagnesemia, 
a mutual disturbance of the Mg2+ and Ca2+ balance is observed (table 2). 
However, IRH distinguishes itself by the fact that despite a disturbed Mg2+ balance, 
the Ca2+ urinary excretion and Ca2+ serum levels are unaffected. In addition, no 
abnormalities were observed for serum levels of Na+, K+, Cl-, HCO3-, PTH, 
calcitonin, renin activity, aldosterone and blood pH. The genetic analysis of this 
family with IRH is discussed in chapter 5 of this thesis.
Isolated dominant hypomagnesemia associated with hypocalciuria (IDHH)
IDHH has been described in two Dutch families with a common ancestor (88, 89). 
The gene FXYD2, encoding the g-subunit of the Na+,K+-ATPase pump, is mutated in 
patients with IDHH, which display hypomagnesemia and lowered renal excretion of 
Ca2+. The Na+,K+-ATPase g-subunit is predominantly expressed in the kidney and 
shows the highest expression levels in DCT and medullary TAL (90). The g-subunit is 
a small (7 kDa) type I membrane protein, which specifically modulates the activity of 
Na+,K+-ATPase (91-93). The identified glycine to arginine mutation at position 41 
(G41R), is located in the single transmembrane domain of the g-subunit and results 
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because passive Mg2+ absorption is not affected (102). When untreated, the disease 
may be fatal or could lead to severe neurological damage. The observed hypocalcemia 
in HSH is a secondary effect possibly caused by parathyroid failure resulting from 
Mg2+ deficiency (103). Using a positional candidate gene-cloning approach, 
mutations in the TRPM6 gene were found to be the cause of autosomal recessive 
HSH (20, 56, 104). This discovery identified TRPM6 as the molecular identity 
facilitating Mg2+ entry in transepithelial Mg2+ (re)absorption. The functional and 
physiological characteristics of TRPM6 have been highlighted in the paragraphs 
described previously. 
Inherited disorders with secondary hypo and 
hypermagnesemia
Several inherited renal tubular disorders are known in which the disturbed serum 
Mg2+ balance is likely a secondary phenomenon (table 1 and 2). These monogenic 
disorders do not directly involve Mg2+ transporting proteins and include the 
Bartter-like syndromes and the Ca2+/Mg2+-sensing receptor (CaSR) disorders. 
Bartter-like syndromes 
The Bartter-like syndromes (comprised of Gitelman syndrome, Bartter syndrome 
type I, II, III, and IV) are all characterized by renal salt wasting, hypokalemic 
metabolic alkalosis, elevated serum renin and aldosterone levels with normal blood 
pressure (114). Although, the underlying gene defects of the CaSR disorders and 
Bartter-like syndromes have been elucidated, the exact cause of the observed 
hypomagnesemia remains to be explained.
Bartter syndrome type I and II: antenatal Bartter syndrome  (aBS) 
aBS manifests in utero and is characterized by severe polyuria and polyhydramnios 
resulting in premature birth in most cases. Postnatally, affected individuals develop 
salt wasting, hypokalemic metabolic alkalosis, hypercalciuria, and nephrocalcinosis 
and only in exceptional cases hypomagnesemia (115). aBS is caused by mutations 
in either the SLC12A1 gene encoding the the furosemide-sensitive Na+,K+,2Cl- 
co-transporter NKCC2 (Bartter type I) (105) or KCNJ1 encoding the K+ channel 
ROMK (Bartter type II) (106, 107). The hypokalemia in the ROMK patients is less 
to the claudin family of tight junction proteins, is specifically expressed in TAL and 
is important for paracellular Mg2+ and Ca2+ reabsorption in this segment (32). 
Moreover, mutations in a second member of the claudin family, CLDN19 encoding 
claudin-19 have been identified. Patients with a CLDN19 mutation show an identical 
phenotype compared to patients affected with CLDN16 mutations, but display an 
additional severe ocular aberration (33). 
Hypomagnesemia, hypertension and hypercholesterolemia, mitochondrial (HHHM)
In a large kindred with patients displaying HHHM, were shown to carry a mutation 
in the mitochondrial tRNAile gene (MTTI) (95). The patients displayed a fractional 
excretion of Mg2+ above 2%, which is inappropriately high in the presence of 
hypomagnesemia, indicating renal Mg2+ wasting (7). Furthermore, the affected 
individuals demonstrated a reduced urinary Ca2+ excretion (95). Electron microscopy 
of a skeletal muscle biopsy from a patient and in vivo nuclear magnetic resonance 
spectroscopy of the same skeletal muscle revealed morphological signs of 
mitochondrial dysfunction and reduced adenosine tri-phosphate production, 
respectively. It was hypothesized that the renal Mg2+ wasting resulting in 
hypomagnesemia is caused by mitochondrial dysfunctioning in DCT cells. As 
described before, DCT cells have the highest energy consumption of the nephron 
(37) and active transcellular Mg2+ transport in DCT requires ATP-dependent Na+ 
reabsorption (38). Consequently, the impaired basolateral extrusion of Mg2+ into the 
blood might result in renal Mg2+ wasting. 
Hypomagnesemia with secondary hypocalcemia (HSH) 
HSH is an autosomal recessive disease of which the gene locus was mapped on 
chromosome 9q22 (96). Affected individuals showed neurological symptoms of 
hypomagnesemic hypocalcemia, including seizures and muscle spasms during 
infancy (20, 56, 97). Although in HSH the defect was originally established at the level 
of the intestine and physiological studies indicated that its pathophysiology is 
principally caused by a primary defect in intestinal Mg2+ transport, there is also 
evidence for impaired Mg2+ reabsorption (20, 98-101). Although most patients 
displayed normal renal Mg2+ conservation, for some patients inappropriately high 
fractional Mg2+ excretion rates with respect to their low serum Mg2+ levels were 
observed (20, 98). This indicates an additional role of impaired renal Mg2+ 
reabsorption in HSH (56, 98, 99). HSH can be treated by high dietary Mg2+ intake 
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renal Cl- channels CLC-Ka and CLC-Kb (110, 111, 122). Barttin is expressed in the 
TAL, thin ascending limb of Henle’s loop and in the stria vascularis of the inner ear 
(111). In contrast to cBS, where mutations in CLC-Kb result in hypomagnesemia in 
approximately 50% of the patients, hypomagnesemia in patients with type IV aBS 
with sensorineural deafness is uncommon.
Gitelman variant of Bartter syndrome (GS)
GS forms the mild form of the salt-wasting renal disorders since GS patients have a 
higher urine concentrating ability than patients with aBS, aBS with sensorineural 
deafness or cBS, resulting in less water and salt loss. GS usually manifests during 
childhood or adolescence. Patients with GS display hypokalemia, metabolic 
alkalosis, hypomagnesemia and hypocalciuria. Furthermore, they show muscle 
weakness or tetanic episodes that are related to profound hypomagnesemia. GS is 
caused by mutations in SLC12A3, which encodes the thiazide-sensitive Na+,Cl- 
cotransporter NCC. NCC is expressed exclusively at the apical membrane of the 
DCT (38). Ablation of SLC12A3 in mice resulted in a phenotype that closely 
resembles GS including hypomagnesemia and hypocalciuria. However, hypokalemia 
was not detected indicating that the hypomagnesemia observed is not secondary 
to this characteristic in GS (39). Chronic thiazide treatment, which is a model for GS, 
does not always result in Mg2+ wasting and hypomagnesemia. Loffing and 
colleagues showed that chronic thiazide treatment in rats, which enhances renal 
Na+ excretion, resulted in an increased rate of apoptosis in DCT cells (40). This is 
in line with the observation that the number and height of DCT cells is decreased in 
NCC knockout mice (39). It could be hypothesized that a reduction in reabsorptive 
surface area results in diminished Mg2+ reabsorption leading to Mg2+ wasting. In 
addition, in SLC12A3 knockout mice, an animal model of GS, and during chronic 
hydrochlorothiazide administration, the hypomagnesemia is accompanied by 
decreased expression levels of TRPM6 (123). Thus, TRPM6 downregulation may 
represent a general mechanism involved in the pathogenesis of hypomagnesemia 
accompanying NCC inhibition or inactivation. 
CaSR disorders 
The CaSR is a large glycoprotein belonging to the superfamily of G protein-coupled 
receptors (124). In kidney, the CaSR is expressed in various nephron segments 
including the proximal convoluted and straight tubule (125), the TAL, DCT and in 
severe compared with the NKCC2 patients (105). Mutations in NKCC2 or ROMK are 
believed to reduce salt reabsorption in the TAL and should thereby not only impair 
paracellular Ca2+ but also Mg2+ transport. However, Mg2+ wasting is not a common 
finding in patients with aBS which is consistent with the observation that NKCC2 
knockout mice also display no disturbances in the Mg2+ balance (116). In addition, 
chronic furosemide treatment is in general not associated with hypomagnesemia. 
The mechanism explaining the absence of Mg2+ wasting in most aBS patients is still 
elusive. Possibly, increased renal prostaglandin synthesis, may contribute to 
increased Mg2+ reabsorption in DCT as has been shown in vitro (117). Alternatively, 
passive Mg2+ reabsorption in the proximal tubule and TAL could be stimulated by 
chronic volume depletion.
Bartter syndrome type III: Classic Bartter syndrome (cBS)
The majority of patients with cBS display hypokalemia, hypochloremia, and failure 
to thrive during the first two years of life (118). However, the clinical phenotype of 
cBS (Bartter type III) is broad ranging from a phenotype similar to aBS to a 
phenotype highly comparable with that of Gitelman syndrome (see below) (119-121). 
Hypomagnesemia is observed in almost 50% of the cBS patients and although the 
excretion of Ca2+ is variable, hypocalciuria is commonly detected (108, 120). cBS is 
caused by mutations in the CLCNKB gene encoding the renal Cl- channel CLC-Kb 
(108, 109). CLC-Kb is basolaterally expressed in TAL and DCT where it mediates 
Cl- efflux from the tubular epithelial cell into the blood (figure 2) (108, 109). Some 
cBS patients display hypomagnesemia combined with hypocalciuria, a characteristic 
phenotype also found in GS and IDHH, both caused by defects in DCT. Therefore, 
it can be hypothesized that disturbed reabsorption of Na+ and Cl- in DCT impairs 
active reabsorption of Mg2+.
Bartter syndrome type IV: antenatal Bartter syndrome with sensorineural 
deafness (aBS with sensorineural deafness)
Patients with aBS with sensorineural deafness (Bartter type IV) form a variant of aBS. 
The clinical phenotype of these patients is different from aBS since hypercalciuria 
and nephrocalcinosis are uncommon and patients often show progression to renal 
failure of unknown origin. In addition, renal water and salt losses can be even more 
severe than in type I and II aBS patients. aBS with sensorineural deafness is caused 
by mutations in the BSND gene which encodes Barttin, an activating ß-subunit of the 
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of Mg2+ in the renal ultrafiltrate is reabsorbed passively in the PCT and TAL, while 
the final excretion is determined in the DCT via an active reabsorption process. The 
mechanism of this latter pathway remains largely unknown. The characterization of 
the epithelial Mg2+ channel TRPM6 as the apical entry mechanism facilitating 
transepithelial Mg2+ transport can help to understand the molecular details of 
active Mg2+ transport. Therefore, the general aim of this thesis was to increase the 
physiologic insight in the molecular regulation of active Mg2+ (re)absorption in 
health and disease in general and in particular in TRPM6. In order to increase our 
knowledge of Mg2+ permeation through TRPM6, the role of the individual residues 
in the putative pore-forming region was studied by patch clamp analysis after site 
directed mutagenesis of the pore-forming amino acids. The identified molecular 
determinants of permeation through TRPM6 are described in chapter 2. In addition 
to the molecular analysis of TRPM6, chapter 3 reports the in vivo regulation of 
TRPM6 in kidney and colon that was investigated in mice fed a Mg2+-deficient, 
some cells of the collecting duct (126-128). It is generally accepted that the CaSR 
can sense both Ca2+ and Mg2+ levels and regulates the reabsorption and thereby 
the total body balance of these ions (34). As described previously, the kidney plays 
an important role in the Ca2+ and Mg2+ homeostasis by adjusting the tubular 
reabsorption of these cations. Frequently a disturbed Mg2+ balance is observed in 
patients with mutations in the CASR gene. The mutations that have been described 
are either activating or inactivating. Activating CASR mutations cause autosomal-
dominant hypoparathyroidism (ADH) (112), which is associated with hypocalcemia, 
hypercalciuria and frequently with hypomagnesemia. This phenotype is explained 
by the enhanced sensitivity of the CaSR for both Ca2+ and Mg2+, resulting in 
decreased PTH secretion and thereby reduced reabsorption of Ca2+ and Mg2+ in 
the cortical TAL and DCT (124). The inactivating CASR mutations can be divided in 
heterozygous mutations that have been identified in patients with familial 
hypocalciuric hypercalcemia (FHH or HHC1) and homozygous or compound 
heterozygous mutations causative for neonatal severe hyperparathyroidism 
(NSHPT). In contrast to ADH, patients with FHH are characterized by hypercalcemia, 
hypocalciuria and display a tendency towards hypermagnesemia (129). Patients 
with NSHPT exhibit hypercalcemia and elevated PTH levels from birth (113). In 
addition, several NSHPT patients display hypermagnesemia (129).
In conclusion, investigations of families with primary and secondary hereditary 
hypomagnesemia have uniquely resulted in the identification of several genes and 
proteins that can be either directly or indirectly linked to renal and/or intestinal Mg2+ 
handling. Interestingly, all identified gene products involved in Mg2+ homeostasis 
are expressed in kidney (figure 4). The importance of studying families with 
hereditary hypomagnesemia is stressed by the fact that no suitable radioactive 
Mg2+ isotope is available, which would greatly facilitate the electrophysiological 
characterization of Mg2+ pathways. 
Outline of this thesis 
Mg2+ is an abundant cation in the human body and is required for a wide variety of 
cellular processes. Serum Mg2+ concentration is maintained within a narrow range 
(0.7-1.1 mM) (24) by changes in urinary Mg2+ excretion in response to altered uptake 
by the intestine. Thus, the kidney plays a key role in Mg2+ homeostasis. The majority 
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Figure 4.  Schematic overview depicting the expression of gene products 
 linked to renal Mg2+ handling in the kidney
 The gene products involved in disorders with primary hypomagnesemia are indicated 
with a dot. The g-subunit depicted refers to the g-subunit of the Na+,K+-ATPase.
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Mg2+-normal and a Mg2+-enriched diet. Furthermore, this chapter discusses the 
regulation of TRPM6 in kidney by hormones including PTH, 1,25(OH)2D3 and 
17ß-estradiol. Chapter 4 illustrates how the Mg2+ balance is influenced in TRPV5 
knockout mice (TRPV5-/-), which display robust hypercalciuria and hypervitaminosis D. 
In addition, the analysis of TRPM6 expression levels and the Mg2+ and Ca2+ 
balance in TRPV5-/- mice fed various Mg2+ diets is described. The aim of the study 
described in chapter 5 was to identify one or more genes involved in renal Mg2+ 
handling and systemic Mg2+ homeostasis. To this end, we performed a positional 
candidate cloning strategy on a family previously described by Geven et al. (86) with 
isolated recessive renal Mg2+ wasting and normocalciuria. This study, presents the 
search for the gene defect causing the aforementioned disease and the mechanism 
underlying the pathophysiology of the observed hypomagnesemia. Furthermore, 
this study provides for the mechanism explaining hypomagnesemia induced by 
cetuximab, which is a monoclonal antibody directed against the epidermal growth 
factor receptor (EGFR). The relation of specific EGFR signaling cascades, elicited 
after EGFR activation, with respect to TRPM6 channel activity is described in 
chapter 6. To this end, various inhibitors, blocking specific EGFR signaling pathways 
and patch clamp analysis were used. Finally, the results of this thesis are 
summarized and discussed in chapter 7.
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Abstract
TRPM6 and its closest relative TRPM7 are members of the Transient Receptor 
Potential Melastatin (TRPM) subfamily of cation channels and are known to be Mg2+ 
permeable. By aligning the sequence of the putative TRPM6 pore with the pore 
sequences of the other subfamily members, we located in the loop between the 5th 
and the 6th transmembrane domain, a stretch of amino acids residues, 1028GEIDVC1033, 
as the potential selectivity filter. Two negatively charged residues, E1024 (conserved in 
TRPM6, TRPM7, TRPM1 and TRPM3) and D1031 (conserved along the entire TRPM 
subfamily), were identified as important determinants of cation permeation through 
TRPM6, because neutralization of both residues into an alanine resulted in non-
functional channels. Neutralization of E1029 (conserved in TRPM6, TRPM7, TRPM4 
and TRPM5) resulted in channels with increased conductance for Ba2+ and Zn2+, 
decreased ruthenium red sensitivity and larger pore diameter compared to wild-type 
TRPM6. Changing the residue I1030 into methionine, resulted in channels with lower 
conductance for Ni2+, decreased sensitivity to ruthenium red block and reduced pore 
diameter. Thus, these data demonstrate that amino acid residues E1024, I1030 and 
D1031 are important for channel function and that subtle amino acid variation in the 
pore region accounts for TRPM6 permeation properties.
Introduction
Being the most abundant intracellular cation after K+, Mg2+ is an important cofactor 
for many biological processes, such as protein synthesis, nucleic acid stability and 
neuromuscular excitability (1, 2). Mg2+ homeostasis involves the kidney as the 
primary regulatory site, the intestine as the absorption place, while the bone is the 
storage location (3). Transcellular Mg2+ transport in renal and intestinal epithelia is 
of vital importance for overall Mg2+ homeostasis. There is both a passive 
(paracellular) mechanism and an active (transcellular) transport for Mg2+ 
(re)absorption in renal and intestine epithelia (2). However, the molecular mechanism 
of transcellular Mg2+ transport is not fully understood. Recently, investigations in 
consanguineous families suffering from hypomagnesaemia with secondary 
hypocalcaemia (HSH) have identified mutations in the gene encoding the Transient 
Receptor Potential Melastatin 6 (TRPM6) protein as the cause of the disease (4, 5). 
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permeation of TRPM6. To this end, a combined approach consisting in site-directed 
mutagenesis and electrophysiological measurements was used to investigate the 
role of amino acid residues from the putative selectivity filter in the permeation 
properties of TRPM6. Our data indicate that a short amino acid stretch of the pore 
region, 1028GEIDVC1033, determines the TRPM6 conductance properties and its 
sensitivity to the channel pore blocker, the hexavalent cation ruthenium red.
Materials and methods
Molecular biology
The full-length open reading frame from N-terminally HA-tagged human (h)TRPM6 
was cloned as a BclI - BspEI fragment in the pCINeo/IRES-GFP vector (6). This 
bicistronic expression vector, pCINeo/IRES-GFP/HA-hTRPM6, was used to 
co-express hTRPM6 and enhanced GFP in Human Embryonic Kidney cells 
(HEK293). Mutagenesis of the amino acids E1024, E1029, I1030, D1031, V1032 and of the 
TRPM6-TRPM4 and TRPM6-TRPV6 chimeric constructs was performed using 
QuickChange™ site-directed mutagenesis (Stratagene, La Jolla, USA). 
The sequence of each mutant was verified by sequence analysis of the 
corresponding cDNA.
Cell culture and transfection
HEK293 cells were grown in Dulbecco's modified Eagle's medium (Bio Whittaker-
Europe, Verviers, Belgium) containing 10% (v/v) fetal calf serum, 2 mM L-glutamine 
and 10 µg/ml ciproxin at 37°C in a humidity-controlled incubator with 5% (v/v) CO2. 
The cells were transiently transfected with the respective constructs using 
Lipofectamine 2000 (Invitrogen-Life Technologies, Breda, the Netherlands), as 
described previously (15), and electrophysiological recordings were performed 16 
to 36 hours post-transfection. Transfected cells were identified by their green 
fluorescence when illuminated at 480 nm. Non-transfected (GFP-negative) cells 
from the same batch were used as controls.
Electrophysiology
Patch clamp experiments were performed in the tight seal whole-cell configuration 
at room temperature (20-25°C) using an EPC-9 patch clamp amplifier computer 
It was demonstrated that TRPM6 functions as a molecular determinant of 
transcellular Mg2+ transport in renal and intestinal epithelia (6).
TRPM6 shares with its closest relative TRPM7 approximately 50% sequence 
homology at the amino acid level (6). TRPM7 appears to be ubiquitously expressed, 
whereas TRPM6 expression is restricted to kidney and intestine (6), where it plays 
an important role in Mg2+ (re)absorption (6). Consistent with a role in Mg2+ 
homeostasis, we demonstrated recently that dietary Mg2+ restriction upregulates 
TRPM6 expression in mice kidney, while a Mg2+-enriched diet increases TRPM6 
expression in colon (7). These diets did not affect TRPM7 expression levels in 
kidney and colon. Atypically for other ion channels, TRPM6 and TRPM7 contain a 
serine/threonine protein kinase domain at the C-terminus resembling that of 
elongation factor 2 (eEF-2) kinase and other α-kinases. The kinase function in 
channel regulation remains elusive (4, 8-12).
Recently, we have functionally characterized TRPM6 using electrophysiological 
analysis (6). This protein forms constitutively active divalent selective cation 
channels, with a higher affinity for Mg2+ than for Ca2+ at physiological membrane 
potentials and divalent concentrations. TRPM6 becomes permeable to monovalent 
cations when all divalent cations are omitted from the extracellular solution. Despite 
this initial characterization of TRPM6, the molecular determinants of its Mg2+ 
permeability remain unknown. Moreover, in a recent paper, Li et al. described in 
detail the functional differences in divalent ion permeability between homomeric 
TRPM6, homomeric TRPM7 and heteromeric TRPM6/TRPM7 channel complexes 
demonstrating unequivocally that TRPM6 can form by itself functional channels 
without TRPM7 co-expression (13). The study also demonstrated that TRPM6 
displays single channel conductance that is 2- and 1.5-fold bigger than TRPM7 and 
TRPM6/TRPM7 complexes.
To date there is limited knowledge about the structures of TRP channels pores and 
even less is known about TRPM channels pores. In a recent study Owsianik et al. 
summarized the current knowledge about permeation and selectivity of TRP 
channels (14). They propose and describe a general approach as a toolkit for 
characterizing the permeation and selectivity of ion channels. Therefore, the aim of 
the present study was to identify the amino acid stretch responsible for Mg2+ 
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Statistical analysis
Data analysis and graphs were prepared using IgorPro software (WaveMetrics, 
Lake Oswego, USA). Data are expressed as mean ± s.e.m. Overall statistical 
significance was determined by analysis of variance. In case of significance 
(p < 0.05), individual groups were compared using Student's t test.
Results
Sequence analysis of the putative pore-forming region of TRPM6
Figure 1 shows a sequence alignment of the putative pore region of the TRPM 
subfamily. The structure of the loop between the 5th and the 6th transmembrane 
domains (TM5 and TM6) was modeled based on the K+ channel KcsA crystal 
structure (19). In this region, TRPM6 shares the highest sequence homology with 
TRPM7, also known to conduct Mg2+ when heterologously expressed in HEK293 
cells (8, 9, 20). TRPM6 and TRPM7 contain two glutamate residues, E1024 and E1029 
(horizontal pattern in figure 1). The E1024 is conserved in TRPM1 and TRPM3. 
In addition, TRPM6 shares an aspartate residue D1031 (vertical pattern in figure 1) 
with all the other members of the TRPM subfamily. To assess the contribution of 
these amino acid residues in the permeation properties of TRPM6, these residues 
were neutralized by alanine substitution (mutants E1024A, E1029A, and D1031A). 
To delineate the role of the conserved aspartate residue (D1031), adjacent amino 
acids were mutated. I1030 was substituted by a methionine in order to mimic the 
pore properties of the monovalent selective channel TRPM4 (mutant I1030M), and 
the V1032 was substituted by an alanine (mutant V1032A). The positions for the amino 
acid residues mutated for this study are marked with asterisks in figure 1.
Functional characterization of TRPM6 pore mutants
To determine which amino acids in the pore region account for the permeation 
properties of TRPM6, the activation kinetics of wild-type channels were compared 
with those of the mutant proteins. The currents recorded from TRPM6-transfected 
cells reached a plateau level of 295 ± 40 pA/pF (n = 30 cells) within 100-200 s, 
while non-transfected (NT) cells (n = 10 cells) displayed only background current, 
probably endogenous TRPM7 (75 ± 27 pA/pF) that is activated over a longer period 
of time, as depicted in figure 2A. When expressed in HEK293 cells, the TRPM6 
controlled by Pulse software (HEKA Electronik, Lambrecht, Germany). Patch 
pipettes had resistances between 2 and 4 MW after filling with the standard 
intracellular solution. Cells were held at 0 mV, and voltage ramps of 450 ms ranging 
from -100 to +100 mV were applied every 2 s. Cell capacitance and access 
resistance were continuously monitored using the automatic capacitance 
compensation of the Pulse software. Extracting the current amplitudes at +80 and 
-80 mV from individual ramp current records assessed the temporal development 
of membrane currents. Current densities were obtained by normalizing the current 
amplitude to the cell membrane capacitance.
Solutions
The standard pipette solution contained (in mM): 150 NaCl, 10 EDTA, and 10 HEPES 
(pH 7.2 adjusted with NaOH). The extracellular solution contained (in mM): 150 NaCl 
and 10 HEPES (pH 7.4 adjusted with NaOH), supplemented with either 1 mM CaCl2 
(to assess the time-course for development of currents), 10 mM EDTA (divalent-free 
solutions, DVF), or the same concentration of divalent cations (for the permeation 
profile determinations). The  relative permeabilities (P×/PNa) of mono-, di-, tri-, and 
tetramethyl ammonium substituents and of N-methyl-D-glucamine (NMDG) were 
measured using solutions in which all Na+ was substituted by the respective cations 
and calculated from the biionic reversal potentials (16). All potentials were corrected 
for possible liquid junction potentials, which were calculated according to Barry 
(17). In these permeation experiments, the standard pipette solution was used as 
intracellular solution. For the ammonium derivates, the following compounds 
diameters were used (in nm): 0.36, 0.46, 0.52, 0.58, and 0.68 for  monomethylammonium 
(MA+), dimethylammonium (DMA+), trimethylammonium (TriMA+), tetramethyl-
ammonium (TetMA+), and for NMDG+ respectively. To fit the points from the graph 
plotting permeability ratios of the different organic cations (C) versus their estimated 
diameters, the excluded volume considering friction of the permeating ion Equation 
1 (18) was used:
Px/PNa = k(1-a/d)2/a 
where a is the organic cation diameter, k is a constant factor and d the minimal pore 
diameter. The ammonium derivates were purchased from Sigma.
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pore mutants showed three different phenotypes: E1029A displayed a time-course of 
activation and a current amplitude similar to wild-type TRPM6 (n = 10 cells) (figure 2B), 
I1030M and V1032A showed activation kinetics similar with TRPM6, while their current 
amplitudes were significantly reduced (178 ± 40 and 150 ± 45 pA/pF respectively 
versus 295 ± 40 pA/pF, p < 0.05, n = 10 cells for each mutant), as depicted in 
figure 2C and D, and E1024A and D1031A showed no current (n = 5 cells) (figure 2E). 
Mutations in the pore region of TRPM6 did not change the current-voltage properties 
of the currents as summarized in figure 2F.
Interestingly, when co-expressed with wild-type TRPM6 in a 1:1 cDNA ratio, D1031A 
showed a dominant negative effect since the currents recorded from these cells 
(n = 8 cells) were identical in the time-course of development, current-voltage 
relation and amplitude with the currents from NT cells as shown in figure 3. 
The dominant negative effect of D1031A suggests that assembly with wild-type 
TRPM6 is not disturbed. Channel complexes containing wild-type and mutant 
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Figure 2. Functional expression of wild-type TRPM6 and pore mutant proteins
 
(A) Average time-course of inward (at -80 mV) and outward currents (at +80 mV) 
 development from cells expressing wild-type TRPM6 (◆), and non-transfected cells (NT ▲). 
(B-E) Average time course of inward  and outward currents development from cells expres-
sing the mutant E1029A (B), I1030M (C), V1032A (D), E1024A (●) and D1031A (i) (E); the dotted 
line indicates the averaged time course for wild-type TRPM6. (F) Current-voltage relations 
from cells transfected with either TRPM6, or mutant proteins as  indicated, obtained under 
experimental conditions as in other panels, measured 200 s after whole-cell establishment. 
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Figure 1. The putative pore-forming region of TRPM6
 
Alignment of the putative pore sequences of the TRPM subfamily on the rows, which  
represent the amino acid sequences from the respective human TRPM subfamily channels. 
The GenBank accession numbers are: NP_002411, AAY22174, NP_066003, NP_060106, 
NP_055370, NP_060132, NP_060142, and NP_076985 starting from TRPM1 to TRPM8.  
The highly conserved hydrophobic residues are highlighted in diagonal pattern, the  
conserved aspartate is shown in vertical pattern, and the conserved residues with polar or 
charged groups are shown in horizontal pattern (adapted from (24, 35)). Asterisks denote 
the amino acid residues mutated in this study. 
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proteins could be retained at the endoplasmic reticulum or reach the plasma 
membrane showing defective pore architecture. Likewise, expression of D1031A 
alone could have the same outcome as the co-expression with wild-type TRPM6. 
Despite repetitive attempts, the low abundance of TRPM6 proteins at the plasma 
membrane did not allow us to determine whether these proteins are expressed at 
the cell surface.
Conductance profile of TRPM6 pore mutants
To establish the conductance properties of TRPM6, we determined the permeation 
profile of the wild-type channel and the functional pore mutants. The permeation 
rank order of divalent cations compared to Ca2+ was assessed by the ratio of 
inward current at -80 mV, when Ca2+ ions are equimolar substituted by other 
divalent cations. When normalized to the inward current amplitude in the presence 
of 10 mM Ca2+, the following conductance profile for TRPM6 was obtained: Ba2+ 
(1.66) > Ni2+ (1.16) > Mg2+ (1.08) > Zn2+ (1.01) ≥ Ca2+ (1.00) (n = 5-8 cells) (figure 4A). 
The permeation rank order obtained for the mutant E1029A was: Ba2+ (2.34) > Zn2+ 
(1.29) > Ni2+ (1.14) > Mg2+ (1.08) > Ca2+ (1.00) (figure 4B). The E1029A displayed 
an increased conductance to Ba2+ and Zn2+ compared to TRPM6. For the 
permeation rank order of the mutant I1030M, the following values were obtained: 
Ba2+ (1.74) > Mg2+ (1.01) ≥ Ca2+ (1.00) ≥ Zn2+ (0.99) > Ni2+ (0.92), (n = 5 cells) 
(figure 4C). The I1030M mutant had a lower conductance for Ni2+ compared to 
TRPM6. These data are summarized in figure 4D. To further characterize the TRPM6 
pore permeability, its permeation profile was compared with the homologous 
TRPM7 channel as previously described by Monteilh-Zoller et al. (20). When 
normalized to the inward current amplitude in 10 mM Ca2+, the following relative 
values were obtained for TRPM7: Ba2+ (4.62) > Ni2+ (3.69) >  Zn2+ (2.11) > Mg2+ 
(1.24) > Ca2+ (1.00) (n = 8 cells). This comparison, summarized in figure 4E, 
revealed that TRPM6 and TRPM7 display different permeation rank orders in the 
way that TRPM6 has a higher conductance for Mg2+ than TRPM7. 
 
Next, the effect of micromolar concentrations of divalent cations (Ca2+ and Mg2+) 
present in the extracellular solutions on inward monovalent (Na+) current was 
investigated. As shown in figure 5A and B, both Mg2+ and Ca2+ inhibited the 
TRPM6 current in the micromolar range. The concentration for half-maximal TRPM6 
current inhibition (IC50) was calculated from the dose-response curve for Mg2+ 
Chapter 2
2
  Permeation through TRPM6
350
300
250
200
150
100
50
0
8
6
4
2
-100 100
300
200
100
0
200150100500
-25
A B
TRPM6+
D1031A
TRPM6
Time (sec)
V (mV)
TRPM6+D
TR
P
M
6
N
T
TR
P
M
6+
D
10
31
A
1031A
C
* *
I (
pA
/p
F)
I (
pA
/p
F)
I (
nA
)
Figure 3. Effect of co-expression of wild-type TRPM6 and the pore mutant D1031A
 
(A) Average time course of inward and outward currents development from cells  expressing 
wild-type TRPM6 (dotted line) or TRPM6 with the pore mutant D1031A. (B) Current-voltage 
relations from HEK293 cells transfected with either wild-type TRPM6, or TRPM6 with the 
pore mutant D1031A, measured 200 s after whole-cell establishment. (C) Histogram 
 summarizing the currents amplitudes measured 200s after whole-cell  establishment at +80 
mV from NT cells, cells transfected with wild-type TRPM6 and cells transfected with TRPM6 
together with the pore mutant D1031A, asterisk denotes p < 0.05  versus wild-type TRPM6. 
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Figure 5. Mg2+ and Ca2+ inhibit TRPM6-mediated inward monovalent currents
 
(A) and (B) Current-voltage relations obtained from HEK293 cells expressing TRPM6 in 
divalent-free solution (DVF) and in the presence of 0.1 and 1 µM Mg2+, or 1 and 5 µM Ca2+. 
(C) Dose-response curve for the inhibition of inward monovalent current at -80 mV by Mg2+. 
(D) Dose-response curve for the inhibition of inward monovalent current at -80 mV by Ca2+. 
(E) and (F) Dose-response curves for the inhibition of inward monovalent current by Mg2+ 
(E) and Ca2+ (F) for the pore mutant proteins, E1029A (●), I1030M (■) and V1032A (▼). 
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Figure 4. Divalent permeation through wild-type TRPM6 and pore mutant proteins
 
(A) Magnified views of the inward currents recorded with extracellular solutions containing  
10 mM of the indicated divalent cations, from HEK293 cells expressing TRPM6 (A), E1029A  
(B), and I1030M (C). (D) Histogram summarizing relative permeation rank order determined 
from the ratio of inward current for the indicated divalent cation, for TRPM6 (black bars) and 
pore mutants E1029A (white bars) and I1030M (grey bars), (asterisks represent p < 0.05 versus 
wild-type TRPM6). (E) Histogram summarizing the relative permeation profile for TRPM6 
(black columns) and TRPM7 (white columns) determined from the ratio of inward current 
amplitude in the presence of the indicated divalent cation, and the inward current amplitude 
with Ca2+ containing extracellular solution. 
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(n = 5 cells for each point) (figure 5C) and Ca2+ (n = 5 cells for each point) (figure 5D) 
and yielded values of 0.9 and 3.5 µM with Hill coefficients of 0.8 and 0.83 
respectively. These values were in concordance with the ones from our previous 
paper (6). For the pore mutants, the IC50 for Mg2+ sensitivity was (in µM): 1.1, 1.0, 
and 0.8, for E1029A, I1030M and V1032A, respectively (figure 5E), while the IC50 for 
Ca2+ sensitivity for the pore mutants was (in µM): 3.4, 3.6 and 3.4 for E1029A, I1030M 
and V1032A, respectively (figure 5F). No significant differences were observed 
between the pore mutants and wild-type TRPM6. 
 
Effect of pore mutations on TRPM6 ruthenium red sensitivity
As previously demonstrated, TRPM6 can be blocked by the hexavalent cation 
ruthenium red (RR) in a voltage-dependent manner (6). As depicted in figure 6 A-D, 
RR blocked specifically the inward monovalent currents carried by wild-type TRPM6 
or the pore mutants. To determine which amino acid residues in the TRPM6 pore are 
involved in the inhibitory effect of RR, a dose-response curve was established for 
RR block of the inward TRPM6 and pore-mutant’s monovalent currents (n = 5 cells 
for each point) (figure 6E). The following IC50 for RR sensitivity were obtained (in 
µM): 15.3 for E1029A with the Hill coefficient of 0.92, 11.9 for I1030M with Hill coefficient 
of 0.77 and 4.8 for V1032A with a Hill coefficient of 0.84 compared to 5.3 for TRPM6 
with a Hill coefficient of 0.90. E1029A and I1030M mutants showed a significantly 
(p < 0.05) reduced sensitivity to RR compared to wild-type channel.
Measurement of the pore diameter of TRPM6
To estimate the TRPM6 pore diameter, the permeability ratios of currents carried by 
organic monovalent cations of increasing size relative to Na+ current were 
measured. When Na+ was used as the sole charge carrier, the current reverted 
close to 0 mV and had a slightly inward-rectifying shape (figure 7A). All Na+ ions 
from the extracellular solution were substituted by methyl-ammonium or its di-, tri- 
and tetra methyl derivatives (MA+, DMA+, TriMA+, TetMA+), or by the larger organic 
cation N-methyl-D-glucamine (NMDG+). All the tested cations were able to 
permeate wild-type TRPM6, E1029A and I1030M channels (figure 7A-C). 
The permeability ratios relative to Na+ (P×/PNa) were calculated from the biionic 
reversal potentials (16): 0.827 ± 0.004, 0.483 ± 0.007, 0.360 ± 0.015, 0.262 ± 
0.016, and 0.230 ± 0.015 for MA+, DMA+, TriMA+, TetMA+, and NMDG+ respectively. 
Figure 7D depicts the permeability ratios of the different cations versus their 
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Figure 6. The inhibitory effect of ruthenium red (RR) on TRPM6 pore mutants
 
(A-D) Current-voltage relations of monovalent currents in absence (solid lines), or in the 
presence of RR either at 5 µM RR (dotted lines) or 10 µM RR (dashed lines) obtained from 
cells expressing wild-type TRPM6 (A), and the pore mutants E1029A (B), I1031M (C) and 
V1032A (D). (E) Dose-response curves for the inhibition of the TRPM6-mediated inward 
monovalent current by RR (◆) and the pore mutant proteins: E1029A (●), I1030M (■) and 
V1032A (▼). 
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Both constructs resulted in non-functional channels when expressed in HEK293 
cells (data not shown).
Discussion
The Mg2+-selective cation channel TRPM6 represents the first molecular key player 
of transcellular Mg2+ (re)absorption in renal and intestinal epithelia. Mutations in 
TRPM6 described for HSH patients imply that TRPM6 indeed plays a crucial role as 
the gatekeeper of Mg2+ (re)absorption. The present study indicates that a short 
amino acid stretch of the pore region, 1028GEIDVC1033, determines the TRPM6 
permeability properties and its sensitivity to the channel pore blocker, RR. 
Our conclusions are based on the following experimental observations. First, the 
mutant E1029A shows different permeation properties compared to wild-type 
TRPM6. Second, the estimated pore diameter of TRPM6 increases when E1029 is 
neutralized into an alanine and decreases when I1030 is changed into a methionine. 
Third, the sensitivity of TRPM6 to RR block depends on the E1029 and I1030 residues 
in the pore forming region of the channel. 
TRPM6 pore localization
Mutations that affect basic pore properties have been mainly described for the 
TRPV  (vanilloid) subfamily, namely TRPV1, TRPV4, TRPV5 and TRPV6 (21-23), while 
the only characterized member of TRPM subfamily is TRPM4 (24). For TRPV5 and 
TRPV6, it has been shown that neutralization of an aspartate residue, D542 in 
TRPV5, which corresponds to D541 in TRPV6, abolishes the Ca2+ permeation, 
Ca2+-dependent current decay and block by extracellular Mg2+, whereas permeation 
of monovalent cations remains basically intact (25). Although the molecular 
determinants of TRPM6 Mg2+ selectivity were not fully revealed with this study, we 
obtained essential evidences that the region between the residues 1028GEIDVC1033 
forms a part of the TRPM6 pore based on the fact that neutralizing the negatively 
charged residues in this region resulted in channels with different characteristics. 
Moreover, replacing the putative selectivity filter of TRPM6 with the previously 
identified pores of both TRPV6 and TRPM4 resulted in non-functional channels 
(data not shown). Similarly to TRPM4, neutralizing the negatively charged amino 
acid residues in this area has dramatic consequences on TRPM6 functionality. 
estimated diameter for TRPM6, E1029A and I1030M (n = 5 cells for each point). 
Data points were fitted using Eq. 1 (see Materials and methods section for more 
details) resulting in significant differences (p < 0.05) in pore diameters of 1.15, 1.25 
and 1.05 nm for TRPM6, E1029A and I1030M, respectively.
To further delineate the selectivity filter of TRPM6, two chimeras were prepared in 
which the identified selectivity filters of TRPM4 or TRPV6 were inserted. To this 
respect an amino acid stretch from the TRPM6 pore 1028GEIDVC1033 was replaced 
by the sequence 981EDMDVA986 to construct the TRPM6-TRPM4 selectivity filter 
chimera and by the sequence 539TIIDGP544 to create the TRPM6-TRPV6 chimera. 
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(A-C) Extracts of current-voltage relations obtained during voltage ramps in divalent-free 
(DVF) solutions containing Na+, methylammonium (MA+), dimethylammonium (DMA+), 
 trimethylammonium (TriMA+), tetramethylammonium (TetMA+), or N-methyl-D-glucamine 
(NMDG+) as the sole extracellular cation, from cells expressing TRPM6 (A), E1029A (B) and 
I1030M (C). (D) The relative permeabilities (PX/PNa) of the different organic cations plotted as 
a function of the cation diameter for TRPM6 (◆) and pore mutants: E1029A (●) and I1030M (■). 
Data points were fitted according to Equation 1 (see Materials and methods for more 
details). 
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TRPM6 pore properties
To investigate the key determinants of TRPM6 pore properties, two main directions 
were followed: first, the negatively charged residues of the putative pore region 
were neutralized, and second, the role of the conserved D1031 and other amino acid 
residues in its close vicinity were investigated. Mutation of the three negatively 
charged residues in the putative TRPM6 selectivity filter (E1024, E1029 and D1031) or 
in the conserved pore helix (E1012, E1016, data not shown) had important functional 
consequences since neutralization of these residues resulted in non-functional 
channels, except for E1029. These data suggest that E1012, E1016, E1024 and D1031 play 
an important role in determining the pore properties of the channel. Neutralization 
of E1029 did not alter the current amplitude, but significantly reduced the sensitivity 
to RR, and Zn2+ and Ba2+ conductance. Most likely, negative charge at the inner 
mouth of the channel pore provides a binding site for positively charged cations, 
inducing open channel block (32). These data are in line with the fact that the pore 
diameter of this mutant is increased. We suggest that E1029 plays an important role 
in the TRPM6 pore architecture and takes part in the RR binding site of TRPM6. 
Second, alteration of the amino acid residues in close vicinity of the conserved 
D1031 had relevant consequences as the mutation of I1030 and V1032 resulted in 
functional channels, but with different characteristics compared to wild-type 
TRPM6. Mutation of I1030 resulted in a channel with a smaller pore size. For this 
latter mutant additional properties have been affected: I1030M is less permeable to 
Ni2+, but displays the same conductance for Zn2+ and Ca2+ with wild-type TRPM6 
and is more sensitive to RR. Despite the fact that Ni2+ has a smaller diameter than 
Ca2+ and Zn2+ and that I1030M forms channels with a reduced pore diameter, the 
altered conductance could be explained by differences in ion’s hydration energy 
with water molecules and by structural changes in the selectivity filter encompassing 
the permeation of ions (33). Next, the V1032A mutant showed no change in RR block 
and pore diameter, but had decreased current amplitudes indicating that the 
molecular determinants of the TRPM6 gating parameters may lay up-stream in the 
TRPM6 sequence. None of these mutations (E1029, I1030, V1032) affected the Ca2+ 
and Mg2+ sensitivity which is in line with the hypothesis that pore mutations are not 
expected to influence Ca2+ binding to the activation site(s) (34).
We and other groups (6, 13) are able to record TRPM6-associated currents in 
HEK293 cells without co-expressing TRPM7, whereas Gudermann and co-workers 
As demonstrated for TRPM4 (24), when mutating D1030 into alanine, which is 
conserved throughout the entire TRPM subfamily, we obtained non-functional 
channels. This non-functional phenotype could be explained by a crucial role of 
D1030 for the integrity of TRPM6 pore. In contrast to TRPM4, at positions 1028 and 
1036, TRPM6 contains non-charged residues while TRPM4 possesses glutamates 
at these positions and therefore, the delineation of the TRPM6 selectivity filter 
sequence appears different. However, we showed by alteration of the pore diameter 
due to mutation of E1029 and I1030 that the region from 1029 to 1031 determines the 
narrowest area of the channel pore.
Traditionally, the minimal pore size of an ion channel can be estimated by the largest 
permeant ion that carries a measurable current (16, 18). Recently, using this 
approach, the pore diameter of TRPV6 was estimated (26). Surprisingly, TRPM6-
associated inward currents could be measured with all organic cations including 
NMDG+ whereas for TRPV6, DMA+ was the largest cation that could permeate the 
channel pore (26). The remarkable inward current measured with NMDG+ as the sole 
charge carrier could be blocked in the presence of RR (data not shown), proving 
clearly that NMDG+ is able to permeate TRPM6 pore. NMDG+ permeation has been 
already described for TRPV1 and purinergic receptors P2X (27, 28). For estimation of 
the pore diameter of TRPM6, fitting of the relative permeation versus the cation 
diameter had to be extrapolated because we did not find any organic cation that 
does not permeate through TRPM6. Interestingly, the estimated diameter of the 
TRPM6 pore (1.15 nm) is significantly larger compared to other channels like TRPV6 
(0.54 nm), voltage-gated Ca2+ channels and estimations for Ca2+ release activated 
currents (0.38 nm in Jurkat cells and 0.32-0.55 nm in rat basophilic leukemia cells 
(29-31). However, further studies are required to debate if molecular sieving is the 
main mechanism underlying the selectivity of Mg2+ channels. Recently, the 
selectivity filter of TRPM4 was revealed by Nilius et al. (24). They demonstrated that 
the pore properties of TRPM4 are determined by a subset of amino acid residues, in 
contrast to members of the TRPV subfamily in which a single amino acid residue 
accounts for the permeability properties of the pore. Our results support their 
observations and prove that members of the TRPM subfamily have a more complex 
pore structure compared to their close relatives of the TRPV subfamily.
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Abstract
The kidney is the principal organ responsible for the regulation of the body Mg2+ 
balance. Identification of the gene defect in Hypomagnesemia with Secondary 
Hypocalcemia (HSH) has recently elucidated TRPM6 as the gatekeeper in 
transepithelial Mg2+ transport, whereas its homolog TRPM7 is implicated in cellular 
Mg2+ homeostasis. The aim of the present study was to determine the tissue 
distribution in mouse and regulation of TRPM6 and TRPM7 by dietary Mg2+ and 
hormones. The present study demonstrates that TRPM6 is predominantly expressed 
in kidney, lung, cecum and colon, whereas TRPM7 is ubiquitously distributed. 
Dietary Mg2+ restriction in mice resulted in hypomagnesemia and renal Mg2+ and 
Ca2+ conservation, whereas a Mg2+ enriched diet led to increased urinary Mg2+ 
and Ca2+ excretion. Conversely, Mg2+ restriction significantly upregulated renal 
TRPM6 mRNA levels, whereas a Mg2+ enriched diet increased TRPM6 mRNA 
expression in colon. Dietary Mg2+ did not alter TRPM7 mRNA expression in mouse 
kidney and colon. In addition, we demonstrated that 17ß-estradiol, but not 
1,25-dihydroxyvitamin D3 and parathyroid hormone, regulate TRPM6 renal mRNA 
levels. Renal TRPM7 mRNA abundance remained unaltered under these conditions. 
The renal TRPM6 mRNA level in ovariectomized rats was significantly reduced, 
whereas 17ß-estradiol treatment normalized TRPM6 mRNA levels. In conclusion, 
kidney, lung, cecum and colon likely constitute the main sites of active Mg2+ 
(re)absorption in the mouse. In addition, Mg2+ restriction and 17ß-estradiol 
upregulated renal TRPM6 mRNA levels, whereas a Mg2+ enriched diet stimulated 
TRPM6 mRNA expression in colon, supporting the gatekeeper function of TRPM6 in 
transepithelial Mg2+ transport.
Introduction
Mg2+ is the second most abundant intracellular cation and plays an essential role 
as co-factor in many enzymatic reactions (1). Mg2+ homeostasis depends on the 
balance between intestinal absorption, renal excretion and exchange with bone (2). 
Regulation of the total body Mg2+ balance principally resides within the kidney that 
tightly matches the intestinal absorption of Mg2+. About 80% of the total plasma 
Mg2+ is filtered in the glomeruli (3, 4), of which the majority is subsequently 
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hormone (PTH). The effect of dietary Mg2+ content was studied by analyzing 
TRPM6 regulation at the mRNA and protein level and Mg2+ excretion and serum 
levels in C57BL6 mice fed a Mg2+ deficient, normal and enriched diet.
Materials and Methods 
Animal studies
To evaluate TRPM6, TRPM7 and TRPV6 mRNA expression in various tissues, a 
cDNA panel was constructed. To this end, four C57BL6 mice, fed a complete diet 
containing 0.2% Mg2+ (w/w) (SSNIFF spezialdiäten GmbH, Soest, Germany), were 
sacrificed and kidney, spleen, brain, heart, skeletal muscle, liver, lung, stomach, 
bone, duodenum, jejunum, ileum, cecum and colon were collected and total RNA 
was isolated. To study the effect of dietary Mg2+ content on TRPM6 and TRPM7 
expression in kidney and colon, C57BL6 mice (12 weeks of age), were fed for 10 days 
either a Mg2+ deficient diet (0.005% w/w Mg), normal Mg2+ diet (0.19% w/w Mg), or 
a Mg2+ enriched diet (0.48% w/w Mg) (SSNIFF spezialdiäten GmbH, Soest, 
Germany). The last 24 hours of the dietary treatment, animals were housed in 
metabolic cages and 24-hours urine was collected. At the end of the dietary 
treatment, blood samples were taken and the animals were sacrificed. Kidney and 
colon tissues were sampled and immediately frozen in liquid nitrogen. 
The effect of 17ß-E2 on the renal TRPM6 mRNA expression level was evaluated by 
sham operated, bilateral ovariectomized (OVX) and OVX rats that received 2 x 500 
µg 17ß-E2/day as described previously (18). The effect of PTH was studied by sham 
operated, parathyroidectomized (PTX) rats and PTX rats that received 6 units/day 
bovine PTH as described previously (19). In addition, the effect of 1,25(OH)2D3 was 
studied by 1α-hydroxylase knockout (1α-OHase-/-) mice, heterozygous (1α-OHase+/-) 
mice phenotypically identical to wild type mice, and 1α-OHase-/- mice intraperitoneally 
supplemented with 1,25(OH)2D3 as described previously (20). The animal ethics 
board of the Radboud University Nijmegen approved all experimental procedures.
Quantitative Real-Time Polymerase Chain Reaction Analysis
Total RNA was extracted from kidney, complete segments of the intestine and the 
other tissues using TriZol Total RNA Isolation Reagent (Gibco BRL, Breda, the 
reabsorbed along the nephron (5). Eighty-five percent of the filtered Mg2+ is 
reabsorbed passively in the proximal tubule and the thick ascending limb of Henle 
(TAL). The distal convoluted tubule (DCT) reabsorbs 5-10% of the filtered Mg2+ and 
the reabsorption rate in this segment defines the final urinary Mg2+ concentration. 
Mg2+ transport in DCT is transcellular in nature and influenced by dietary Mg2+ 
restriction and a number of hormones (6, 7). However, the molecular details and 
regulation of this pathway remain largely unknown (5, 6, 8, 9).
Hereditary disorders with primary hypomagnesemia have greatly facilitated the 
identification of epithelial ion transporters in the kidney. For instance, the elucidation 
of the genetic basis of Isolated Dominant Hypomagnesemia (IDH) and 
Hypo magnesemia with Secondary Hypocalcemia (HSH) resulted in the identification 
of the g-subunit of the Na+,K+-ATPase and the epithelial Mg2+ channel TRPM6, 
respectively (10-12). TRPM6, which is a member of the Transient Receptor Potential 
(TRP) superfamily, is localized along the apical membrane of the DCT. Heterologous 
expression in human embryonic kidney 293 cells of TRPM6, but not TRPM6 mutants 
identified in HSH patients, induces a Mg2+-permeable cation channel tightly 
regulated by the intracellular Mg2+ concentration (13). TRPM6 shows the highest 
homology with TRPM7, which has been identified as a Mg2+-permeable ion channel 
primarily required for cellular Mg2+ homeostasis (13-15).
In analogy with active Ca2+ (re)absorption in the distal part of the nephron and the 
small intestine through the epithelial Ca2+ channels (TRPV5 and TRPV6) (16), the 
process of transcellular Mg2+ transport is envisaged by the following sequential 
steps. Driven by a favorable transmembrane potential, Mg2+ enters the epithelial 
cell through the apical epithelial Mg2+ channel TRPM6. Next, Mg2+ will diffuse 
through the cytosol to be extruded actively across the basolateral membrane (13). 
The molecular identity of these latter Mg2+ transporters is not known. Most 
physiological studies favor a Na+-dependent exchange mechanism (17). The Mg2+ 
entry appears to be the rate-limiting step and the site of regulation.
The aim of the present study was to determine the sites of active Mg2+ absorption 
in mice by investigating the expression profile of TRPM6. In addition, we established 
whether TRPM6 is regulated by dietary Mg2+ content and the calciotropic hormones 
17ß-estradiol (17ß-E2), 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and parathyroid 
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Netherlands) according to the manufacturer’s protocol. The obtained RNA was 
subjected to DNase treatment (Promega, Madison, WI) to prevent genomic DNA 
contamination. Thereafter, 2 µg of RNA was reverse transcribed by Molony-Murine 
Leukemia Virus-Reverse Transcriptase (Gibco BRL) as described previously (21). 
The cDNA was used to determine TRPM6, TRPM7 and TRPV6 mRNA expression 
levels, as well as mRNA levels of the housekeeping gene hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) as an endogenous control. The mRNA 
expression levels were quantified by real-time PCR on an ABI Prism 7700 Sequence 
Detection System (PE Biosystems, Rotkreuz, Switzerland). Primers and probes 
targeting the genes of interest were designed using the computer program Primer 
Express (Applied Biosystems, Foster City, CA) and are listed in table 1. 
In vivo 45Ca2+ absorption assay 
Intestinal Ca2+ absorption was assessed in 2 groups of C57BL6 mice by measuring 
the amount of 45Ca2+ in serum at early time points after oral gavage (15 µl/g body 
weight). Mice were fasted 12 hours before the test. Animals were hemodynamically 
stable under anesthesia during the experiment. The solution used to measure Ca2+ 
absorption contained 0.1 mM CaCl2, 125 mM NaCl, 17 mM Tris pH 7.4, and 1.8 g/l 
fructose and was enriched with 20 µCi 45CaCl2/ml (18 Ci/g; New England Nuclear, 
Newton, Massachusetts, USA). One group received the 45Ca2+ solution 
supplemented with MgCl2 to a final concentration of 10 mM, whereas the 45Ca2+ 
solution of group 2 was not supplemented with MgCl2. Blood samples were 
obtained at different time intervals (2, 4, 8, 12 minutes). Radioactive 45Ca2+ was 
analyzed in serum (10 µl) by liquid scintillation counting. The change in the serum 
Ca2+ concentration was calculated from the 45Ca2+ content of the serum samples 
and the specific activity of the administrated Ca2+.
Analytical procedures
Serum Mg2+ and Ca2+ were measured using a colorimetric assay kit according the 
manufacturer’s protocol (Roche Diagnostics, Woerden, the Netherlands). Urinary 
Mg2+ and Ca2+ excretion was determined by atomic absorption spectrophotometry 
on a Perkin Elmer AAnalyst 300 (Perkin Elmer, Milano, Italy).
Immunohistochemistry
Immunohistochemical staining was performed on 7 µm cryosections of periodate-
Chapter 3
3
  Regulation of TRPM6 and TRPM7
Ta
b
le
 1
. 
S
eq
ue
nc
es
 o
f p
rim
er
s 
an
d
 T
aq
m
an
 p
ro
b
es
 fo
r 
re
al
-t
im
e 
q
ua
nt
ita
tiv
e 
P
C
R
G
en
e 
 
F
o
rw
ar
d
 p
ri
m
er
 
R
ev
er
se
 p
ri
m
er
 
P
ro
b
e
 
R
 
5'
-T
AT
C
AG
AC
TG
A
AG
AG
C
TA
C
TG
TA
AT
G
AC
C
-3
' 
5'
-T
TA
C
C
AG
TG
TC
A
AT
TA
TA
TC
TT
C
A
AC
A
AT
C
-3
' 
5'
-T
G
AG
AG
AT
C
AT
C
TC
C
AC
C
A
AT
A
AC
TT
TT
AT
G
TC
C
C
-3
'
H
P
R
T
 
M
 
5’
-T
TA
TC
AG
AC
TG
A
AG
AG
C
TA
C
TG
TA
AT
G
AT
C
-3
’ 
5’
-T
TA
C
C
AG
TG
TC
A
AT
TA
TA
TC
TT
C
A
AC
A
AT
C
-3
’ 
5’
-T
G
AG
AG
AT
C
AT
C
TC
C
AC
C
A
AT
A
AC
TT
TT
AT
G
TC
C
C
-3
’
 
R
 
5’
-A
A
AG
C
C
AT
G
C
G
AG
TT
AT
C
AG
C
-3
’ 
5’
-C
TT
C
AC
A
AT
G
A
A
A
AC
C
TG
C
C
C
-3
’ 
5’
-C
C
TG
G
TC
TG
AG
G
AT
G
AT
G
TT
C
TC
A
AG
C
C
-3
’
TR
P
M
6
 
M
 
5’
-A
A
AG
C
C
AT
G
C
G
AG
TT
AT
C
AG
C
-3
’ 
5’
-C
TT
C
AC
A
AT
G
A
A
A
AC
C
TG
C
C
C
-3
’ 
5’
-C
C
TG
G
TC
TG
AG
G
AT
G
AT
G
TT
C
TC
A
AG
C
C
-3
’
 
R
 
5’
-G
G
TT
C
C
TC
C
TG
TG
G
TG
C
C
TT
-3
’ 
5’
-C
C
C
C
AT
G
TC
G
TC
TC
TG
TC
G
T-
3’
 
5’
-T
TC
C
C
A
AG
TG
C
TG
TT
TC
TC
C
C
C
C
A-
3’
TR
P
M
7
 
M
 
5’
-G
G
TT
C
C
TC
C
TG
TG
G
TG
C
C
TT
-3
’ 
5’
-C
C
C
C
AT
G
TC
G
TC
TC
TG
TC
G
T-
3’
 
5’
-T
TC
C
C
A
AG
TG
C
TG
TT
TC
TC
C
C
C
C
A-
3’
TR
P
V
6 
M
 
5’
-A
TC
C
G
C
C
G
C
TA
TG
C
AC
A-
3’
 
5’
 A
G
TT
TT
TC
TC
C
TG
A
AT
C
TT
TT
TC
C
A
A-
3’
 
5’
-T
TC
C
AG
C
A
AC
A
AG
AT
G
G
C
C
TC
TA
C
TC
TG
A-
3’
P
C
R
 p
ri
m
er
s 
an
d
 f
lu
o
re
sc
en
t p
ro
b
es
 (
5’
FA
M
–3
’T
A
M
R
A
) 
w
er
e 
d
es
ig
ne
d
 u
si
ng
 t
he
 c
o
m
p
ut
er
 p
ro
g
ra
m
 P
ri
m
er
 E
xp
re
ss
 (
A
p
p
lie
d
 B
io
sy
st
em
s)
 
an
d
 p
ur
ch
as
ed
 f
ro
m
 B
io
le
g
io
 (
M
al
d
en
, t
he
 N
et
he
rl
an
d
s)
. H
P
R
T:
 h
yp
ox
an
th
in
e
-g
ua
ni
ne
 p
ho
sp
ho
ri
b
o
sy
l t
ra
ns
fe
ra
se
. R
, r
at
; 
M
, m
o
us
e
76 77
lysine-paraformaldehyde-fixed kidney samples. Sections were stained with affinity-
purified guinea pig anti-TRPM6, as described previously (13). Photographs of the 
entire cortex were taken with a Zeiss fluorescence microscope (Sliedrecht, the 
Netherlands) equipped with a digital photo camera (Nikon DMX1200). For semi-
quantitative determination of protein levels, images were analyzed with the Image Pro 
Plus 4.1 image analysis software (Media Cybernetics, Silver Spring, MD), resulting in 
quantification of the protein levels as the mean of integrated optical density (22).
Statistical analysis
Values are expressed as mean ± SEM. Differences between groups were tested by 
one-way analysis of variance (ANOVA) and further evaluated using Fisher’s multiple 
comparison procedure. Differences in means with p < 0.05 were considered statistically 
significant. All analyses were performed using the Statview Statistical Package (Power 
PC version 4.51, Berkeley, California, USA) on a Macintosh computer. 
Results
Tissue distribution of TRPM6 and TRPM7 in mouse
In order to study the quantitative expression levels of TRPM6 and TRPM7 in various 
tissues, a mouse cDNA panel was constructed. Subsequently, TRPM6 and TRPM7 
mRNA levels were quantified by real-time PCR analysis and normalized for HPRT 
expression. The highest level of TRPM6 expression was measured in kidney, 
intestine and lung (figure 1A), while TRPM7 showed a ubiquitous expression pattern 
(figure 1B). To determine in more detail the intestinal site of active Mg2+ absorption 
in relation to transcellular Ca2+ absorption, mRNA expression levels of TRPM6, 
TRPM7 and TRPV6 were quantified in different segments of the mouse intestinal 
tract by real-time PCR analysis and presented relative to their total intestinal 
expression. The highly Ca2+ selective channel TRPV6 forms the apical entry 
mechanism in active Ca2+ absorption in the small intestine. TRPM6 was 
predominantly expressed in cecum and colon, whereas no expression was 
detectable in duodenum and jejunum (figure 1C). TRPM7 was equally expressed in 
the different segments of the intestinal tract. The epithelial Ca2+ channel TRPV6 was 
primarily expressed in duodenum, cecum and colon, but was not detectable in 
jejunum and ileum (figure 1C). 
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Figure 1. Expression profile of TRPM6 and TRPM7 in various mouse tissues
 
The mRNA expression levels of TRPM6 (A) and TRPM7 (B) in a panel of mouse tissues 
were measured by using quantitative real-time PCR. (C) Quantification of mRNA 
 expression levels of TRPM6 (black), TRPM7 (white) and TRPV6 (grey) along the  intestinal 
tract are presented as percentage of total intestinal mRNA expression.  
mRNA quantified by real-time PCR analysis is calculated as ratio to the HPRT RNA level. 
Data are presented as means ± SEM (n = 4). 
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metabolism of Mg2+ and Ca2+. The serum Mg2+ and Ca2+ concentrations and total 
urinary Mg2+ and Ca2+ excretion are shown in figure 2 and 3, respectively. The 
Mg2+ deficient diet resulted in significant hypomagnesemia (figure 2B), whereas 
serum Ca2+ values were not significantly altered in mice fed the different Mg2+ diets 
(figure 2A). Dietary Mg2+ restriction significantly reduced the urinary Mg2+ and 
Ca2+ excretion compared to mice fed a normal Mg2+ diet (figure 3). The Mg2+ 
enriched diet significantly increased the urinary Mg2+ and Ca2+ excretion, 
compared to mice fed the normal diet. 
Effect of dietary Mg2+ on 45Ca2+ absorption 
To investigate whether dietary Mg2+ competes with the rate of Ca2+ absorption, 
2 groups of C57BL6 mice were orally administered a 45Ca2+ solution containing 
0.1 mM Ca2+ with or without 10 mM MgCl2. Changes in the serum 45Ca2+ 
concentration (DmM) were measured within 10 minutes after administration of the 
45Ca2+ solutions. No significant differences in the rate of 45Ca2+ absorption were 
observed between the group administered the 45Ca2+ solution containing an 
excess of Mg2+ and the group that received the 45Ca2+ solution only (figure 4).  
 
Effect of dietary Mg2+ content on TRPM6 and TRPM7 expression 
The effect of dietary Mg2+ content on renal and intestinal expression of TRPM6 and 
Urine and serum analysis of mice fed various Mg2+ diets
Mice were fed a Mg2+ deficient (0.005% w/w), normal (0.19% w/w) and enriched diet 
(0.48% w/w) for 10 days. At the end of this period, mice were housed for 24 hours 
in metabolic cages and urine samples were collected to investigate the electrolyte 
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Figure 4. Effect of dietary Mg2+ content on Ca2+ absorption
 
Changes in the serum 45Ca2+ concentration (∆µM) within 10 minutes after  administration of 
45Ca2+ by oral gavage to C57BL6 mice. Data are averaged values ± SEM (n = 5) from 
mice of 12 weeks old.  ; 0.1 mM Ca2+ and ■; 0.1 mM Ca2+ + 10 mM Mg2+. 
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Figure 2. Effect of dietary Mg2+ content on serum Mg2+ and Ca2+ concentrations
 
The effect of a Mg2+ deficient diet (0.005% w/w), normal Mg2+ diet (0.19% w/w) and the 
enriched Mg2+ diet (0.48% w/w) on serum Ca2+ (A) and Mg2+ (B) concentration in 
mouse. Values are presented as means  ± SEM (n = 6). * p < 0.05 versus all groups. 
Figure 3. Effect of dietary Mg2+ content on the total urinary excretion of Mg2+ and Ca2+
 
Net urinary excretion of Mg2+ (A) and Ca2+ (B) of mice on a Mg2+ deficient diet (0.005% 
w/w), normal Mg2+ diet (0.19% w/w), and the enriched Mg2+ diet (0.48% w/w). Values are 
presented as means ± SEM (n = 6). * p < 0.05 versus all groups. # p < 0.05 versus all 
groups.  
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kidney cortex. In these immunopositive tubules, TRPM6 was localized to the apical 
membrane of DCT.  For semiquantitative assessment of TRPM6 protein expression, 
the relative amounts of immunopositive tubules in the complete kidney cortex were 
counted for each kidney section. Figure 5D presents the average values for each 
experimental group. The levels of TRPM6 protein expression in mice fed the Mg2+ 
deficient (0.005% w/w), were significantly higher than those in the other groups. The 
regulation of TRPM6 and TRPM7 mRNA levels in colon was studied. The Mg2+ 
enriched diet resulted in an upregulation of TRPM6 mRNA expression level in colon 
compared to mice on a Mg2+ deficient diet (figure 6A). Like in kidney, variation in 
dietary Mg2+ content did not alter TRPM7 mRNA expression levels in complete colon 
sections (figure 6B) and in the mucosa of the colon (data not shown). 
Hormonal regulation of renal TRPM6 and TRPM7 expression
To determine the effect of the calciotropic hormones including 1,25(OH)2D3, PTH 
and 17ß-E2, on renal mRNA expression levels of TRPM6 and TRPM7, different 
animal models were used. 1α-OHase-/- mice represent a unique animal model to 
TRPM7 mRNA was studied. The Mg2+ deficient diet resulted in a significant 
upregulation of the renal TRPM6 mRNA level (figure 5A). In addition, differences in 
dietary Mg2+ content did not influence renal TRPM7 mRNA expression (figure 5B). 
Next, the abundance of TRPM6 protein in kidneys was examined. Figure 5C 
presents representative immunofluorescence labeling of distal tubules in sections of 
kidney from mice fed the Mg2+ deficient (0.005% w/w), normal (0.19% w/w) and 
enriched diet (0.48% w/w). More TRPM6 protein was detected in tissue from mice fed 
the Mg2+ deficient (0.005% w/w) diet, as indicated by the increased staining in the 
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Figure 6.  Effect of dietary Mg2+ content on TRPM6 and TRPM7 mRNA  
expression levels in colon of mice
 
mRNA expression levels of TRPM6 (A) and TRPM7 (B) mRNA in colon of mice fed the 
 deficient Mg2+ diet (0.005% w/w), normal Mg2+ diet (0.19% w/w), and enriched Mg2+ diet 
(0.48% w/w) were assessed by quantitative real-time PCR analysis and calculated as ratio 
to HPRT RNA. Data are presented as means ± SEM (n = 6). * p < 0.05 versus 0.005% (w/w) 
Mg2+ diet. 
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Figure 5.  Effect of dietary Mg2+ content on renal expression levels of   
TRPM6 and TRPM7
 
Real-time quantitative PCR was used to determine TRPM6 and TRPM7 mRNA  expression 
levels in kidney of mice fed the deficient Mg2+ diet (0.005% w/w), normal Mg2+ diet (0.19% 
w/w), and enriched Mg2+ diet (0.48% w/w) (A,B). TRPM6 protein abundance was 
 determined by computerized analysis of immunohistochemical images and is presented 
as integrated optical density (IOD) (C,D). Data are presented as means ± SEM (n = 6). * 
p < 0.05 versus all groups.  
82 83
expression levels remained unaffected in 1α-OHase-/- compared to 1α-OHase+/- 
mice and 1α-OHase-/- mice supplemented with 1,25(OH)2D3 (figure 7A). Similarly, 
no effect was observed of PTH (figure 7C). However, a two-fold decrease in TRPM6 
mRNA expression levels was measured in kidneys of ovariectomized (OVX) rats 
(figure 7E). Importantly, administration of 17ß-E2 normalized the TRPM6 expression 
levels in kidney of OVX rats. No differences in renal expression level of TRPM7 
mRNA were observed in 1α-OHase-/-, PTX and OVX animals (figure 7B, D, F). 
Discussion 
The present study shows novel regulatory hallmarks of TRPM6 further supporting a 
gatekeeper function in the process of transepithelial Mg2+ transport. First, this 
epithelial Mg2+ channel was predominantly expressed in mouse epithelia including 
kidney, cecum, colon and lung. Second, 17ß-E2 specifically upregulated TRPM6 
mRNA expression in kidney pointing to the first magnesiotropic hormone in the 
maintenance of the Mg2+ balance. Third, Mg2+ depletion increased TRPM6 mRNA 
expression in kidney, whereas a Mg2+ enriched diet increased TRPM6 mRNA levels 
in colon. Fourth, the high abundant expression of TRPM6 in cecum and colon, 
together with the low expression level in duodenum and jejunum suggests that 
active Mg2+ absorption takes place primarily in the distal part of the intestine.
Our study showed that the expression of TRPM6 is restricted to epithelial tissues 
including kidney, whereas TRPM7 can be found in all tested tissues. Previous 
immunohistochemical studies in mouse kidney indeed indicated that TRPM6 is 
localized exclusively along the apical domain in DCT, which is in line with the 
postulated gatekeeper function in the process of active Mg2+ reabsorption (13). 
Here, we now show that Mg2+ excretion and TRPM6 expression in kidney is strongly 
regulated by the dietary Mg2+ content. Dietary Mg2+ restriction resulted in Mg2+ 
conservation, whereas a Mg2+ enriched diet increased urinary Mg2+ excretion. 
The Mg2+ deficient diet resulted in a significant upregulation of renal TRPM6 mRNA 
and protein levels, while the enriched diet tended to reduce TRPM6 abundance. 
TRPM7 expression was not influenced by the dietary Mg2+ content supporting a 
general role in cellular Mg2+ homeostasis (14, 15). Interestingly, dietary Mg2+ 
restriction in humans also leads to renal Mg2+ conservation (24-26), while high 
study the effect of the hormone 1,25(OH)2D3 (23). To investigate the effect of PTH 
and 17ß-E2, parathyroidectomized and ovariectomized rats were used, respectively 
(18, 19). Quantitative real-time PCR demonstrated that renal TRPM6 mRNA 
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Figure 7.  Effect of 1,25(OH)2D3, PTH and 17ß-E2 on the expression of TRPM6  
and TRPM7 mRNA in kidney
 
The effect of 1,25(OH)2D3, PTH and 17ß-E2 on renal TRPM6 (A, C, E) and TRPM7 (B, D, 
F) mRNA expression levels was quantified by real-time PCR analysis and  normalized for 
HPRT expression. Data are presented as means ± SEM (n = 4 - 5). * p < 0.05 versus all 
groups. 
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Despite early proposals for the existence of a specific hormonal control of the Mg2+ 
balance, our understanding of the endocrine factors that regulate circulating or 
urinary Mg2+ is incomplete. Several hormones including PTH, calcitonin, vitamin D, 
insulin, glucagons, antidiuretic hormone, aldosterone and sex steroids have been 
reported to influence the Mg2+ balance (2, 34, 35). It was suggested that these 
hormones are only indirect regulators of Mg2+ homeostasis, because Mg2+ lacks a 
specific endocrine control similar to that existing for Ca2+, Na+ and K+ (34). 
Interestingly, our study indicates a magnesiotropic role for estrogens in Mg2+ 
homeostasis via the regulation of the Mg2+ channel TRPM6. In OVX rats the renal 
TRPM6 mRNA level was significantly reduced and subsequently normalized by 
17ß-E2 supplementation. Interestingly, it has been demonstrated that postmenopausal 
hypermagnesuria significantly decreased after estrogen substitution therapy (36, 
37). This finding is in line with our results and suggests that 17ß-E2 increases Mg2+ 
reabsorption via an enhanced renal TRPM6 expression. This stimulatory effect of 
17ß-E2 could be attributable to enhanced transcriptional activity or mRNA 
stabilization. Thus far, detailed analysis did not result in 17ß-E2-responsive elements 
in the putative promoter sequence of human and mouse TRPM6. The magnesiotropic 
action of estrogens in Mg2+ homeostasis via regulation of TRPM6 could be of 
importance during the menstrual cycle, pregnancy, and pre-eclampsia. However, 
different studies measuring estrogen levels in plasma from pre-eclamptic woman 
have been inconsistent (38-41). Interestingly, menstrual migraine is preceded by a 
decline in the plasma estrogen level and shows a high incidence of free ionized 
Mg2+ deficiency (42). Further studies should elucidate the possible interrelationship 
of estrogens and TRPM6 in Mg2+ homeostasis during the menstrual cycle, 
pregnancy, and pre-eclampsia. 
Previous reports demonstrated that PTH stimulates Mg2+ reabsorption in TAL and 
DCT (43, 44). In addition, 1,25(OH)2D3 has also been shown to enhance the influx 
of Mg2+ in a mouse distal convoluted tubule (mDCT) cell line (5). Our study 
suggests that PTH and 1,25(OH)2D3 are not involved in the stimulation of Mg2+ 
reabsorption via upregulation of renal TRPM6 expression levels since 1,25(OH)2D3 
and PTH did not change the TRPM6 expression in kidney. In addition, Karbach et 
al. demonstrated that cellular Mg2+ transport in rat colon is not responsive to 
1,25(OH)2D3 (45, 46).
dietary Mg2+ intake markedly stimulates Mg2+ excretion without significant 
increases in plasma Mg2+ which is in accordance with the results of our study in 
mouse (27). Thus, upregulation of TRPM6 in kidney supports a critical role of this 
channel facilitating maximal Mg2+ reabsorption during Mg2+ deficiency. 
Interestingly, dietary Mg2+ content also influenced the Ca2+ excretion in our study 
since Mg2+ restriction resulted in Ca2+ conservation, whereas Mg2+ supplementation 
led to an increased urinary Ca2+ excretion. In accordance with this finding, Shafik 
and Quamme have shown that urinary Ca2+ excretion decreases in rats maintained 
on a low Mg2+ diet (7). This coupling between the Mg2+ and Ca2+ excretion 
observed under various dietary Mg2+ regimes could occur at the level of intestinal 
absorption and/or renal excretion. Since dietary Mg2+ contents did not affect the 
intestinal Ca2+ absorption rate, the coupling mechanism presumably resides within 
the kidney. This implies the existence of a common pathway or regulatory 
mechanism facilitating urinary Mg2+ and Ca2+ excretion. In this respect it is 
interesting to notice that paracellin-1 has been shown to be instrumental for the 
paracellular reabsorption of both divalent cations in TAL (28, 29). Importantly, the 
majority of the renal Mg2+ reabsorption takes place in this particular segment where 
the lumen positive transepithelial potential difference drives paracellular transport 
of cations (30). It can thus be envisaged that Mg2+ and Ca2+ are competitively 
transported by paracellin-1. This competition would imply that paracellular Ca2+ 
reabsorption in TAL is favored in the presence of a low luminal Mg2+ concentration 
resulting from Mg2+ deficiency. Conversely, renal Ca2+ excretion will be increased 
by a high Mg2+ load due to a Mg2+ enriched diet. Indeed, Ikari et al. demonstrated 
that 45Ca2+ transport across monolayers of cells expressing paracellin-1 is inhibited 
by increased Mg2+ concentration (31). In addition, in patients with Gitelman 
syndrome or IDHH the observed hypomagnesemia is accompanied by a seriously 
diminished urinary Ca2+ excretion (32). Thus, competition between Mg2+ and Ca2+ 
for a common paracellular route could explain the observed coupling between the 
urinary Mg2+ and Ca2+ excretion in response to different Mg2+ diets. In addition, 
the extracellular Ca2+ sensing receptor (CaSR) could play a role in the coupling 
between the Mg2+ and Ca2+ excretion under various dietary Mg2+ conditions, 
because the CaSR is believed to sense Ca2+-and Mg2+ levels and to regulate the 
reabsorption of these ions (33). 
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The unaltered expression levels of TRPM6 mRNA in colon during Mg2+ restriction 
suggests that the Mg2+ absorptive capacity is sufficient to obtain maximal 
transcellular Mg2+ transport. The ubiquitous and diet-unresponsive expression of 
TRPM7 suggests that this particular Mg2+ channel does not participate in the 
extracellular Mg2+ homeostasis. In line with previous studies, this indicates that 
TRPM7 is primarily involved in cellular Mg2+ homeostasis (14, 15). 
Interestingly, besides kidney and the intestine, TRPM6 is also highly abundant in 
lung tissue. The exact function of TRPM6 in this organ, however, remains to be 
elucidated. The importance of Mg2+ in lung is supported by the fact that dietary 
Mg2+ intake is directly related to lung function, airway reactivity and respiratory 
symptoms in the general population (53). Moreover, treatment of subjects with 
chronic asthma is currently receiving attention, because of a role for Mg2+ in 
relaxation of arterial and bronchial smooth muscle cells (54-56). Further research is 
certainly needed to determine the precise function of TRPM6 in lung (patho)
physiology. 
In conclusion, TRPM6 is predominantly expressed in kidney, cecum, colon and lung 
suggesting that these organs are primarily involved in Mg2+ (re)absorption. 
Furthermore, we provide evidence that the intestinal site of active Mg2+ absorption 
is primarily located in the distal part of the intestine. In addition, 17ß-E2 and dietary 
Mg2+ are positively involved in the regulation of TRPM6 underlining the gatekeeper 
function of this epithelial Mg2+ channel. 
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The predominant expression of TRPM6 in cecum and colon together with the low 
expression level in duodenum and jejunum suggests that active Mg2+ absorption 
takes place exclusively in the distal part of the intestine. Although initial studies 
already detected TRPM6 in small intestine, a quantitative comparison in the 
expression along the gastrointestinal tract was, however, not established (11, 13). The 
highly abundant expression of TRPM6 in colon is further supported by the fact that 
colectomy in rat results in a syndrome of Mg2+ deficiency with decreased urinary 
Mg2+ excretion, normal serum Mg2+ levels and interestingly decreased bone Mg2+ 
content (47). Remarkably, our data further implies that active intestinal Mg2+ 
absorption only partly overlaps with the process of active Ca2+ absorption. The 
transepithelial absorption of Ca2+ takes predominantly place in duodenum and 
possibly colon as illustrated by the robust expression of the epithelial Ca2+ channel 
TRPV6 in these particular intestinal segments. TRPV6 constitutes the luminal Ca2+ 
entry mechanism in active Ca2+ absorption (48, 49). Thus, active Mg2+ and Ca2+ 
absorption simultaneously take place in the distal part of the intestine, whereas in 
duodenum solely active Ca2+ absorption occurs. Expression levels of TRPM6 mRNA 
in colon were upregulated by the Mg2+ enriched diet, whereas Mg2+ restriction did 
not significantly affect TRPM6 mRNA expression levels. This suggests that mice can 
increase their transcellular Mg2+ absorption capacity when fed a Mg2+ enriched diet. 
In comparison with Ca2+ absorption and TRPV6 expression, Brown et al. demonstrated 
that in rats fed a low Ca2+ diet, TRPV6 mRNA levels in duodenum were significantly 
increased (50). In contrast, Van Abel et al. showed that supplementation of 1α-OHase 
knockout mice with a high dietary Ca2+ intake resulted in an increase of duodenal 
TRPV6 mRNA levels (51). Thus, if the calciotropic hormone 1,25(OH)2D3 is not 
present, duodenal TRPV6 mRNA expression is upregulated in response to high 
dietary Ca2+ intake. The important difference between intestinal regulation of TRPM6 
and TRPV6 is that there is not a magnesiotropic hormone identified, which regulates 
intestinal TRPM6 expression and thereby Mg2+ absorption. We suggest that 
physiologically, an excess of Mg2+ absorption due to high dietary Mg2+ intake 
together with TRPM6 upregulation in colon, can be totally corrected by the kidney. 
Normally the kidney excretes only 2-4% of the filtered Mg2+ but is capable of 
increasing fractional excretion to nearly 100% in the face of increased serum Mg2+ 
levels (52). Thus, the absence of a magnesiotropic hormone regulating intestinal 
TRPM6 expression and Mg2+ absorption could explain why TRPM6 mRNA levels in 
colon are upregulated in response to high dietary Mg2+ content. 
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Abstract
The Mg2+ and Ca2+ balance is controlled by the concerted action of intestinal 
absorption, renal excretion, and exchange with bone of these ions. Primary 
disturbances of the Ca2+ balance often display a concomitant disturbance of Mg2+ 
homeostasis and vice versa.  The kidney tightly regulates the amount of Mg2+ and 
Ca2+ that is excreted in the urine. The epithelial Mg2+ channel transient receptor 
potential melastatin member 6 (TRPM6) is predominantly expressed in kidney and 
colon and constitutes the gatekeeper and postulated rate-limiting entry step in 
active Mg2+ (re)absorption. The epithelial Ca2+ channels TRPV5 and TRPV6 have a 
similar function in active Ca2+ (re)absorption in kidney and small intestine, 
respectively. The aim of this study was to study the Mg2+ balance and regulation of 
TRPM6 and TRPM7 by dietary Mg2+ content in TRPV5 knockout (TRPV5-/-) mice, 
which display severe hypercalciuria and hypervitaminosis D-mediated Ca2+ 
hyperabsorption. First, ablation of the TRPV5 gene in mice resulted in 
hypermagnesuria and a significant downregulation of the renal TRPM6 mRNA and 
protein expression levels. Second, a Mg2+-deficient diet upregulated renal TRPM6 
mRNA and protein expression levels in wild-type (TRPV5+/+) and TRPV5-/- mice and 
resulted in concomitant renal Mg2+ and Ca2+ conservation. Third, dietary Mg2+ 
supplementation resulted in increased expression levels of TRPM6 mRNA in colon 
and increased the urinary excretion of Mg2+ and Ca2+. Fourth, this study provided 
evidence that hypervitaminosis D, which is present in TRPV5-/- mice, and not the lack 
of TRPV5 caused the hypermagnesuria. The results of this study showed that the 
Mg2+ and Ca2+ balance in TRPV5-/- mice is tightly coupled and provided new insight 
about the regulation of TRPM6 in the absence of the epithelial Ca2+ channel TRPV5.
Introduction
Numerous enzymatic reactions are dependent on the presence of Mg2+ and Ca2+. 
Moreover, maintenance of the body Mg2+ and Ca2+ balance is of crucial importance 
for many physiological functions including neural excitability, muscle contraction, 
and cell adhesion (1-5). The Mg2+ and Ca2+ balance is controlled by the concerted 
action of intestinal absorption, renal excretion, and exchange with bone. In kidney, 
the majority of Mg2+ and Ca2+ reabsorption occurs via passive paracellular 
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Both TRPM6 and TRPM7 are unique bifunctional proteins as they combine channel 
function with protein kinase activity (13, 18, 19). The analogous epithelial influx 
pathway for Ca2+ is constituted by the epithelial Ca2+ channels TRPV5 and TRPV6 
(1). These channels are by far the most Ca2+ selective channels of the TRP 
superfamily and constitute the rate-limiting influx step in active Ca2+ (re)absorption 
that takes place in kidney, small intestine, placenta and bone (1, 20).
Many diseases have been reported in which patients show mutual disturbances of 
the Mg2+ and Ca2+ balance and a tight coupling of the Mg2+ and Ca2+ homeostasis 
is frequently observed in animal models (6, 21). For most of these diseases, the 
cascades of cellular and molecular events that lead to this combined disturbance are 
largely unknown. Previous studies showed that TRPV5 knockout (TRPV5-/-) mice 
displayed renal Ca2+ wasting, hypervitaminosis D, compensatory Ca2+ hyperabsorption 
and bone abnormalities (22). Since mutual disturbances of the Mg2+ and Ca2+ 
balance are common and TRPV5-/- mice display renal Ca2+ wasting, the aim of the 
present study was to reveal the effect of TRPV5 ablation and the effect of dietary 
Mg2+ content on the Mg2+ and Ca2+ balance in TRPV5-/- mice. To this end, the 
current study investigated the systemic Mg2+ balance and the expression levels of 
the Mg2+ transport proteins TRPM6 and TRPM7 in kidney and colon of TRPV5-/- mice 
fed a Mg2+-deficient, Mg2+-normal or a Mg2+-enriched diet. In addition, the effect of 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) on the urinary excretion of Mg2+ was studied 
in 25-hydroxyvitamin D3-1α-hydroxylase knockout (1α-OHase–/–) and TRPV5/1α-
hydroxylase double knockout (TRPV5–/–/1α-OHase–/–) mice, which show undetectable 
serum 1,25(OH)2D3 levels because the ablation of the cytochrome P450 enzyme 
25-hydroxyvitamin D3-1α-hydroxylase prevents the synthesis of 1,25(OH)2D3 (22-24).
Materials and methods
Animal experiments
To study the effect of dietary Mg2+ content on TRPM6 and TRPM7 expression in 
kidney and colon, wild-type (TRPV5+/+), and TRPV5 knockout (TRPV5-/-) mice 
(12 weeks of age) were fed for 10 days a Mg2+-deficient diet (0.005% w/w Mg2+), 
a Mg2+-normal diet (0.19% w/w Mg2+), or a Mg2+-enriched diet (0.48% w/w Mg2+; 
SSNIFF spezialdiäten GmbH, Germany). 
transport in the proximal tubule and the thick ascending loop of Henle (1, 6, 7). The 
distal convoluted tubule (DCT) reabsorbs 5-10% of the filtered Mg2+ and beyond 
this segment virtually no Mg2+ reabsorption takes place. Reabsorption of Mg2+ in 
DCT is active and transcellular in nature and determines the final amount of Mg2+ 
excreted in the urine. Of the filtered Ca2+, approximately 10-15% is actively 
reabsorbed in DCT and the connecting tubule (CNT). Thus, the DCT fine-tunes the 
urinary Mg2+ concentration and DCT and CNT together do the same for the urinary 
Ca2+ concentration. Similarly, intestinal Ca2+ and Mg2+ absorption consists of a 
passive paracellular and an active transcellular pathway (8-10).  
Transcellular transport of Mg2+ and Ca2+ through the renal and intestinal epithelia 
can be envisaged by three sequential steps. First, driven by a favorable 
transmembrane potential, Mg2+ enters the cell through the luminal Mg2+ channel 
TRPM6, whereas Ca2+ enters through TRPV5 and TRPV6. The second step is the 
intracellular diffusion to the basolateral side of the cell. During this process Ca2+ 
is bound to the Ca2+-binding proteins calbindinD9K and/or calbindin-D28K. 
The presence and identity of the cytosolic Mg2+ binding proteins facilitating 
intracellular diffusion of Mg2+ are completely unknown. Finally, Mg2+ and Ca2+ are 
extruded at the basolateral side of the cell. Ca2+ is extruded basolaterally by two 
pathways: the plasma membrane Ca2+-ATPase and the Na+/Ca2+ exchanger. 
The protein(s) involved in the extrusion of Mg2+ remain(s) to be identified. Since the 
luminal Mg2+ and Ca2+ influx forms the initial step of transcellular transport, the 
transporters involved in this process provide efficient targets for the regulation of 
Mg2+ and Ca2+ (re)absorption.
A positional candidate gene-cloning approach identified mutations of TRPM6 in 
patients with hypomagnesemia with secondary hypocalcemia (HSH) (8, 11). The 
TRPM6 protein is a member of the TRP superfamily and is homologous to the more 
ubiquitously expressed Mg2+ channel TRPM7. The epithelial Mg2+ channel TRPM6 
facilitates Mg2+ influx in the process of active Mg2+ (re)absorption and is localized 
along the luminal membrane of the DCT and in the brush border membrane of the 
small intestine (12). TRPM7 has been identified as a Mg2+-permeable ion channel 
primarily required for cellular Mg2+ homeostasis (13-15). TRPM6 and TRPM7 are 
cation channels with permeability for Mg2+, which play a pivotal role in Mg2+ 
homeostasis in vertebrates at the body and cellular level, respectively (8, 11, 15-17). 
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TRPV5-/- mice were generated as described previously (22). During the last 24 hours 
of the dietary treatment, animals were housed in metabolic cages and urine was 
collected. Subsequently, blood samples were taken and the animals were sacrificed. 
Kidney and colon tissues were sampled and frozen immediately in liquid nitrogen. 
In order to evaluate the effect of the active form of vitamin D, 1,25-dihydroxyvitamin 
D3 (1,25(OH)2D3) on the Mg2+ balance, the 24-hour urinary Mg2+ excretion was 
analyzed of TRPV5+/+, TRPV5-/-, 25-hydroxyvitamin D3-1α-hydroxylase knockout 
(1α-OHase–/–) (25) and TRPV5/1α-hydroxylase double knockout (TRPV5–/– 
/1α-OHase–/–) mice. Cross-breeding 1α-OHase–/– and TRPV5–/– mice resulted in 
offspring heterozygous for both TRPV5 and 1α-OHase (TRPV5+/–/1α-OHase+/–). 
This offspring was subsequently intercrossed to obtain TRPV5–/–/1α-OHase–/– mice 
(24). Genotypes were determined by PCR analysis, using specific primers as 
described previously (22, 25). In order to obtain 24-hour urine samples of all mouse 
genotypes, 12 week old mice were kept in a light- and temperature-controlled room 
in metabolic cages that enabled 24-h urine collection. Standard pelleted chow (1.1% 
w/w Ca2+, 0.19% w/w Mg2+, SSNIFF spezialdiäten GmbH, Soest, Germany) and 
drinking water were available ad libitum. The animal ethics board of the Radboud 
University Nijmegen Medical Centre approved all experimental procedures.
Quantitative real-time PCR analysis
Total RNA was extracted from kidney and colon using TriZol Total RNA Isolation 
Reagent (Life Technologies BRL, Breda, the Netherlands) according to the 
manufacturer’s protocol. The obtained RNA was subjected to DNase treatment 
(Promega, Madison, WI, USA) to prevent genomic DNA contamination. Thereafter, 
2 µg of RNA was reverse transcribed by Molony-Murine Leukemia Virus-Reverse 
Transcriptase (Invitrogen, Breda, the Netherlands) as described previously (26). 
The cDNA was used to determine TRPM6 and TRPM7 mRNA expression levels, as 
well as mRNA levels of the housekeeping gene hypoxanthine-guanine phosphoribosyl 
transferase (HPRT) as an endogenous control. The mRNA expression levels were 
quantified by real-time PCR on an ABI Prism 7700 Sequence Detection System 
(PE Biosystems, Rotkreuz, Switzerland). Primers and probes that target the TRPM6, 
TRPM7 and HPRT cDNA were designed using the Primer Express software (Applied 
Biosystems, Foster City, CA, USA) and are listed in table 1.
Chapter 4
4
  Hypermagnesuria in TRPV5 knockout mice
Ta
b
le
 1
. 
S
eq
ue
nc
es
 o
f p
rim
er
s 
an
d
 T
aq
m
an
 p
ro
b
es
 fo
r 
re
al
-t
im
e 
q
ua
nt
ita
tiv
e 
P
C
R
G
en
e 
 
F
o
rw
ar
d
 p
ri
m
er
 
R
ev
er
se
 p
ri
m
er
 
P
ro
b
e
H
P
R
T 
M
 
5’
-T
TA
TC
AG
AC
TG
A
AG
AG
C
TA
C
TG
TA
AT
G
AT
C
-3
’ 
5’
-T
TA
C
C
AG
TG
TC
A
AT
TA
TA
TC
TT
C
A
AC
A
AT
C
-3
’ 
5’
-T
G
AG
AG
AT
C
AT
C
TC
C
AC
C
A
AT
A
AC
TT
TT
AT
G
TC
C
C
-3
’
TR
P
M
6 
M
 
5’
-A
A
AG
C
C
AT
G
C
G
AG
TT
AT
C
AG
C
-3
’ 
5’
-C
TT
C
AC
A
AT
G
A
A
A
AC
C
TG
C
C
C
-3
’ 
5’
-C
C
TG
G
TC
TG
AG
G
AT
G
AT
G
TT
C
TC
A
AG
C
C
-3
’
TR
P
M
7 
M
 
5’
-G
G
TT
C
C
TC
C
TG
TG
G
TG
C
C
TT
-3
’ 
5’
-C
C
C
C
AT
G
TC
G
TC
TC
TG
TC
G
T-
3’
 
5’
-T
TC
C
C
A
AG
TG
C
TG
TT
TC
TC
C
C
C
C
A-
3’
P
C
R
 p
ri
m
er
s 
an
d
 f
lu
o
re
sc
en
t p
ro
b
es
 (
5’
FA
M
–3
’T
A
M
R
A
) 
w
er
e 
d
es
ig
ne
d
 u
si
ng
 t
he
 c
o
m
p
ut
er
 p
ro
g
ra
m
 P
ri
m
er
 E
xp
re
ss
 (
A
p
p
lie
d
 B
io
sy
st
em
s,
 N
ie
u
w
er
ke
rk
 a
an
 d
e 
Ijs
se
l, 
th
e 
N
et
he
rl
an
d
s)
 a
nd
 p
ur
ch
as
ed
 f
ro
m
 B
io
le
g
io
 (
N
ijm
eg
en
, 
th
e 
N
et
he
rl
an
d
s)
. 
TR
P
M
6:
 t
ra
ns
ie
nt
 r
ec
ep
to
r 
p
o
te
nt
ia
l 
m
el
as
ta
tin
 m
em
b
er
 6
; 
TR
P
M
7:
 t
ra
ns
ie
nt
 r
ec
ep
to
r 
p
o
te
nt
ia
l m
el
as
ta
tin
 m
em
b
er
 7
; 
H
P
R
T:
 h
yp
ox
an
th
in
e
-g
ua
ni
ne
 p
ho
sp
ho
ri
b
o
sy
l t
ra
ns
fe
ra
se
. 
100 101
Mg2+-deficient diet resulted in a significant hypomagnesemia in TRPV5+/+ mice 
(0.59 ± 0.05 mM vs. 1.49 ± 0.08 mM, p < 0.05) as well as in TRPV5-/- mice (0.67 
± 0.05 mM vs. 1.46 ± 0.02 mM) (figure 1). 
In contrast, no significant differences were observed in serum Mg2+ and Ca2+ 
concentrations when mice were fed the Mg2+-enriched diet. To examine the effect 
of dietary Mg2+ content on the urinary Mg2+ and Ca2+ excretion in TRPV5-/- mice, 
both TRPV5+/+ and TRPV5-/- mice were placed in metabolic cages to enable 24 
hours urine sample collection. TRPV5-/- mice fed a Mg2+-normal (0.19% w/w) diet 
displayed robust hypercalciuria compared to TRPV5+/+ mice (9.9 ± 0.7 µmol/24h/
mouse vs. 0.6 mM ± 0.3 µmol/24h/mouse, respectively, p < 0.05). Hypercalciuria 
in TRPV5-/- mice was observed in all three dietary Mg2+ groups. However, the total 
amount of urinary Ca2+ excreted in 24 hours by TRPV5-/- mice varied among these 
groups. TRPV5-/- mice on a Mg2+-deficient diet excreted significantly less Ca2+ than 
TRPV5-/- mice on a Mg2+-normal diet (1.9 µmol/24h/mouse ± 0.8 vs. 9.9 µmol/24h/
mouse ± 0.7, respectively, p < 0.05). In contrast, TRPV5-/- mice on a Mg2+-enriched 
diet excreted significantly more Ca2+ than TRPV5-/- mice fed a Mg2+-normal diet 
(25.9 ± 3.5 µmol/24h/mouse vs. 9.9 ± 0.7 µmol/24h/mouse, respectively, p < 0.05) 
(figure 2A). Interestingly, besides hypercalciuria, TRPV5-/- mice display robust 
hypermagnesuria compared to TRPV5+/+ mice (32.6 ± 6.6 µmol/24h/mouse vs. 5.6 
± 3.0 µmol/24h/mouse, respectively, p < 0.05) (figure 2B). 
Similarly with hypercalciuria in TRPV5-/- mice, the presence of hypermagnesuria in 
these mice is independent of dietary Mg2+ content but the magnitude of the 
hypermagnesuria decreases significantly when fed a Mg2+-deficient diet compared 
to a Mg2+-normal diet (0.2 ± 0.1 µmol/24h/mouse vs. 5.6 ± 3.0 µmol/24h/mouse, 
respectively, p < 0.05). In addition, increased Mg2+ excretion was observed when 
TRPV5-/- mice were fed the Mg2+-enriched diet compared to TRPV5-/- mice fed the 
Mg2+-normal diet (92.6 ± 7.7 µmol/24h/mouse vs. 5.6 ± 3.0 µmol/24h/mouse, 
respectively, p < 0.05) (figure 2B). 
Effect of dietary Mg2+ content on the renal TRPM6 and TRPM7 expression levels
To determine the molecular mechanism responsible for the hypermagnesuria 
presented by TRPV5-/- mice, renal TRPM6 and TRPM7 mRNA expression levels 
were determined by quantitative real-time PCR. A significant decrease in renal 
Analytical procedures
Serum Mg2+ and Ca2+ concentrations were measured using a colorimetric assay kit 
according to the manufacturer’s protocol (Roche Diagnostics, Almere, the Netherlands). 
Urinary Mg2+ and Ca2+ concentration was determined by atomic absorption 
spectrophotometry on a Perkin Elmer Analyst 300 (Perkin Elmer, Milano, Italy). 
Immunohistochemistry
Immunohistochemical staining was performed on 7 µm cryosections of periodate-
lysine- paraformaldehyde–fixed kidney samples. Sections were stained with an 
affinity-purified guinea pig anti-TRPM6 antibody, as described previously (12). 
Pictures covering the entire kidney cortex were taken with a Zeiss fluorescence 
microscope (Sliedrecht, the Netherlands) equipped with a digital photo camera 
(Nikon DMX1200). For semi-quantitative determination of protein levels, images 
were analyzed with the Image Pro Plus 4.1 image analysis software (Media 
Cybernetics, Silver Spring, MD, USA), resulting in semi-quantification of the protein 
levels as the mean of integrated optical density (27).
Statistical analysis
Values are expressed as means ± SEM. Differences between groups were tested 
by one-way ANOVA and evaluated using Fisher's multiple comparison procedure. 
Differences in means with p < 0.05 were considered statistically significant. 
All analyses were performed using the Statview Statistical Package (Power PC 
version 4.51; Berkeley, CA, USA) on a Macintosh computer. 
Results
Effect of dietary Mg2+ content on the Mg2+ and Ca2+ balance 
TRPV5-/- mice and their TRPV5+/+ (wild-type) littermates were fed a Mg2+-deficient 
(0.005% w/w), Mg2+-normal (0.19% w/w) and a Mg2+-enriched diet (0.48% w/w) for 
10 days. Directly after this period blood was sampled for Mg2+ and Ca2+ analysis. 
The serum Mg2+ and Ca2+ concentrations are depicted in figure 1. As previously 
shown, inactivation of both alleles of the TRPV5 gene did not result in altered serum 
Mg2+ and Ca2+ concentrations (22). Moreover, dietary Mg2+ content did not 
influence serum Ca2+ levels in TRPV5+/+ and TRPV5-/- mice. Interestingly, the 
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expression, the relative amounts of immunopositive tubules in the total kidney 
cortex were counted for each section. The averaged values for each experimental 
group are presented in figure 4B. Within all dietary groups, significantly reduced 
TRPM6 protein abundance was detected in TRPV5-/- mice compared to TRPV5+/+ 
mice (All values TRPV5+/+ vs. TRPV5-/-, respectively: Mg2+-deficient diet; 251 ± 61 
vs. 102 ± 46, Mg2+-normal diet; 100 ± 41 vs. 19 ± 4, Mg2+-enriched diet; 129 ± 19 
vs. 42 ± 15, p < 0.05), whereas an increase in renal TRPM6 protein expression was 
observed in TRPV5+/+ and TRPV5-/- mice fed the Mg2+-deficient diet compared to 
those mice fed the Mg2+-normal diet (All values Mg2+-deficient diet vs. Mg2+-normal 
diet, respectively: TRPV5+/+; 251 ± 61 vs. 100 ± 41 and TRPV5-/-; 102 ± 46 vs. 19 
± 4, p < 0.05), (figure 4).  
Effect of dietary Mg2+ content on TRPM6 and TRPM7 expression in colon 
The effect of dietary Mg2+ content on intestinal TRPM6 and TRPM7 mRNA 
expression levels was studied by quantitative real-time PCR. The abundance of 
TRPM6 mRNA in colon of TRPV5+/+ and TRPV5-/- mice was not significantly 
TRPM6 mRNA expression was observed in TRPV5-/- mice fed a Mg2+-normal and 
Mg2+-enriched diet compared to TRPV5+/+ mice on a Mg2+-normal and 
Mg2+-enriched diet, respectively (0.019 ± 0.004 and 0.015 ± 0.001 vs. 0.033 ± 
0.005 0.026 ± 0.002, respectively, p < 0.05) (figure 3A). Interestingly, increased 
renal TRPM6 mRNA expression levels were observed in TRPV5+/+ and TRPV5-/- 
mice fed a Mg2+-deficient diet (0.049 ± 0.006 and 0.047 ± 0.009, respectively) 
compared to TRPV5+/+ and TRPV5-/- mice, respectively, fed a Mg2+-normal (0.034 
± 0.005 and 0.019 ± 0.004, respectively, p < 0.05) or a Mg2+-enriched diet (0.026 
± 0.002 and 0.015 ± 0.001, respectively, p < 0.05)  (figure 3A). The Mg2+-enriched 
diet did not result in altered renal TRPM6 mRNA levels in TRPV5+/+ and TRPV5-/- 
mice compared to both mice fed the Mg2+-normal diet. No difference in TRPM6 
mRNA expression was observed between TRPV5+/+ and TRPV5-/- mice fed a 
Mg2+-deficient diet. In contrast to TRPM6, TRPM7 mRNA expression levels were 
unaffected in TRPV5-/- mice. Furthermore, renal TRPM7 mRNA expression levels 
were not altered by dietary Mg2+ content in these mice. Next, the abundance of 
TRPM6 protein in kidneys was examined by immunohistochemistry. Figure 4A 
presents representative immunofluorescence labeling of DCT in renal sections of 
mice fed the various Mg2+ diets. In order to semi-quantify TRPM6 protein 
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Figure 2.  Effect of dietary Mg2+ content on the 24-h urinary Mg2+ and Ca2+  
excretion
 
Net urinary excretion of Ca2+ (A) and Mg2+ (B) in TRPV5+/+ (black bars) and TRPV5-/- mice 
(white bars) on a Mg2+-deficient diet (0.005% w/w), Mg2+-normal diet (0.19% w/w), and 
Mg2+-enriched diet (0.48% w/w). Values are presented as means ± SEM  
(n = 6). # p < 0.05 versus TRPV5+/+ mice fed a 0.005% w/w Mg2+ diet. * p < 0.05  
versus TRPV5+/+ mice fed a 0.19% w/w Mg2+ diet. ‡ p < 0.05 versus TRPV5+/+ mice  
fed a 0.48% w/w Mg2+ diet.  
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Figure 1.  Effect of dietary Mg2+ content on serum Mg2+ and Ca2+   
concentrations
 
The effect of a Mg2+-deficient diet (0.005% w/w), Mg2+-normal diet (0.19% w/w), and Mg2+-
enriched diet (0.48% w/w) on serum Ca2+ (A) and Mg2+ (B) concentrations in TRPV5+/+ 
(black bars) and TRPV5-/- mice (white bars). Values are presented as means  
± SEM (n = 6). * p < 0.05 versus all groups fed a 0.19% w/w and 0.48% w/w Mg2+ diet.  
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different when fed the same diet (figure 4). However, the Mg2+-enriched diet 
resulted in a significant upregulation of TRPM6 mRNA expression levels in colon of 
TRPV5+/+ and TRPV5-/- mice compared to both groups, respectively, fed the 
Mg2+-deficient diet (0.54 ± 0.09 and 0.49 ± 0.08 vs. 0.27 ± 0.02 and 0.33 ± 0.05, 
respectively, p < 0.05) (figure 4A). In addition, no differences in TRPM7 mRNA 
expression levels in colon were observed between TRPV5+/+ and TRPV5-/- mice. 
Moreover, differences in dietary Mg2+ content did not influence TRPM7 mRNA 
expression levels in colon of both TRPV5+/+ and TRPV5-/- mice (figure 4B). 
Effect of 1,25(OH)2D3 on urinary excretion of Mg2+ 
To assess whether hypervitaminosis D in TRPV5–/– mice has an effect on the 
amount of urinary Mg2+ excreted, TRPV5+/+, TRPV5–/–, 1α-OHase–/– and TRPV5–/–
/1α-OHase–/– mice were placed in metabolic cages to collect urine over a 24 hour 
period, enabling the subsequent analysis of the urinary Mg2+ excretion. 
Hypermagnesuria was observed for TRPV5–/– mice compared to wild-type mice 
(47.3 ± 4.7 µmol/24h/mouse vs. 23.7 ± 3.9 µmol/24h/mouse, respectively, p < 0.05), 
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Figure 4.  Effect of dietary Mg2+ content on TRPM6 and TRPM7 mRNA  
expression levels in colon of TRPV5+/+ and TRPV5-/- mice
 
mRNA expression levels of  TRPM6 (A) and TRPM7 (B) mRNA in colon of TRPV5+/+ and 
TRPV5-/- mice fed the Mg2+-deficient diet (0.005% w/w), Mg2+-normal diet (0.19% w/w), and 
Mg2+-enriched diet (0.48% w/w) were assessed by quantitative real-time PCR  analysis and 
calculated as ratio to HPRT mRNA expression levels. Data are presented as means ± SEM 
(n = 6). * p < 0.05 versus all groups fed the 0.005% w/w Mg2+ diet. HPRT: hypoxanthine-
guanine phosphoribosyltransferase.   
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Figure 3.  Effect of dietary Mg2+ content on renal TRPM6 and TRPM7  
expression levels
 
Real-time quantitative PCR was used to determine TRPM6 (A) and TRPM7 (B) mRNA 
expression levels in kidney of TRPV5+/+ (black bars) and TRPV5-/- mice (white bars) fed a 
Mg2+-deficient diet (0.005% w/w), Mg2+-normal diet (0.19% w/w), and Mg2+ -enriched diet 
(0.48% w/w). TRPM6 protein abundance was determined by computerized analysis of 
immunohistochemical images and is presented as integrated optical density (IOD)  
(C and D). Data are presented as means ± SEM (n = 6). † p < 0.05 versus TRPV5+/+ mice 
fed a 0.19% w/w, Mg2+ diet. # p < 0.05 versus TRPV5-/- mice fed a 0.19% w/w Mg2+ diet.  
* p < 0.05 versus TRPV5+/+ mice fed a 0.19% w/w Mg2+ diet. ‡ p < 0.05  versus TRPV5+/+ 
mice fed a 0.48% w/w Mg2+ diet. † p < 0.05 versus TRPV5+/+ mice fed a 0.48% w/w Mg2+ 
diet. Values are presented as a percentage of the value observed for TRPV5+/+ mice fed a 
Mg2+-normal diet (0.19% w/w).
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excretion (28). The mechanism responsible for the concomitant excretion of Ca2+ in 
response to altered dietary Mg2+ intake remains elusive. Possibly, Mg2+ and Ca2+ 
are competitively (re)absorbed in intestine and kidney via a paracellular pathway. 
Thus, in the presence of low luminal Mg2+ concentrations when fed the Mg2+-deficient 
diet, Ca2+ (re)absorption is favoured, which could explain the renal conservation of 
Ca2+. Conversely, the Mg2+-enriched diet could result in a high luminal Mg2+-load 
in intestine and kidney resulting in decreased (re)absorption of Ca2+. Therefore, 
competition between Mg2+ and Ca2+ for a common paracellular route could explain 
the observed coupling between the urinary Mg2+ and Ca2+ excretion in response 
to different Mg2+ diets. In addition, the extracellular Ca2+ sensing receptor could 
play a role in the coupling between the Mg2+ and Ca2+ excretion under various 
dietary Mg2+  conditions, because the Ca2+ sensing receptor is believed to sense 
Ca2+ and Mg2+ levels and to regulate the (re)absorption of these ions (29). 
The Mg2+-deficient diet significantly upregulated renal TRPM6 mRNA and protein 
levels, possibly maximizing Mg2+ reabsorption in the presence of a reduced filtered 
Mg2+ load. Although TRPV5-/- mice fed the Mg2+-deficient diet were hypomagnesemic, 
these mice still displayed hypermagnesuria compared to TRPV5+/+ mice fed the 
whereas the 1α-OHase–/– and TRPV5–/–/1α-OHase–/– mice, which show undetectable 
levels of serum 1,25(OH)2D3, show significantly lowered 24 hour urinary Mg2+ 
excretion compared to TRPV5+/+ mice (6.5 ± 3.8 µmol/24h/mouse and 5.1 ± 2.9 
µmol/24h/mouse, respectively, vs. 23.7 ± 3.9 µmol/24h/mouse, p < 0.05) (figure 5). 
Discussion
This present study showed that the Mg2+ and Ca2+ balance in TRPV5-/- mice is 
tightly coupled and how TRPM6 is regulated in the absence of the epithelial Ca2+ 
channel TRPV5. First, ablation of the TRPV5 gene in mice resulted in robust 
hypermagnesuria and a significant reduction in renal TRPM6 mRNA and protein 
abundance. TRPM7 mRNA expression levels in kidney and colon were unaltered in 
TRPV5-/- mice. Second, dietary Mg2+ restriction resulted in upregulation of renal 
TRPM6 expression and simultaneous renal Mg2+ and Ca2+ conservation in 
TRPV5+/+ and TRPV5-/- mice. Third, dietary Mg2+ supplementation resulted in an 
upregulation of TRPM6 expression levels in colon of both TRPV5+/+ and TRPV5-/- 
mice and increased the urinary excretion of Mg2+ and Ca2+. Fourth, absence of 
1,25(OH)2D3 results in hypomagnesuria even in mice in which TRPV5 is knocked out.
Our study demonstrated that TRPV5-/- mice, which display robust renal Ca2+ 
wasting and compensatory intestinal Ca2+ hyperabsorption (22), also present 
hypermagnesuria. Interestingly, serum Mg2+ levels and TRPM6 mRNA expression 
levels in colon were unaffected, whereas renal TRPM6 expression levels were 
downregulated in TRPV5-/- mice. Although reduced renal TRPM6 expression levels 
can explain increased urinary Mg2+ excretion, the mechanism underlying diminished 
TRPM6 expression is elusive. 
In addition, Mg2+ excretion and TRPM6 expression in kidney and colon are strongly 
regulated by dietary Mg2+ content in TRPV5-/- mice. Dietary Mg2+ restriction 
resulted in Mg2+ conservation, whereas a Mg2+-enriched diet increased urinary 
Mg2+ excretion. Interestingly, the dietary Mg2+ content also influenced the Ca2+ 
excretion in TRPV5-/- mice. Mg2+ restriction resulted in Ca2+ conservation, whereas 
Mg2+ supplementation stimulated urinary Ca2+ excretion. Similarly, Shafik and 
Quamme reported that rats fed a low Mg2+-diet displayed decreased urinary Ca2+ 
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Figure 5. The effect of 1,25(OH)2D3 on urinary Mg2+ excretion 
Urinary Mg2+ excretion was determined in wild-type (TRPV5+/+), TRPV5 knockout  
(TRPV5-/-), 1α-hydroxylase knockout (1α-OHase–/–) and TRPV5/1α-hydroxylase double 
knockout mice (TRPV5–/–/1α-OHase–/–). Data are presented as means ± SEM (n = 5). 
*p < 0.05 versus TRPV5+/+ mice.   
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of 1,25(OH)2D3 in the Mg2+ homeostasis of these mice, the Mg2+ balance and 
TRPM6 expression levels in kidney and colon of 1α-OHase–/– mice should be 
studied after different dietary Mg2+ regimes and during 1,25(OH)2D3 supplementation. 
Moreover, the observed hypomagnesuria in TRPV5–/–/1α-OHase–/– mice strongly 
suggest the involvement of hypervitaminosis D as a cause for the hypermagnesuria 
in TRPV5-/- mice. Therefore, we hypothesize that hypervitaminosis D in TRPV5-/- 
mice, which stimulates the compensatory hyperabsorption of Ca2+, results in 
parallel hyperabsorption of Mg2+. Consequently, to maintain a normal Mg2+ balance 
the surplus of Mg2+ absorbed needs to be corrected by the kidney, which responds 
by downregulation of TRPM6 resulting in hypermagnesuria. Although there is 
evidence that increased paracellular Mg2+ transport can be stimulated by 
1,25(OH)2D3, the presence of simultaneous hyperabsorption of Mg2+ and Ca2+ in 
TRPV5-/- mice needs further research (35). Karbach demonstrated that cellular 
Mg2+ transport in rat colon is not responsive to 1,25(OH)2D3 and paracellular 
transport of Ca2+ has been suggested to be positively influenced by 1,25(OH)2D3 
via an yet unknown mechanism (1, 36, 37). In the intestinal tract, the duodenum 
constitutes the site which absorbs most of the ingested Ca2+ and would therefore 
be the obvious segment to study simultaneous 1,25(OH)2D3-induced hyperabsorption 
of Mg2+ and Ca2+ (1, 36, 37). Possibly hypervitaminosis D stimulates paracellular 
Mg2+ and Ca2+ transport or increases transcellular Mg2+ absorption via TRPM6 in 
colon. Whether hypervitaminosis D results in hypermagnesuria, the Mg2+ balance 
of TRPV5+/+ mice with induced hypervitaminosis D needs to be investigated. 
Although it is tempting to speculate that hypermagnesuria and renal TRPM6 
downregulation in TRPV5-/- mice is caused by hypervitaminosis D, the Mg2+ 
balance and TRPM6 expression in kidney and intestine of 1α-OHase–/– and TRPV5–
/–/1α-OHase–/– mice could provide additional evidence to delineate the role and 
mechanism of the coupled Mg2+ and Ca2+ balance with respect to 1,25(OH)2D3.
In conclusion, TRPV5-/- mice, which display hypercalciuria, hypervitaminosis D and 
compensatory Ca2+ hyperabsorption showed hypermagnesuria and renal TRPM6 
downregulation. Furthermore, dietary Mg2+ restriction and supplementation are 
positively involved in the regulation of TRPM6 in kidney and colon of TRPV5-/- mice, 
respectively. In addition, we demonstrated that not the functional loss of TRPV5 is 
primarily responsible for the hypermagnesuria in TRPV5–/– mice and that disruption 
of 1,25(OH)2D3 synthesis in TRPV5–/– mice results in hypomagnesuria, indicating an 
same diet, indicating the presence of renal Mg2+-loss. However, the renal 
upregulation of TRPM6 protein in TRPV5-/- mice fed the Mg2+-deficient diet was 
significantly less compared to TRPV5+/+ mice fed the same diet. After 10 days of 
dietary Mg2+ restriction, the TRPV5-/- mice still displayed hypermagnesuria. Thus, 
the upregulation of renal TRPM6 protein abundance after this dietary period was 
insufficient to normalize the Mg2+ reabsorption for the TRPV5-/- mice. In contrast, 
renal TRPM6 mRNA abundance of wild-type and TRPV5-/- mice fed a Mg2+-deficient 
diet was similar, suggesting equal amounts of TRPM6 protein expression. 
Interestingly, in both TRPV5+/+ and TRPV5-/- mice, TRPM6 mRNA levels in colon are 
upregulated when fed a Mg2+-enriched diet but not during dietary Mg2+-restriction. 
Previously, we suggested that this apparent discrepancy in the regulation of TRPM6 
expression upon dietary Mg2+ content is caused by the absence of a hormone 
regulating intestinal Mg2+ absorption (30). In analogy with Ca2+, feeding a 
Ca2+-enriched diet to 1α-OHase–/– mice, in which the synthesis of 1,25(OH)2D3 is 
prevented, resulted in increased duodenal mRNA expression levels of the epithelial 
Ca2+ channel TRPV6 (31). The molecular mechanisms resulting in the opposite 
regulation of TRPM6 expression in kidney and colon in response to Mg2+ restriction 
and a Mg2+-enriched diet, need additional investigation. Possibly, the Ca2+ sensing 
receptor, which is present in kidney and colon (32-34), exerts an opposite function 
in the regulation of renal and intestinal TRPM6 expression levels upon Mg2+ 
restriction and supplementation. Dietary Mg2+ content did not influence TRPM7 
expression levels in kidney and colon, excluding a major role for TRPM6 closest 
homologue in systemic Mg2+ handling (15, 17). 
Previously, it was reported that hypervitaminosis D mediates compensatory Ca2+ 
hyperabsorption in TRPV5-/- mice, in order to maintain normocalcemia (24). Here, 
we show that 1α-OHase–/– and TRPV5–/–/1α-OHase–/– mice, which both have 
undetectable levels of 1,25(OH)2D3, display hypomagnesuria. Thus, the lack of 
TRPV5 does not directly result in hypermagnesuria and renal TRPM6 downregulation. 
Interestingly, 1α-OHase–/– mice  display hypomagnesuria and unaltered renal 
TRPM6 mRNA expression levels compared to wild-type mice (30). This suggests 
that the disturbance of the Mg2+ balance in these mice originates from the intestine 
possibly due to disturbed Mg2+ absorption in the absence of 1,25(OH)2D3. Thus, 
the normal renal TRPM6 expression levels in 1α-OHase–/– mice are relatively high in 
the presence of the suggested reduction of Mg2+ absorption. To delineate the role 
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Mg2+ balance, which may lead to new insights regarding Mg2+ and Ca2+ 
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Impaired basolateral 
sorting of pro-EGF causes 
isolated recessive  
renal hypomagnesemia
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Abstract
Primary hypomagnesemia constitutes a rare heterogeneous group of disorders 
characterized by renal or intestinal magnesium (Mg2+) wasting resulting in generally 
shared symptoms of Mg2+ depletion, such as tetany and generalized convulsions, 
and often including associated disturbances in calcium excretion. However, most of 
the genes involved in the physiology of Mg2+ handling are unknown. Through the 
discovery of a mutation in the EGF gene in isolated autosomal recessive renal 
hypomagnesemia, we have, for what we believe is the first time, identified a 
magnesiotropic hormone crucial for total body Mg2+ balance. The mutation leads 
to impaired basolateral sorting of pro-EGF. As a consequence, the renal EGFR is 
inadequately stimulated, resulting in insufficient activation of the epithelial Mg2+ 
channel TRPM6 (transient receptor potential cation channel, subfamily M, member 6) 
and thereby Mg2+ loss. Furthermore, we show that colorectal cancer patients 
treated with cetuximab, an antagonist of the EGFR, develop hypomagnesemia, 
emphasizing the significance of EGF in maintaining Mg2+ balance. 
Introduction
Mg2+ is established as a central electrolyte in a large number of cellular metabolic 
reactions, including DNA and protein synthesis, neurotransmission, and hormone-
receptor binding. It is a component of GTPase and a cofactor for Na+,K+-ATPasae, 
adenylate cyclase, phospho-inositide kinases and phosphofructokinase (1). Mg2+ 
is also important for the regulation of parathyroid hormone release (2, 3). 
Accordingly, Mg2+ deficiency (plasma Mg2+ concentrations below 0.70 mM) has an 
effect on multiple body functions. Symptoms of Mg2+ deficiency are mostly related 
to muscle dysfunctioning, such as tetany, prolonged QT interval and cardiac 
arrhythmias (4). Children with hypomagnesemia often present with tetany and/or 
convulsions. Hypomagnesemia is a problem frequently observed in more than 10% 
of the hospitalized patients and can be as high as 65% in intensive care patients (5). 
A long-term complication seen in many adult patients with chronic hypomagnesemia 
is chondrocalcinosis, which can lead to impairment of joint function (4). Mg2+ 
deficiency can be secondary to systemic diseases (for instance diabetes mellitus 
and Crohn's disease) or to the use of osmotic agents, diuretics and drugs such as 
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Materials and methods
Statistical analysis 
In all experiments, data are expressed as mean ± SEM. Overall statistical 
significance was determined by ANOVA. Where differences between the means of 
2 groups were significant, they were analyzed by pairwise comparison using 
Scheffe’s method. For the statistical analysis in figure 4B, an unpaired t-test was 
performed. p < 0.05 was considered significant. The statistical analysis was 
performed using the SPSS software 12.0 (SPSS). 
Subjects
Informed consent was obtained from the parents and unaffected daughters of the 
family in this study. The parents gave proxy consent for the 2 affected daughters in 
this study. In this family, 2 Dutch sisters suffered from primary renal Mg2+ loss 
associated with normocalciuria. These women are the offspring of a consanguineous 
mating, and since both parents did not display this disorder, the inheritance pattern 
was likely to be autosomal recessive. The clinical data of this family have previously 
been described in detail by Geven et al. (13). In short, 2 patients of this family, V3 and 
V4, had serum Mg2+ levels of 0.53 mM and 0.56 mM and urinary Mg2+ values of 3.9 
mmol/24 h and 3.7 mmol/24 h, respectively. Given the low serum Mg2+ levels, urinary 
Mg2+ excretion was relatively high, indicating a renal Mg2+ reabsorption defect. Both 
patients suffer from epileptic seizures that started in their first year of life and are 
controlled by conventional antiepileptic drugs. During childhood, they showed 
psychomotor retardation, and they are presently moderately mentally retarded 
women. Serum and urinary Ca2+ were in the normal range, as were serum Na+, K+, 
Cl–, HCO3–, and blood pH values. In both patients, plasma renin activity, plasma 
aldosterone, and parathyroid hormone concentrations were in the normal range. 
Blood was collected for genotyping from the parents, both affected and both 
unaffected daughters, the sister of the father, and the sister’s 2 unaffected children.
Mutation analysis
We extracted DNA using standard protocols. The exons of the EGF gene were 
amplified separately from genomic DNA, using the primers listed in table 1. PCR 
products were purified with QIAGEN PCR Purification Kit according to the manufacturer’s 
protocol, and products were sequenced using the same primers. Mutation analysis of 
cyclosporin and cysplatin (6). In addition, primary Mg2+ deficiency is observed in 
several monogenetic disorders. Failure of early diagnosis or noncompliance with 
treatment can be fatal or result in permanent neurological damage. 
The plasma Mg2+ concentration is regulated within a narrow range by changes in 
urinary Mg2+ excretion in response to altered uptake by the intestine. Thus, the 
kidney plays a key role in the Mg2+ homeostasis (4, 7). Most renal reabsorption of 
Mg2+ occurs in the proximal tubule and the thick ascending limb of the loop of 
Henle via a passive paracellular transport process, but the fine-tuning of the Mg2+ 
excretion takes place in the distal convoluted tubule (DCT), where Mg2+ is 
reabsorbed via an active transcellular transport process (6, 7). Apical entry into DCT 
cells is mediated by the Mg2+ permeable channel; transient receptor potential 
channel subfamily M, member 6 (TRPM6) driven by a favourable transmembrane 
voltage (8). The mechanism of basolateral Mg2+ transport into the interstitium is 
unknown. Mg2+ has to be extruded against an unfavourable electrochemical 
gradient, most likely by a Na+/Mg2+ dependent exchange mechanism and/or a 
Mg2+-ATPase. Finally, 3-5% of the filtered Mg2+ is excreted in the urine.
Despite the critical role in Mg2+ handling, the exact mechanisms of transepithelial 
Mg2+ transport remain obscure. Studies of disorders with primary hypomagnesemia 
are very important to gaining more insight into the molecular and cellular 
mechanisms that underlie Mg2+ (re)absorption. Genetic studies in families with 
hereditary renal Mg2+ wasting syndromes have identified several genes that are 
either directly or indirectly involved in active Mg2+ handling. In the past few years, 
genetic studies of inborn errors of the Mg2+ balance revealed several new proteins 
unexpectedly involved in transepithelial Mg2+ transport in the DCT, e.g., thiazide-
sensitive sodium chloride cotransporter (NCC), the g subunit of the Na+,K+-ATPasae, 
and the previously mentioned epithelial Mg2+ channel, TRPM6 (9-12). 
The aim of the present study was, therefore, to elucidate the gene defect and 
molecular mechanism underlying Isolated Recessive Hypomagnesemia (IRH) that 
is characterized by renal Mg2+ loss. To this end, a homozygosity-based mapping 
strategy and mutation detection was performed. In addition, the molecular 
mechanism of IRH was studied in vitro using patch clamp analysis and in vivo by 
clinical studies in humans.
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was kindly donated by Merck KGaA. Informed consent was obtained from all 
subjects investigated in this study.
Calculation of FEMg
The FEMg was calculated using the following formula: 
  UMg x PCr
FEMg = ––––––––––––––––––  x100
  (0.7 x PMg) x UCr 
U and P refer to the urine and serum concentrations of Mg2+ (Mg) and creatinine 
(Cr). Serum Mg2+ concentration was multiplied by 0.7, since only approximately 
70% of the circulating Mg2+ was unbound by albumin and therefore able to be 
filtered across the glomerulus.
Expression profiling
PCRs were performed in 50 ml reaction volumes containing 1 µl of cDNA, 10 pmol 
of each primer (table 2), 2.5 mM MgCl2, 200 µM of each deoxyribonucleotide 
triphosphate (dATP, dTTP, dCTP, and dGTP), and 0.5 U of Taq polymerase. PCRs 
had an initial denaturation stage of 1 minute at 95°C, followed by 39 cycles of 30 
seconds at 95°C, 1 minute at 55°C, 1 minute at 72°C, and a final extension step at 
72°C for 10 minutes.
Immunohistochemistry
Staining of rat kidney sections for NCC and EGF was performed on 7-µm 
cryosections of periodate-lysine paraformaldehyde–fixed kidney samples. Sections 
were stained with affinity-purified anti-NCC (1:200) and affinity-purified rabbit 
anti-EGF (1:100) (Calbiochem; EMD Biosciences). Images were made with a 
Bio-Rad MRC 1000 laser scanning confocal imaging system using a ×60 
oil-immersion objective.
the EGF gene was performed by forward sequencing of the coding regions of the gene 
of the youngest affected family member. Forward and reverse sequencing of exon 22 
was subsequently performed on all family members.
                      
Subjects with colorectal cancer treatment
We prospectively studied consecutive patients with metastatic colorectal cancer for 
which treatment with cetuximab was initiated at the University Hospital Gasthuisberg 
(Leuven, Belgium). Most patients were included in phase II or III trials. Cetuximab 
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Table 1.  Primers used for mutation detection of EGF
Table 2.  Primers used for expression profiling of EGF and EGFR
 Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
Exon 1 cagaggctcactcaagtgtc gacaaactttgttaaatgccc
Exon 2 gacaatttacaaagtggagtg gcctatatttggcagacacg
Exon 3/4 caattttggaactgcataaag caaaatctatggcctaaacc
Exon 5 ttagctcagagtatgaggag cttacaggggtctattatgac
Exon 6 cgtgagagatgcagctgtag tagtcttcaggggttgtgtg
Exon 7 gactttccatgatcaattac tctcaccatgttgcccaggc
Exon 8 tggctcacacctgtaatccc aagttagacgctatgctgtc
Exon 9 gggtgaaagagtgaaactcc ctagttatattgttattactc
Exon 10 tgtcttcacctataccacac cattcagaacttagcagagg
Exon 11 agttcgaatttagttgcagg ccaaccaaatgcccagcaac
Exon 12 tactttgtttgtgggtgggg atgaggaattcatgctgaag
Exon 13 ctcttcttctgtattccttag tccctggagaagtctgtctc
Exon 14 gtgggctttccttgaggcag gtgaaagttacaaaatcccc
Exon 15 gatacactgcatttctctcc ctcaaaactcagcagaagag
Exon 16 agaccctgacagtttctctg catcattcagaagagacagac
Exon 17 taagcgtttctatttggagg gtctcattttctatgcatgtc
Exon 18 gatgttggcaacagcacctg caagaatggaaatacgtcag
Exon 19 ggtctctgagaacatatagc tctcaagcccagcatcgtcc
Exon 20 gtcccttctagtagttcttc aatgaagtgcacacacgtgg
Exon 21 tttcaactgacccctgatgg tgcacccagcctatttcacg
Exon 22 cttctctcccacacaagtac cctagctgatgtggtcttgg
Exon 23 aggctcctcactgaatgttg atggcatttcaatacagccc
Exon 24 gtgtctcattttcaggccag tgagatcctatcctctctcc
 Forward primer (5’ to 3’) Reverse primer (5’ to 3’) 
EGF tacctgcatgtgtgctggac tacctgcatgtgtgctggac
EGFR gtaacaagctcacgcagttg tgcagcctgcagcacactgg
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was verified by DNA sequence analysis. To generate plasmid CB7 constructs for the 
stable expression of the full-length EGF precursor and the P1070L mutant in MDCK 
type I cells, PCR was performed on the pSAD-EGF and pSAD-EGF-P1070L 
constructs, respectively, using Pyrococcus furiosus DNA polymerase according to 
the manufacturer’s protocol (Stratagene). Primers used were 5'-CGGGGTACCGCC
ACCATGCTGCTCACTCTTATCATTC-3' and 5'-CGCTCTAGAGTCACTGAGTCAGCTC
CATTTG-3'. PCR products were cloned into the plasmid CB7 vector using the 
restriction enzymes KpnI and XbaI and verified by DNA sequence analysis.
Electrophysiology
The bicistronic expression vector pCINeo-IRES-GFP containing the full-length open 
reading frames of N terminally HA-tagged human TRPM6 (GenBank accession 
number NM_017662) was used to coexpress human TRPM6 and enhanced GFP in 
HEK293 cells. HEK293 cells were grown in DMEM (BioWhittaker) containing 10% 
(v/v) fetal calf serum, 2 mM L-glutamine, and 10 µg/ml Ciproxin at 37°C in a 
humidity-controlled incubator with 5% (v/v) CO2. Cells were transiently transfected 
with the respective constructs using Lipofectamine 2000 (Invitrogen), as described 
previously (16), and electrophysiological recordings were performed 48 hours after 
transfection. Transfected cells were identified by their green fluorescence when 
illuminated at 480 nm. Nontransfected (GFP-negative) cells from the same batch 
were used as controls. Patch clamp experiments were performed in the tight seal 
whole-cell configuration at room temperature (20-25°C) using an EPC-10 patch 
clamp amplifier computer controlled by PatchMaster Classic 1.20 software (HEKA 
Elektronik). Currents were digitized at 10 kHz and digitally filtered at 2.9 kHz. Patch 
pipettes had resistances between 2 and 5 MW after filling with the standard 
intracellular solution. Cells were held at 0 mV, and voltage ramps of 200 ms duration 
ranging from -100 to +100 mV were applied every 2 seconds. Extracting the current 
amplitudes at +80 mV from individual ramp current records provided an assessment 
of the temporal development of membrane currents. Current densities were 
obtained by normalizing the current amplitude to the cell membrane capacitance. 
The time course of current development was determined by measuring the current 
at +80 mV. Step protocols were applied from holding potentials of 0 mV and 
consisted of 400-ms steps to -100 to +100 mV (increment of 20 mV). The standard 
pipette solution contained 150 mM NaCl, 10 mM EDTA, and 10 mM HEPES/NaOH 
(pH 7.2). Extracellular solutions contained 150 mM NaCl and 10 mM HEPES/NaOH 
Linkage analysis
Samples of peripheral EDTA blood were collected from each person, and genomic 
DNA was isolated using standard procedures. Homozygosity mapping was 
performed with a genome-wide set of 400 evenly distributed microsatellite markers 
(LMS-MD10 2.5; Applied Biosystems), with an average intermarker distance of 10 
cM, on the basis of Marshfield genetic maps (http://research.marshfieldclinic.org/
genetics/GeneticResearch/compMaps.asp).
The average heterozygosity of these markers was 0.76. Five additional markers, 
D4S1570, D4S2623, D4S2392, D4S1615, and D4S422, were selected for fine 
mapping purposes from the public databases on chromosome 4 (http://research.
marshfieldclinic.org/genetics/Genetic Research/data/Maps/Map4.txt and http://
genome.ucsc.edu/cgi-bin/hgGateway). The analysis of the markers was according 
to the protocol provided for the LMS-MD10 version 2.5 with some small modifications. 
PCRs were performed in 10 µl reaction volumes containing 40 ng of genomic DNA, 
5 pmol of each primer, 2.5 mM MgCl2, 250 µM dATP, dTTP, dCTP, and dGTP each, 
10 mM Tris/HCl (pH 8.3), 50 mM KCl, and 0.4 U of Taq polymerase (AmpliTaq TM 
Gold; Applied Biosystems). PCRs had an initial denaturation stage of 12 minutes at 
95°C, followed by 10 cycles of 15 seconds at 94°C, 15 seconds at 55°C, and 30 
seconds at 72°C, then 22 cycles of 15 seconds at 89°C, 15 seconds at 55°C, and 
30 seconds at 72°C, and a final extension step at 72°C for 10 minutes. Reactions for 
each marker were performed separately, with products being pooled into size-specific 
sets before typing. Markers were typed on an ABI 3100 sequencer (Applied 
Biosystems) using GeneMapper 4.0 software (Applied Biosystems). Allele binning 
was performed with the Excel 2000 (Microsoft) macro linkage designer developed 
by van Camp and coworkers (14), and we checked Mendelian inheritance of alleles 
with PedCheck 1.0 software (http://watson.hgen.pitt.edu). Multipoint LOD scores 
were calculated with the GeneHunter, version 2.1 release 5, program in the 
easyLINKAGE software package.  
Constructs
The full-length EGF precursor in vector pSAD was kindly provided by G.I. Bell (15) 
(University of Chicago, Chicago, Illinois, USA). The full-length EGF precursor 
P1070L mutant was obtained by in vitro mutagenesis of the pSAD-EGF vector 
according to the protocol described by the manufacturer (Invitrogen). The construct 
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Transfection of HEK293 cells
HEK293 cells were transiently transfected with pSAD-EGF, pSAD-EGF-P1070L, or 
empty-vector pCINeo-IRES-GFP cDNA using polyethylenimine (Polysciences Inc.). 
Six million cells were seeded on a petri dish (57 cm2) (10 plates per vector) in a total 
volume of 5 ml DMEM. After 3 hours, the cells were transfected. The transfection mix 
for each plate consisted of 15 µg cDNA and 90 µl polyethylenimine (1 µg/µl) in a 
total volume of 500 µl Opti-MEM (Invitrogen). The transfection mix was incubated for 
20 minutes at room temperature. Subsequently, the transfection mix was added to 
the cells and incubated overnight. After 1 day of transfection, the culture media was 
replaced by 8 ml DMEM medium as described above but without FCS.
Collection and concentration of conditioned culture media
Two days after replacement of the medium of HEK293 and MDCK cells, the 
FCS-free culture media was collected and proteinase inhibitors were added (1 mM 
PMSF, 1 µg/ml pepstatin A, and 10 ng/ml leupeptin). Subsequently, the collected 
FCS-free culture media of HEK293 cells with added proteinase inhibitors was 
concentrated 400 times using Centriprep YM-3 followed by Microcon YM-3 
(Millipore). Prior to concentration of the collected HEK293 medium, 2 ml of the 
collected FCS-free culture medium was kept separately and used for patch clamp 
analysis.
 
Human EGF ELISA
EGF concentrations were determined in 400 times concentrated culture supernatant 
by using Centriprep columns and a human EGF ELISA kit according the 
manufacturer’s protocol (RayBiotech Inc.).
Results and Discussion
IRH is characterized by low serum Mg2+ levels and mental retardation. Two affected 
sisters V3 and V4 (figure 1A) displayed low serum Mg2+ levels (0.53-0.66 mM) in 
combination with urinary fractional excretion (FE) values of Mg2+ of 4.8% and 3.6%, 
respectively. These values are well above a FE of 2% indicating renal Mg2+ wasting 
as previously described (5, 20). Thus, the fact that the urinary excretion of Mg2+ is 
in the normal range, while their serum Mg2+ values are hypomagnesemic, points to 
(pH 7.4) supplemented with 1 mM CaCl2. The osmolarity of the solutions was 
adjusted to 300-310 mOsm/kg with mannitol.
Pre-treatment with EGF, pre-conditioned media and cetuximab
The effect of EGF on TRPM6 activity in HEK293 cells transiently transfected with 
TRPM6 was measured after a 30-minute preincubation with 10 nM mouse EGF 
(Sigma-Aldrich) in DMEM (modified as described above) or the preconditioned 
medium. Cetuximab pretreatment for 1 hour with 2 µg/ml in DMEM (modified as 
described above) was performed prior to treatment with EGF or preconditioned 
medium. Subsequently, cells were analyzed by the patch clamp technique as 
described above.
Generation of a MDCK cell line stably expressing pro-EGF and pro-EGF-P1070L
MDCK type-I cells (17) were grown in DMEM containing 5% (v/v) FCS (HyClone), 13 
mM NaHCO3, 2 mM L-glutamine, and 10 µg/ml ciproxin (Bayer) at 37°C in a 
humidity-controlled incubator with 5% (v/v) CO2. For stable transfection of MDCK 
cells, 25 µg circular DNA was transfected using the Ca2+-phosphate precipitation 
technique (18). Cells were trypsinized 24 hours after transfection, seeded on Petri 
dishes, and cultured in DMEM containing 75 µg/ml hygromycin B (Invitrogen). 
Between 10 and 14 days after transfection, individual colonies were selected by 
means of cloning rings and expanded. Total RNA was extracted from each colony 
that had been grown until confluent in a 24-well culture plate using TRIZOL Total 
RNA Isolation Reagent (Invitrogen) according to the manufacturer’s protocol. 
The obtained RNA was subjected to DNase treatment (Promega) to prevent 
genomic DNA contamination. Thereafter, 1.5 µg of RNA was reverse transcribed by 
Moloney Murine Leukemia Virus Reverse Transcriptase (Invitrogen) as described 
previously (19). The cDNA was used to determine pro-EGF expression with the 
primers described in table 2. MDCK cells stably expressing plasmid CB7-EGF, 
plasmid CB7-EGF-P1070L, or empty vector (5 clones of each) were used to seed 10 
24-mm Transwell filter wells of each condition (Corning Inc.). We seeded 1.5 × 105 
cells/cm2 on permeable filter supports; these were grown for 4 days until they 
reached confluency and an electrical resistance of greater than 2,400 Wηcm2. Next, 
the media were replaced by DMEM medium as described below but without FCS 
and harvested after 2 days.
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childhood, and presently they are moderately mentally retarded women who suffer 
from epileptic seizures. The previously identified genes involved in renal Mg2+ 
handling encoding the thiazide-sensitive sodium chloride cotransporter NCC 
(SLC12A3), paracellin-1 (CLDN16), the g subunit of the Na+,K+-ATPasae (FXYD2), 
and the epithelial Mg2+ channel (TRPM6) have been excluded for these 2 affected 
sisters (figure 1A) (8, 11, 12, 21). To determine the disease locus of this 
consanguineous family, a homozygosity-based mapping strategy with a set of 
highly polymorphic microsatellite markers spread over the genome was performed 
and followed by fine-mapping. This resulted in the identification of a critical linkage 
interval with LOD score 2.66 (p < 0.004) on chromosome 4 of 18.4 cM between 
markers D4S2623 and D4S1575 (figure 1B). A search for candidate genes within 
this region revealed the EGF gene that was considered a highly relevant positional 
candidate since it had previously been linked to electrolyte homeostasis (22).
We sequenced EGF in the affected individuals (figure 1A) and identified the 
homozygous mutation C3209T in exon 22, which cosegregated with the disorder 
and was absent in 126 ethnically matched control chromosomes (figure 1C). 
The mutation causes the substitution of the highly conserved proline 1070 within the 
cytoplasmic tail of pro-EGF by leucine (P1070L) (figure 1D and E). We found that 
both parents (figure 1A) and the two unaffected sisters (figure 1A) of this Dutch 
family were heterozygous for the mutation. Furthermore, the paternal aunt was 
heterozygous for the mutation, whereas her 2 children (figure 1A) exhibited the 
homozygous wild-type genotype (figure 1A and C). 
The EGF gene consists of 24 exons encoding a large type I membrane-anchored 
precursor protein of 1,207 amino acid residues that exists as a membrane-bound 
molecule, which is proteolytically cleaved into pro-EGF to finally generate the 
53-amino acid peptide hormone EGF (15). EGF has a profound effect on cell 
differentiation in vivo and is a potent mitogenic factor for a variety of cultured cells 
of both ectodermal and mesodermal origin (23). EGF belongs to the EGF-like family 
of growth factors that bind with high-affinity to the EGFR. Other members of this 
family are TGF-α, amphiregulin, heparin-binding EGF-like growth factor, betacellulin 
and epiregulin (24-26). These membrane-anchored growth factor precursors are 
characterized by the fact that they are biologically active at the cell surface, although 
they can be proteolytically cleaved to release soluble, diffusible factors (24-26).
a diminished tubular Mg2+ reabsorption. Apart from hypomagnesemia, other 
biochemical abnormalities were not identified; in particular, there was no disturbance 
in urinary Ca2+ excretion (13). Both sisters showed psychomotor retardation during 
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Figure 1. Molecular analysis of EGF
 
(A) Pedigree of the family in which specific members suffer from IRH. Filled symbols represent 
affected individuals, half-filled symbols are heterozygous for the mutation C3209T, and open 
symbols represent clinically unaffected family members not screened for the mutation. Slash 
marks indicate deceased individuals, and double lines show consanguinity. (B) Schematic 
representation of the critical interval between polymorphic markers D4S2623 and D4S1575  
on chromosome 4q and the intron-exon structure of the EGF gene, depicting the identified 
mutation. The position of the polymorphic markers is indicated by vertical bars. The horizontal 
arrow below the schematical boxed representation of EGF depicted between the polymorphic 
markers indicates the localization and orientation of the EGF gene. Cen, centromeric; tel,  
telomeric. (C) Genomic mutation sequence analysis of EGF in wild-type, heterozygous, and 
affected individuals. The mutated nucleotide and resulting amino-acid change is shown under 
the affected individual’s sequence. The black bar under that sequence indicates the mutated 
codon. The black bars under the sequences of the WT and heterozygous specify codon 1070 of 
EGF. The affected individuals both have a homozygous mutation C3209T in exon 22, resulting in 
the amino acid substitution P1070L. (D) Schematic model of pro-EGF, which resides as a type I 
membrane protein at the plasma membrane. The position of the P1070L mutation is depicted. 
(E) Sequence homology analysis of juxtamembrane domain and flanking residues. P1070 is 
strongly conserved among different species and forms the second proline of a basolateral PXXP 
sorting motif. TM, transmembrane domain.
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expression was detected in the adrenal gland, liver, cerebellum and placenta. The 
EGFR showed a ubiquitous expression pattern since all tissues tested were positive 
by RT-PCR analysis (figure 2A). Immunohistochemistry on rat kidney sections 
showed that EGF is consistently coexpressed with NCC, a marker of the DCT (27) 
(figure 2B). Interestingly, the immunopositive staining is mainly localized along the 
apical domain in DCT. Coffey and coworkers demonstrated that human pro-EGF 
overexpressed in Madin-Darby Canine Kidney (MDCK) cells is delivered equally to 
the apical and basolateral membrane but is found predominantly at the apical 
membrane domain (28). They proposed that preferential ectodomain cleavage at 
the basolateral surface explains the apparent apical localization of pro-EGF. 
Sack and Talor provided evidence for the existence of specific binding sites in 
tubular basolateral membranes suggesting a physiologic role of EGF in the kidney 
(29). In kidney, the EGFR was detected in glomerular endothelial cells, peritubular 
capillaries and arteriolar walls, as well as along the thick ascending limb of Henle's 
loop and DCT (30, 31). Immunohistochemical analysis revealed that the EGFR was 
located particularly along the basolateral membrane of the tubular cells. The DCT 
reabsorbs approximately 10% of the filtered Mg2+ load and the reabsorption rate in 
this segment defines the final urinary Mg2+ excretion, because virtually no 
reabsorption takes place beyond this section (1). In kidney, the epithelial Mg2+ 
channel TRPM6 is specifically expressed in DCT, where it forms the rate-limiting 
step of epithelial Mg2+ transport (8). Thus, pro-EGF and TRPM6 are both 
predominantly expressed in DCT, the main site of active renal Mg2+ reabsorption (1, 
15, 22, 32). To determine whether EGF can regulate the activity of TRPM6, Human 
Embryonic Kidney 293 (HEK293) cells were transiently transfected with TRPM6 and 
treated for 30 minutes with EGF (10 nM), resulting in increased channel activity 
(figure 3A). Western blot analysis demonstrated endogenous expression of EGFR 
in these HEK293 cells (data not shown). EGF dose-dependently stimulated TRPM6 
activity with half maximal effective concentration of 1.7 nM, an apparent affinity that 
is in the physiological range as reported previously (figure 3B) (29). 
Previous in vivo studies showed that the predominant form of EGF released from 
epithelial cells is the high-molecular mass 160-170 kDa EGF, as found at high 
concentrations in serum, urine and milk (33, 34). To investigate the functional effect 
of the identified mutation, HEK293 cells were transfected with wild-type or mutant 
 
To study the tissue distribution of pro-EGF and EGFR, we performed RT-PCR on 
various human tissues (figure 2A). For EGF, PCR amplification products were 
detected in, e.g., kidney, salivary gland, cerebrum, and prostate, whereas no 
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Figure 2. Expression profiling of EGF and EGFR
 
(A) The expression of EGF and EGFR mRNA was determined by RT-PCR on various human 
 tissues. Signals for EGF were detected in, e.g., kidney, salivary gland, prostate, and cerebrum 
whereas no signals were detected in the adrenal gland, cerebellum, liver, lung, and placenta. 
The EGFR showed a ubiquitous expression pattern since PCR amplification products were 
obtained in all tissues tested. hEGF, human EGF; hEGFR, human EGFR.  
(B) Immunohistochemical analysis of EGF (green) and thiazide-sensitive sodium chloride 
cotransporter (NCC, red) in rat kidney sections (upper panel, overview of a cortical region; 
lower panel, magnified image of an immunopositive tubule). EGF colocalized with NCC,  
a marker for the DCT. Original magnification, ×180 (B, top panels); ×360 (B, bottom panels).
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pro-EGF and after 2 days their supernatant was collected. TRPM6-expressing 
HEK293 cells were subsequently incubated for 30 minutes with these preconditioned 
media and analyzed for channel activity using the patch clamp technique. 
Interestingly, the supernatant obtained from mutant pro-EGF-expressing HEK293 
cells failed to stimulate TRPM6 activity, whereas a significant channel activation was 
observed with the wild-type EGF-containing supernatant (figure 3C). Quantification 
of EGF in both supernatants using ELISA indicated that the secretion of mutant 
pro-EGF is impaired (figure 3D).
To demonstrate that the observed stimulatory effects are due to EGFR activation, a 
preincubation with cetuximab was performed. This IgG human/mouse chimeric 
monoclonal antibody competitively inhibits the activation of the EGFR. It binds 
externally to the EGFR to block binding of the ligand and subsequent signal 
transduction mediated via the receptor-associated tyrosine kinase and prevents 
phosphorylation of the EGFR and other downstream proteins in the signal 
transduction cascade (35). The stimulatory effect of the supernatant collected from 
pro-EGF-expressing HEK293 cells on TRPM6 was significantly inhibited by 
preincubation for 1 hour with cetuximab (191 ± 22 pA/pF, 491 ± 62 pA/pF, and 286 
± 48 pA/pF for TRPM6-expressing HEK293 cells measured at +80 mV and treated 
with mock supernatant, EGF supernatant, or EGF supernatant plus cetuximab, 
respectively; p < 0.05, n = 6). Thus, the stimulatory effect of the supernatant on 
TRPM6 activity is due to direct activation of the EGFR.
As outlined above the localization of EGFR is restricted to the basolateral membrane, 
whereas pro-EGF is present at both the apical and basolateral membranes (28). 
This prompted us to investigate in detail the cellular metabolism of pro-EGF. 
Recently, several basolateral sorting motifs were identified including the sequence 
motif PXXP (with X being an arbitrary amino acid), determining the targeting of 
proteins to the basolateral membrane in MDCK cells (36). Our mutation substitutes 
the second highly conserved proline in the cytoplasmic 1067PKNP1070 motif into a 
leucine (figure 1D). We hypothesized that this mutation results in improper 
trafficking of pro-EGF thereby preventing an adequate secretion of the hormone into 
the circulation. Since, EGFR is only localized basolaterally, the mutation should 
prevent the ligand from reaching its receptor. Interestingly, He and coworkers have 
shown previously that a 22-amino acid sequence in the EGFR juxtamembrane 
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Figure 3.  Electrophysiological analysis of pro-EGF and pro-EGF-P1070L on  
TRPM6 channel activity
 
(A) Average time course of outward (at +80 mV) current densities from HEK293 cells transfected 
with TRPM6 in control conditions (open circles) and after EGF treatment (30 minutes, 10 nM, filled 
circles) in comparison with mock-transfected cells without EGF treatment (triangles) and after EGF 
stimulation (filled triangles). n = 17-20. (B) Dose-response curve of EGF-induced current in TRPM6-
transfected HEK293 cells indicating half maximal effective concentration of 1.7 nM. n = 11-14. (C) 
Histogram presenting the current densities at +80 mV of TRPM6-transfected cells (200 seconds 
after establishment of the whole-cell configuration) treated with mock (mock),  pro-EGF (EGF WT) or 
pro-EGF-P1070L (EGF-P1070L) supernatant. All treatments were performed for 30 minutes at 37°C. 
White bars indicate experimental  conditions in which HEK293 cells were transfected with mock DNA 
whereas black bars indicate HEK293 cells transfected with TRPM6. Asterisk indicates significance 
in comparison with nontreated TRPM6-transfected cells. p = 0.024; n = 6. (D) Supernatants of 
mock-, pro-EGF-, or pro-EGF-P1070L-transfected HEK293 cells were analyzed by ELISA. Asterisk 
indicates mock and pro-EGF-P1070L supernatant were significantly different from EGF supernatant. 
p = 0.006; n = 4. (E) Histogram summarizing the current density (pA/pF) at +80 mV (200 seconds 
after break-in) of HEK293 cells treated with the apical or basolateral supernatant of MDCK cells 
stably transfected with either wild-type pro-EGF, pro-EGF-P1070L, or mock DNA (30 minutes, 37°C). 
White bars indicate experimental conditions in which HEK293 cells were transfected with mock DNA 
whereas black bars indicate HEK293 cells transfected with TRPM6. Crosses indicate significance in 
comparison with the mock treatment at the apical side (wild-type pro-EGF apical, p = 0.0001,  
n = 6; pro-EGF-P1070L apical, p = 0.029, n = 6), and pound symbol represents significance in 
comparison with the mock treatment at the basolateral side (wild-type pro-EGF basolateral  
p = 0.031, n = 6). (F) Schematic model illustrating how pro-EGF-P1070L mutation results in IRH.  
The pro-EGF-P1070L mutation leads to impaired basolateral sorting of pro-EGF, resulting in  
abrogated stimulation of the EGFR localized at the basolateral membrane. Activation of the EGFR in 
DCT by EGF is necessary to prevent renal Mg2+ wasting by stimulation of the epithelial Mg2+  
channel TRPM6.
132 133
mutations at P667 and P670 were associated with impaired basolateral delivery of 
the EGFR.
To determine the effect of the mutation on the sorting of pro-EGF in polarized 
epithelial cells, MDCK cells stably expressing either wild-type or mutant pro-EGF 
were grown on semipermeable filter supports until they reached confluency. After 2 
days, media of the basolateral and apical compartment were collected individually. 
Next, HEK293 cells expressing TRPM6 were treated with the collected preconditioned 
media of wild-type pro-EGF, mutant pro-EGF, or mock-expressing cells. Equal 
stimulation of TRPM6 channel activity was observed when the cells were incubated 
with the apically collected media of wild-type or mutant pro-EGF-expressing MDCK 
cells (figure 3E). However, stimulation of TRPM6 channel activity was only observed 
with basolaterally collected wild-type pro-EGF medium, not with the basolateral 
mutant pro-EGF media (figure 3E). Of note, the apically and basolaterally collected 
mock medium did not affect TRPM6 activity. These observations suggest that the 
basolateral release of mutant pro-EGF is diminished, seriously hampering the 
EGF-dependent activation of the basolaterally localized EGFR (figure 3F).
Clinical trials directed to the treatment of patients with colorectal cancer have 
demonstrated that cetuximab is synergistic with chemotherapy for these patients 
(37). We observed that serum Mg2+ levels gradually decreased in all studied 
colorectal cancer patients on cetuximab treatment (figure 4A). This is in line with a 
recent report showing that a significant number of similarly treated patients develop 
hypomagnesemia (35). Our patients treated with cetuximab displayed an FE of Mg2+ 
of 5.1%, which is inappropriately high given their hypomagnesemia (figure 4B). 
As previously established by Agus (5), an FE of Mg2+ above 2% in the presence of 
hypomagnesemia indicates renal Mg2+ loss.
The 2 affected sisters with IRH exhibited a similar relatively high Mg2+ excretion 
profile (figure 4B). The urinary Mg2+ patterns of the patients treated with EGFR 
antibodies, the patients described in our Dutch family and patients with 
Hypomagnesemia with Secondary Hypocalcemia (HSH; OMIM 602014) (11, 12) 
were identical and suggest mutual defects in renal TRPM6 activity. Indeed, 
preincubation with cetuximab abolished the stimulatory effect of EGF on TRPM6 
activity as shown by patch clamp analysis of TRPM6-expressing HEK293 cells 
(figure 4C). Taken together, these data strongly suggest a pivotal role for EGFR 
domain contains autonomous sorting information necessary for basolateral 
localization of the receptor in MDCK cells (36). This sorting motif contains a 
polyproline core comprising residues P667 and P670 (667PXXP670). Site-directed 
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Figure 4. Effect of cetuximab treatment on Mg2+ balance and TRPM6 activity
 
(A) Changes in serum Mg2+ levels from baseline over time during cetuximab therapy are shown for 
20 colorectal cancer patients. Solid lines represent individual linear regression lines of the data 
points for each individual patient. Open symbols denote end of treatment. (B) Cetuximab treatment 
leads to renal Mg2+ loss and hypomagnesemia. Serum samples and urine (over a 24-hour period) 
was collected from 8 patients at baseline in normomagnesemic conditions (open circles),  
12 patients on cetuximab treatment in hypomagnesemic conditions (filled circles), and patients  
(V-3, V-4) with IRH (triangles), then analyzed for FE of Mg2+. FE Mg2+ was plotted against the serum 
Mg2+ concentrations for the tested individuals. Hypomagnesemia in combination with an 
 inappropriately high excretion of Mg2+ was observed in patients with the P1070L mutation as well as 
in individuals treated with cetuximab. Large circles represent the averaged values of patients on 
cetuximab treatment (filled) and patients at baseline in normomagnesemic conditions (open). 
Asterisk indicates a significant difference in serum (Mg2+) compared with that in control patients.  
p = 0.001; n = 8-12. (C) Histogram depicting the current densities at +80 mV of TRPM6-transfected 
cells that were exposed for 30 minutes to EGF, cetuximab, or EGF in combination with cetuximab. 
Cross indicates a significant difference compared with nontreated (CTRL) HEK293-TRPM6 cells.  
p < 0.026; n = 6.
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signaling in the maintenance of normal Mg2+ balance and indicate TRPM6 as a 
critical link between EGFR inhibition and IRH.
Through the discovery of an EGF mutation in IRH, we have for the first time, to our 
knowledge, identified a magnesiotropic hormone crucial for total body Mg2+ 
balance that directly stimulates renal tubular Mg2+ reabsorption via activation of the 
epithelial Mg2+ channel TRPM6. Moreover, it raises the question of whether EGF 
plays a role in mental development since our IRH patients (figure 1A) are mentally 
retarded. EGF is present in cerebrospinal fluid, and EGF mRNA has been detected 
in the developing brain of various species. Furthermore, EGF is a well-known 
neurotrophic factor regulating the development of various neuronal cells (38). 
Fatamura et al. reported that serum EGF levels were markedly decreased in 
schizophrenic patients and suggested that EGF might provide a link between 
impaired EGF signaling and the pathology/etiology of schizophrenia (39). 
An association between an EGF polymorphism and schizophrenia has been 
suggested although data from several studies are conflicting (40, 41). Interestingly, 
in our Dutch family with IRH, 1 unaffected, EGF P1070L-carrier sister (figure 1A) 
suffers from schizophrenia, and 2 brothers and 1 sister of the carrier mother (figure 
1A) are known with cluster A (Diagnostic and statistical manual of mental disorders, 
fourth edition, text revision) personality disorders. In addition, EGF could be 
involved in Mg2+ absorption in the intestine, a site that also expresses TRPM6. 
Future therapeutic intervention might be able to treat hypo- and hypermagnesemia 
by regulating EGFR activity.
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EGF activates the distal 
tubular magnesium channel, 
TRPM6, via a Src kinase and 
Rac1 mediated increase in  
plasma membrane expression
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Abstract
A mutation in the epidermal growth factor (EGF) gene, causing isolated recessive 
hypomagnesemia, was recently identified. EGF was shown to increase the activity 
of the epithelial Mg2+ channel TRPM6. The aim of this study is to elucidate the 
molecular mechanism mediating this effect. To this end, whole-cell patch clamp 
recordings of TRPM6 expressed in Human Embryonic Kidney 293 (HEK293) cells 
were employed. EGF receptor stimulation increased TRPM6, but not TRPM7, current 
independently of its unique carboxy-terminal α-kinase domain. This activation relied 
on both the Src family of tyrosine kinases and the downstream effector Rac1. 
Activation of Rac1 increased the mobility of TRPM6, as assessed by fluorescent 
recovery after photobleaching. Moreover, dominant negative Rac1 decreased 
TRPM6 mobility, abrogated current development and prevented the EGF-mediated 
increase in activity. In contrast, a constitutively active mutant of Rac1 mimicked the 
stimulatory effect of EGF on TRPM6 mobility and activity. TRPM6 activation was 
ultimately the result of increased cell surface abundance. In summary, EGF-
mediated stimulation of TRPM6 activity occurs via signaling through Src kinases 
and Rac1, thereby redistributing endomembrane TRPM6 to the plasma membrane.
Introduction
Recently we described a mutation in the EGF gene, encoding pro-EGF, which is 
responsible for a rare form of renal magnesium (Mg2+) wasting, Isolated Recessive 
Hypomagnesemia (IRH) (1). A link between a defect in EGF and renal Mg2+ wasting was 
made by demonstrating that pro-EGF is expressed in the distal convoluted tubule (DCT), 
where regulated transcellular Mg2+ reabsorption occurs via transient receptor potential 
M6 (TRPM6). Further, supernatant from the basolateral compartment of polarized 
epithelial cells expressing pro-EGF was able to activate TRPM6, while supernatant from 
cells expressing the mutant pro-EGF was unable to. The EGF receptor (EGFR/ErbB1) is 
expressed in the basolateral membrane of DCT, suggesting an autocrine/paracrine 
activation of TRPM6 by EGF through its receptor. This has not however been confirmed, 
nor have the molecular details of this activation been elucidated.
EGFR activation mediates its downstream effects via numerous signaling cascades, 
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site-directed mutagenesis and Polymerase Chain Reaction (PCR) based on the TRPM6 
cDNA in pCINeo/IRES-GFP. The α-kinase (L1749X) mutant was created using the 
QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according 
to the manufacturer’s protocol (5). All constructs were verified by sequence analysis. 
Rac1-T17N and Rac1-G12V plasmids in the pcDNA3.1+ vector were purchased from 
UMR cDNA resource center (Rolla, MO, USA). Mouse TRPM7 in pTracer-CMV2 was a 
kind gift from David Clapham (Harvard, Boston, MA, USA). A HA-tag has been inserted 
at the C-terminus of TRPM7.
Immunoblotting
Protein samples were denatured by incubation for 30 min at 37°C in Laemmli buffer, and 
then subjected to SDS-PAGE. Blots were incubated with either a goat anti-EGFR polyclonal 
antibody (1:500, Santa-Cruz, CA, USA) or a rabbit anti-GFP polyclonal antibody (1:5,000 
Transduction Laboratories), at 4ºC for 16 h. Subsequently, blots were incubated with a 
goat anti-rabbit or donkey anti-goat, peroxidase-conjugated secondary antibody (both 
1:10,000, Sigma, St Louis, MO, USA) and then visualized using the enhanced 
chemiluminescence method (Pierce, Rockford, IL, USA) as described previously.
Electrophysiology
A ramp protocol, consisting of linear voltage ramp from -100 to +100 mV (within 450 ms) 
was applied every 5 s from a holding potential of +0 mV. Extracting the current 
amplitudes at +80 and -80 mV from individual ramp current records assessed the 
temporal development of membrane currents. Current densities, expressed in units of 
membrane capacitance, were calculated from the current at +80 and -80 mV during the 
ramp protocols. The step protocol consisted of a series of 100 ms long voltage steps 
applied from the resting membrane potential to voltages between -100 and +100 mV 
with an increment of 20 mV. The standard pipette solution (150 mM NaCl, 10 mM EDTA 
and 10 mM HEPES / NaOH, pH 7.2) was used. The extracellular solution (150 mM NaCl, 
10 mM HEPES / NaOH, pH 7.4) was supplemented with 1 mM CaCl2. All experiments 
were performed at room temperature. Transfected cells were identified by their green 
appearance and GFP-negative cells from the same batch of cells were used as 
negative controls.
Fluorescence recovery after photobleaching
HEK293 cells were transfected with GFP-TRPM6 and empty vector or the Rac1 
including the extracellular signal-regulated kinase (ERK) limb of the mitogen-activated 
protein kinase (MAPK) superfamily, protein kinase A (PKA), protein kinase C (PKC), 
phosphoinositide 3-kinase (PI3K), and the phospholipases C and D pathways (2). 
Activation of the EGFR in DCT could therefore result in phosphorylation and consequently 
activation of the previously described target proteins. That EGFR signaling is implicit to 
Mg2+ homeostasis is further supported by the observation that patients treated with 
cetuximab, a monoclonal antibody directed against the EGFR, develop hypomagnesemia 
(1, 3, 4). However, the signaling pathway(s) downstream of EGFR activation, which 
stimulate TRPM6-mediated Mg2+ influx, remain to be determined.
The aim of the present study was to ascertain the downstream signaling events, after 
EGFR engagement, and ultimately the mechanism responsible for increased TRPM6 
activity. Elucidation of the molecular details responsible for EGFR-mediated stimulation 
of TRPM6 will facilitate the development of treatments for hypomagnesemia in general 
and during cetuximab treatment. Using electrophysiological measurements in 
combination with biochemical and live cell imaging techniques we provide evidence 
that EGF stimulates TRPM6 through the specific activation of the EGFR. This activates 
the Src family of tyrosine kinases and the small Rho-GTPase, Rac1, which results in a 
redistribution of vesicular TRPM6 to the plasma membrane.
Materials and methods
Reagents
EGF, AG1478/tyrphostin, forskolin, U73122, U17343, LY492005, cytochalasin D and 
wortmannin were from Sigma-Aldrich (Steinheim, Germany). UO126, PP2 (4-Amino-5-
(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine), PP3 (4-Amino-7-phenyl pyrazol-
[3,4-d]pyrimidine), PD98059 (2’-Amino-3’-methoxyflavone) and RG13022 were obtained 
from Calbiochem Inc. (La Jolla, CA, USA). The EZ-link Sulfo-NHS-LC-LC-Biotin was 
purchased from Pierce (Rockford, IL, USA) and Neutravidin agarose resin from Thermo 
Scientific (Rockford, IL, USA).
DNA constructs
Wild-type TRPM6 in the pCINeo/IRES-GFP vector was HA-tagged at the N-terminal tail 
as described previously (7). GFP-fused-TRPM6 in pCINeo vector was constructed by 
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using the method of Scheffé. Differences in means with p < 0.05 were considered 
statistically significant. The statistical analysis was performed using the SPSS 
software (SPSS Inc, Chicago, Illinois, USA).
Results
EGF activates TRPM6 current in HEK293 
The presence of the EGFR was first confirmed in HEK293 cells by immunoblotting, 
where it was detected as a single immunopositive band with the expected molecular 
size of 170 kD (figure 1A). Thus, HEK293 cells provide an excellent model to study 
the effect of EGF on TRPM6 activation. TRPM6 has been expressed and 
characterized in this model system where it is detectable at the appropriate 
molecular weight of 230 kD (figure 1B) (8). The effect of EGF on TRPM6 current 
activity was then assessed using whole-cell recordings. All time courses were 
analyzed at +80 and -80 mV for a 200s period. EGF pre-incubation stimulated 
TRPM6 current by 34 ± 6 % and 65 ± 8 % at +80 and -80 mV respectively, 
compared to TRPM6 current in the absence of EGF (figure 1C and D). TRPM6 
displayed an outwardly rectifying current-voltage relation with a reversal potential 
close to 0 mV. This was unaltered by EGF pre-treatment (figure 1E).
EGF-stimulated TRPM6 current is specifically mediated by the EGFR 
To address whether the stimulatory action of EGF was specific to activation of the 
EGFR, the receptor antagonist, AG1478 (also named tyrphostin) was added prior to 
treatment with EGF. Incubation of TRPM6-expressing HEK293 cells with AG1478 
prevented the EGF stimulatory effect (figure 2A). To confirm that EGFR stimulation 
mediated the observed increase in TRPM6 current, a specific tyrosine kinase 
receptor inhibitor, RG13022, was used to block EGFR activation (9). Following a 
10 min exposure, EGF failed to elicit an increase in TRPM6 activity (figure 2B). 
In fact, incubation with either of these compounds reduced baseline TRPM6 activity 
(figure 2A and B). TRPM7, the closest homologue of TRPM6, was also examined 
for an EGF-mediated increase in activity. Consistent with the notion that EGFR 
engagement by EGF is specific for TRPM6 activation, treatment with EGF did not 
affect TRPM7 activity (figure 2C). 
mutants. The samples were plated onto glass bottom Petri dishes (0.17 mm thick 
Wilco Wells, USA) chambers and then mounted on the stage of a confocal laser 
scanning microscope (Zeiss LSM 510) and bathed in a standard solution (130 mM 
NaCl, 20 mM HEPES / Tris, pH 7.4, 1 mM CaCl2, 1 mM MgCl2 and 5 mM KCl) with 
or without EGF. A confocal plane through the center of the cell was brought into 
focus, and two equal areas (2 µm in diameter) were defined. After acquiring two 
base-line fluorescence measurements, one of the selected areas was irreversibly 
photobleached, and then the fluorescence of both areas was measured over time. 
The fractional fluorescence recovery of the bleached area was determined relative 
to the average of the two measurements acquired before photobleaching. The 
unbleached area was used to estimate possible bleaching incurred during image 
acquisition. FRAP data were fitted by nonlinear regression analysis. 
Cell culture and transfection
HEK293 cells were cultured in (DMEM) medium with 10% FCS and transfected as 
described previously (5). Electrophysiological recordings, live cell imaging and 
biochemical assays were performed 48 h post-transfection. MDCK cells were 
maintained in DMEM medium with 10% FCS. MDCK cells were stably transfected 
with GFP-TRPM6, generated by sub-cloning TRPM6 into the GFP- vector as outlined 
below. To select a stable line (MDCK-GFP-TRPM6), the cells were cloned by limiting 
dilution in the presence of 500 µg/ml G418 and screened by immunofluorescence 
and immunoblotting for expression of GFP-tagged TRPM6. The experiments were 
performed at least 72 h after the monolayers had reached confluence.
Cell surface biotinylation 
MDCK-GFP-TRPM6 cells were incubated at 37°C in the presence or absence of EGF 
(10 nM, 30 min) before cells were placed on ice to inhibit endo- and exocytosis. 
Biotinylation was performed on ice, and cells were lysed as described previously (7). 
Subsequently, cell surface proteins were precipitated with neutravidin-agarose beads. 
The purified biotinylated surface proteins were probed for the presence of TRPM6 by 
immunoblotting with an anti-GFP antibody (Sigma-Aldrich, St. Louis, USA).
Statistical analysis
Values are expressed as mean ± SE. Statistical significance between groups was 
determined by analysis of variance (ANOVA) followed by pair-wise comparison 
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Stimulation of TRPM6 by EGF involves both Src-family kinases and MAPK 
Src family tyrosine kinases, including Fyn and Lyn, are important downstream signaling 
intermediates of the EGFR. They are also known to regulate ion channel activity (10). 
We therefore examined whether Src family tyrosine kinases were necessary for TRPM6 
activation by EGF. Pre-incubation with PP2, a compound that selectively inhibits Src 
kinases (11), prevented the stimulatory effect of EGF while its inactive analog PP3, failed 
to prevent EGF from stimulating TRPM6 activity (figure 3B).
Stimulation of TRPM6 by EGF does not require the α-kinase domain
TRPM6 uniquely encompasses an α-kinase domain with a channel. To determine whether 
the α-kinase domain is necessary for EGFR-mediated stimulation of TRPM6 activity, 
HEK293 cells transiently expressing an α-kinase-truncated TRPM6 mutant (TRPM6 
α-kinase) (7) were treated with EGF and subjected to whole-cell recordings. EGFR 
stimulation by EGF was able to increase TRPM6 channel activity, even in the absence of 
the α-kinase domain. EGF increased the current in TRPM6 α-kinase transfected cells by 
75 ± 11% and 73 ± 8% at +80 and -80 mV, respectively (figure 3A). 
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Figure 1. EGF treatment of HEK293 cells stimulates TRPM6 current
 
(A) EGFR protein expression in HEK293 cells by immunoblot analysis. (B) Immunoblot of TRPM6, 
using the HA tag, in transiently transfected HEK293 cells. Time course of the current development 
(pA/pF) at (C) +80 mV and (D) -80 mV of TRPM6 transfected HEK293 cells with (black triangles) 
or without (black circles) EGF pre-treatment (10 nM, 30 min, 37°C) and empty vector transfected 
HEK293 cells with (open triangles) or without (open circles) EGF pre-treatment (n=11-15 cells). 
(E) Representative current-voltage relations of TRPM6 transfected HEK293 cells with (black 
 triangles) or without (black circles) EGF pre-treatment and mock transfected HEK293 cells with 
(open triangles) or without (open circles) EGF pre-treatment after 200s. 
Figure 2. EGFR stimulation by EGF mediates TRPM6 current increase
 
(A) Time course of the TRPM6 current development (pA/pF) at +80 mV (in transiently  transfected 
HEK293 cells) pre-treated with AG1478 (tyrphostin, 1 µM, 1 hour) alone (open  triangles) or prior 
to EGF pre-treatment (black triangles) in comparison to non-treated (open circles) or EGF-treated 
(black circles) cells (n=9-13 cells). (B) Time course of TRPM6  current development (pA/pF) at 
+80 mV in transiently transfected HEK293 cells pre-treated with RG13022 (tyrosine kinase inhibi-
tor, 50 µM, 10 min) alone (open diamonds) or prior to EGF  pre-treatment (black diamonds) relative 
to non-treated (open circles) or EGF-treated (black  circles) cells (n=11-14 cells). (C) Time course 
of the TRPM7 current development (pA/pF) at +80 mV after transient transfection of HEK293 cells 
with (black circles, n=21) or without (open circles, n=16) EGF pre-treatment and empty vector 
transfected HEK293 cells with (black  triangles) or without (stars) EGF pre-treatment (n=9-14 
cells). 
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To confirm that ERK1/2 activation was necessary for the EGF-mediated increase in 
TRPM6 activity we pre-treated TRPM6-transfected HEK293 cells with forskolin, 
thereby activating PKA. Application of forskolin had no effect on TRPM6 current, it 
did however prevent EGF-mediated activation (figure 3B). These findings support 
the conclusion that TRPM6 activation following EGFR engagement is mediated via 
activation of the MAPK pathway. 
Stimulation of TRPM6 by EGF depends on Phosphoinositide Kinase-3 (PI3K) 
and Rac1
A downstream target of Src family kinases is the PI3K/Akt pathway. To address 
whether PI3K is involved in the EGF-mediated stimulation of TRPM6, cells were 
preincubated with the PI3K inhibitors LY294005 or wortmannin. Preincubation with 
either compound prevented the EGF-induced activation of TRPM6 (figure 4A). 
Neither compound altered the TRPM6 current when used in isolation (data not 
shown). A common PI3K effector, implicated in cytoskeletal remodeling and 
membrane traffic is Rac1 (13-15). We therefore sought to ascertain whether 
modulation of Rac1 activity would alter baseline or the EGF-mediated increase in 
TRPM6 current. HEK293 cells were transiently co-transfected with either a dominant 
negative mutant of Rac1 (Rac1-T17N) and TRPM6, or a constitutively active mutant 
of Rac1 (Rac1-G12V) and TRPM6, and then subjected to patch clamp analysis. 
Control cells were transiently co-transfected with empty vector and TRPM6. Cells 
co-expressing Rac1-T17N and TRPM6 displayed significantly decreased TRPM6 
currents compared to TRPM6-transfected cells (figure 4B and C). In these cells, 
EGF pre-treatment did not restore TRPM6 current. In contrast, cells co-transfected 
with Rac1-G12V and TRPM6 exerted a significant increase in TRPM6 current (figure 
4B and C). The addition of EGF to HEK293 cells co-expressing Rac1-G12V and 
TRPM6 did not further increase the TRPM6 current.
EGF increases cell surface expression of TRPM6
Activation of Rac1 results in actin cytoskeletal rearrangement. To assess whether 
this downstream effect of Rac1 was responsible for the EGF-mediated activation of 
TRPM6, the cells were incubated with cytochalasin D, alone or in combination with 
EGF, before obtaining whole-cell recordings. Cytochalasin D alone did not affect 
TRPM6 activity. This agent however prevented the stimulation of TRPM6 activity by 
EGF (figure 4D).
Next, a series of experiments were conducted to identify which signaling pathway(s), 
downstream of the Src family kinases, are necessary for TRPM6 activation. The 
involvement of phospholipase C-gamma (PLCg) was excluded using the PLC 
inhibitor, U73122 and its inactive analog, U73343 (figure 3B). The putative role of 
the MEK1/2 and ERK1/2 limb of the MAPK superfamily was then evaluated. To this 
end, HEK293 cells were pre-incubated with selective inhibitors of MEK1/2 and 
ERK1/2 activation, UO126 and PD98059, respectively. Treatment with either UO126 
or PD98059 prevented EGF from increasing TRPM6 activity, implicating the ERK1/2 
pathway in this signaling cascade (figure 3B). None of these agents had an effect 
on TRPM6 in the absence of EGF. Stimulation of ERK1/2 by the EGFR is preceded 
by Raf-1 activation, an event that can be blocked by protein kinase A (PKA) (12). 
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Figure 3.  EGF mediates a Src family kinase and MAP kinase dependent  
activation of TRPM6 independently of the α-kinase domain
 
(A) Histogram summarizing the current density (pA/pF) at +80 mV and -80 mV after 200s in mock 
(open bars) or TRPM6 α-kinase (closed bars) transfected HEK293 cells in the presence or 
absence of EGF as indicated. * Indicates p < 0.05 compared to cells transfected with α-kinase 
in the absence of EGF treatment (n=13-19 cells). (B) Histogram summarizing the averaged 
 current density (pA/pF) at +80 mV and -80 mV after 200s, of TRPM6 transfected HEK293 cells, 
pre-treated with PP2 (5 µM, 10 min), PP3 (5 µM, 10 min), U73122 (10 µM, 15 min), U17343 (10 µM, 
15 min), PD98059 (15 µM, 25 min), UO126 (50 µM, 25 min) or forskolin (10 µM, 15 min) without 
(open bars) or with (closed bars) EGF pretreatment (10 nM, 30 min). * Indicates p < 0.05 
 compared to TRPM6 current in the absence of EGF treatment (n=9-25 cells). 
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Implicit to the observed prevention of TRPM6 activation by cytochalasin D is the 
notion that EGFR signaling promotes the mobility of endomembrane TRPM6, 
presumably by redistributing endomembrane channels into the plasma membrane. 
To this end, we measured the mobility of TRPM6 in HEK293 cells. This was 
accomplished with a GFP-fused TRPM6 construct and the imaging technique, 
fluorescence recovery after photobleaching (FRAP). GFP-TRPM6 can be expressed 
and detected in HEK293 cells by immunoblotting and fluorescent microscopy 
(figure 5A and B). The electrophysiological characteristics of GFP-TRPM6 were 
evaluated by patch clamp analysis and shown to display a similar baseline and 
EGF-stimulated current (data not shown). As is evident from figure 5C and E, EGF 
treatment increased both the rate and fraction of endomembrane TRPM6 that is 
mobile. That Rac1 alters the mobility of endomembrane TRPM6 was further 
supported by repeating these measurements after co-transfection with either 
Rac1-G12V, the constitutively active mutant, or Rac1-T17N, the dominant negative 
mutant (figure 5D and E). Consistent with the whole-cell patch clamp analysis 
(figure 4C), Rac1-G12V increased both the rate of recovery and the mobile fraction 
of TRPM6 (figure 5D and E). Moreover, EGF treatment failed to further increase the 
mobility or the mobile fraction. Conversely, a decreased mobile fraction is observed 
in cells co-transfected with Rac1-T17N. EGF treatment in the presence of Rac1-T17N 
failed to even return the mobile fraction of TRPM6 to that of the control (figure 5D 
and E). These observations correspond to decreased channel activity irrespective 
of EGF treatment (figure 4C). Taken together these findings support the concept 
that EGFR activation stimulates Rac1, alters cytoskeletal dynamics, and consequently 
increases the mobility of endomembrane TRPM6.
  
Given that TRPM6 current is enhanced by EGF treatment together with the above 
FRAP results, this implies that endomembrane TRPM6 is moving into the plasma 
membrane, thereby increasing the number of active channels there. To confirm that 
this was occurring cell surface biotinylation experiments were performed, utilizing 
the fused GFP for immuno-detection. We used a TRPM6 stably expressing renal 
epithelial cell line, Madin Darby Canine Kidney (MDCK), to perform these studies 
(referred to hereafter as MDCK-GFP-TRPM6). Quantification of cell surface expressed 
TRPM6 by this method revealed a significant increase in the cell surface expression 
of TRPM6 after incubation with EGF (figure 6). 
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Figure 4.  Stimulation of TRPM6 by EGF depends on PI3K, Rac1 and the  
actin cytoskeleton
 
(A) Time course of the current development (pA/pF) at +80 mV of TRPM6 transfected HEK293 
cells pre-treated with wortmannin (10 nM, 20 min, up triangles) or LY492005 (50 µM, 20 min, down 
triangles) prior to treatment with EGF. For comparison cells that were not treated at all (open cir-
cles) or just treated with EGF (black circles) are included (n=9-13 cells). (B) Time course of the 
current development (pA/pF) at +80 mV of TRPM6 and empty vector (circles), TRPM6 and Rac1-
G12V (triangles) and TRPM6 and Rac1-T17N (diamonds) transfected HEK293 cells, pre-treated 
(black symbols) or not (open symbols) with EGF (n=13-19 cells). (C) Histogram summarizing the 
current density (pA/pF) at +80 mV and -80 mV of TRPM6 and empty vector (Control), TRPM6 and 
Rac1-T17N (T17N) and TRPM6 and Rac1-G12V (G12V) transfected HEK293 cells pre-treated or 
not with EGF as indicated. Open bars indicate  experimental conditions in which HEK293 cells 
were transfected with the empty vector whereas closed bars indicate HEK293 cells transfected 
with TRPM6 in the absence or presence of Rac1 mutants. * Indicates p < 0.05 compared to 
TRPM6 current in empty vector transfected, non- treated conditions (n=13-19 cells). (D) Histogram 
summarizing the current density (pA/pF) at +80 mV and -80 mV of TRPM6 transfected HEK293 
cells pre-treated or not with EGF or  cytochalasin D (CytD) (10 µM, 40 min) as indicated. Open 
bars indicate experimental conditions in which HEK293 cells were transfected with empty vector 
whereas closed bars indicate HEK293 cells transfected with TRPM6. * Indicates p < 0.05 com-
pared to TRPM6 current in non-treated conditions (n=14-16 cells). 
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elucidate the downstream signaling events. This revealed TRPM6 stimulation to be 
dependent on the activation of the Src family of tyrosine kinases, the ERK/MEK 
pathway and PI3K. Cytoskeleton remodeling was clearly implicated. This was 
evinced through a pharmacological inhibition of EGF-mediated activation by 
cytochalasin D, an observed parallel increase in TRPM6 current induced by 
constitutively active Rac1 and abrogation of this effect in the presence of dominant 
negative Rac1. FRAP was further employed to demonstrate that EGF increases the 
mobility of TRPM6, an effect that is also Rac1 dependent. Ultimately, it is shown that 
EGF activates TRPM6 by increasing the number of channels at the plasma 
membrane. Together these findings clearly outline the activation of TRPM6 by EGF 
(figure 6C), a process fundamental to Mg2+ homeostasis.
EGFR signaling pathway and TRP channel regulation
Our study is the first to demonstrate that EGF regulates the melastatin subfamily of TRP 
channels. Further, the effect is specific to member TRPM6 as no increase in TRPM7 
Discussion
The present study delineates the molecular details of TRPM6 stimulation by EGF, 
from receptor to channel. First, it was demonstrated that EGF specifically activates 
TRPM6 via engagement of its receptor, the EGFR. A combination of live cell 
imaging, biochemical and electrophysiological approaches were employed to 
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Figure 6. EGF increases the cell surface fraction of TRPM6
 
(A) Representative immunoblots of total cellular TRPM6, the input (upper panel) and the 
 biotinylated, cell surface fraction (lower panel) after treatment of GFP-TRPM6-MDCK cells with 
EGF (30 min, 10 nM) or vehicle (Control). Non-transfected MDCK cells (WT) and cells that were 
not treated with biotin (No Biotin) are included for comparison. (B) Quantification of experiment 
in A. * Indicates p < 0.05 compared to vehicle treated condition (n=11 per condition). 
(C) EGFR stimulation by EGF leads to tyrosine kinase, Src, PI3K and Rac1 activation. This latter 
effector, modifies actin polymerization leading to increased mobility and plasma membrane 
insertion of TRPM6 subsequently, Mg2+ influx through the channel is increased.
Figure 5. EGF increases the mobility of TRPM6
 
(A) Immunoblot of GFP-TRPM6 transiently transfected in HEK293 cells and (B) a confocal slice 
through a representative cell. (C) A plot of fluorescence recovery over time in the presence  (filled 
squares) or absence (open circles) of EGF. (D) Similar curves of cells co-transfected with GFP-
TRPM6 and Rac1-G12V, Rac1-T17N or mock in the presence or absence of EGF (open squares 
mock, open triangles mock + EGF, crosses Rac1-G12V, stars Rac1-G12V + EGF, open diamonds 
Rac1-T17N and open circles Rac1-T17N + EGF). (E) A histogram displaying the final recovery of 
TRPM6 in the presence or absence of EGF when co-transfected with mock (Control), Rac1-G12V 
or Rac1-T17N as indicated. * Indicates p < 0.05 compared to TRPM6 final recovery without EGF 
treatment in the presence of mock co-transfection (n=14-21 cells).
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TRPM6 was moving and the fraction that was mobile. Indeed the application of EGF 
appeared to mobilize an immobile subset of TRPM6 (figure 5, C and E). 
The co-expression of Rac1 mutants altered the mobile fraction of TRPM6, in parallel 
to the observed changes in activity. Moreover, co-expression of these constructs 
prevented the EGF-mediated alteration in TRPM6 mobility. That EGF activation 
ultimately leads to increased expression at the plasma membrane was substantiated 
by cell surface biotinylation analysis. Together, these observations provide strong 
evidence that EGF increases the abundance of TRPM6 at the plasma membrane. 
What then explains the increased abundance of TRPM6 at the plasma membrane? 
We propose that TRPM6 activation subsequent to EGFR stimulation regulates the 
amount of recycling TRPM6 and/or the balance between constitutive exocytosis 
and endocytosis in favor of TRPM6 accumulation at the cell surface. This hypothesis 
is supported by our FRAP analysis which demonstrates that EGFR activation 
increases the mobility of endomembrane TRPM6 and releases a pool of immobile, 
or poorly mobile, endomembrane channels. The total number of channels within the 
plasma membrane is determined by the combined effects of membrane insertion, 
retrieval and number of recycling channels. EGFR activation likely increases the 
number of recycling channels and the balance between endocytosis and exocytosis, 
to favor increased plasma membrane expression. Consistent with an effect of EGF 
on the recycling kinetics of the TRP family of channels, EGF prevents the 
internalization of plasma membrane TRPC3 (23). 
Potential role(s) of EGF-mediated regulation of TRPM6
Our findings implicate both Raf-1 and the ERK1/2 limb of the MAPK superfamily in 
EGF-mediated activation of TRPM6. EGF is known to alter ion homeostasis through 
inhibition of the amiloride-sensitive Na+ reabsorption from collecting duct. This also 
occurs downstream of ERK1/2 activation (24). In kidney, TRPM6 and EGF are 
predominantly expressed in DCT, the nephron segment responsible for regulated, 
transepithelial Ca2+ and Mg2+ reabsorption (25). TRPM6 mediates and regulates 
this latter process, a conclusion supported by its unique permeation characteristics, 
carrying almost exclusively divalent cations with a higher affinity for Mg2+ than Ca2+ 
(5, 8) and its specific localization to Mg2+-transporting epithelia. That this process 
is regulated by the MAP kinases is consistent with previous findings. However in 
DCT, EGF appears to uniquely activate TRPM6, to the exclusion of TRPM7, TRPV5 
current, the closest homologue, was observed upon EGF application. To confirm that 
EGF specifically activates the EGFR we demonstrated the presence of this receptor in 
our model system and then showed an inhibition of the observed effect when the 
receptor was blocked with selective antagonists. Further evidence that EGFR 
engagement is required for TRPM6 activation was provided by the demonstration that 
inhibition of the receptor’s tyrosine kinase activity, prevented the EGF-induced increase 
in TRPM6 activity. Thus, EGF-mediated activation of TRPM6 is novel within this 
subfamily of channels and requires the specific engagement of the EGFR.
Among EGFR effectors, PLCg is a known regulator of TRPC channel activity (13, 16). 
Furthermore, TRPM7 has been shown to interact with PLCg and ß isoforms (17) and 
to be inactivated by PIP2 hydrolysis (18). However, inhibition of PLCg failed to 
prevent EGF-mediated TRPM6 regulation, suggesting that PLCg is not necessary for 
the activation of TRPM6 by EGF. Thus, PLCg is a potential discriminator between 
EGF regulation of TRPM6 and other TRP channels (16, 17). Further, because TRPM7 
is activated by PLCg and not EGF, this finding highlights the specificity of the EGF 
signaling cascade for TRPM6.
Inhibition of PI3K activity prevented EGF from activating TRPM6. The role of the small 
Rho GTPase Rac1, a common effector of PI3K was, therefore, investigated (19). 
Dominant negative Rac1 (T17N) abrogated TRPM6 current development and prevented 
the EGF-mediated increase in TRPM6 activity. In contrast, a constitutively active mutant 
of Rac1 (G12V) mimicked the EGF stimulation of TRPM6 activity. Both PI3K and Rac1 
components have been implicated in TRPC5 and TRPV1 stimulation upon EGF and 
nerve growth factor application, respectively (13, 20). Therefore, in addition to the 
regulation of brain function such as neurite extension and pain perception through TRP 
channels, our findings implicate Rac1 in renal Mg2+ reabsorption via the regulation of 
TRPM6 channel activation, independently of the constitutively expressed TRPM7.
Regulation of TRPM6 at the plasma membrane
The requirement of PI3K, Rac1 and a dynamic actin cytoskeleton for EGF-mediated 
activation of TRPM6 implies that altered endomembrane traffic and potentially 
redistribution to the plasma membrane is responsible for the increased current 
observed (21, 22). To test this hypothesis we measured the mobility of TRPM6 
before and after treatment with EGF. This increased both the rate that endomembrane 
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and TRPV6 (figure 2C & data not shown). TRPV5 mediates active transcellular 
Ca2+ reabsorption from the distal part of the nephron, hence EGFR signaling 
confers a precision to the control of Mg2+ homeostasis and can therefore be 
defined as a magnesiotropic hormone.
The specificity of this pathway is highlighted by clinical examples. The patient we 
originally described (1), displayed clinical symptoms secondary to hypomagnesemia, 
and lacked evidence of altered Ca2+ homeostasis. Further, treatment with the 
anti-EGFR antibody, cetuximab, specifically alters plasma Mg2+ levels (1, 3). The 
work described herein delineates the pathway between EGFR engagement and 
apical Mg2+ influx through TRPM6. A process whose specificity is mediated by the 
restricted location of TRPM6 and unique signaling within this location. Both the Src 
family of tyrosine kinases and the small Rho GTPase, Rac1 are central to the latter. 
The increased activity of TRPM6 is ultimately the result of increased cell surface 
expression. These findings provide molecular insight into a novel mechanism 
specifically regulating transepithelial Mg2+ transport and consequently whole body 
Mg2+ homeostasis.
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Introduction
Mg2+ is an important, predominantly intracellular cation that is indispensable for a 
wide variety of biological processes (1). Although Mg2+ is a dominant divalent 
intracellular cation and is required for the function of diverse types of enzymes that 
participate in virtually every cellular process, the molecular mechanisms that 
regulate its homeostasis are poorly understood. The plasma Mg2+ concentration is 
regulated within a narrow range by changes in urinary Mg2+ excretion in response to 
altered uptake by the intestine. Thus, the kidney plays a key role in Mg2+ homeostasis 
(2). Most renal reabsorption of Mg2+ occurs in the proximal tubule and the thick 
ascending limb of Henle’s loop (TAL) via a passive paracellular transport process, 
but the fine-tuning of the Mg2+ excretion takes place in the distal convoluted tubule 
(DCT), where Mg2+ is reabsorbed via an active transcellular transport process (2). 
The first step of transcellular transport is the influx of Mg2+ across the apical plasma 
membrane of the epithelial cell. Subsequently Mg2+ diffuses or is transported to the 
basolateral membrane where it is extruded into the bloodstream. Genetic studies of 
disorders with hereditary hypomagnesemia have proven to be very important in 
gaining more insight into the molecular and cellular mechanisms that underlie Mg2+ 
(re)absorption. Through the discovery of the epithelial Mg2+ channel TRPM6 by 
studying patients with hypomagnesemia with secondary hypocalcemia (HSH) and 
the identification of its closest homologue TRPM7, the knowledge of active Mg2+ 
transport was greatly boosted. TRPM6 constitutes the gatekeeper of transcellular 
Mg2+ transport in kidney and intestine and is essential for the maintenance of total 
body Mg2+ homeostasis. In contrast, TRPM7 displays a ubiquitous expression 
pattern and is important for Mg2+ homeostasis at the cellular level. Since TRPM6 
forms the entry gate for Mg2+ into the DCT cells, it is the ideal target for hormonal 
regulation of active Mg2+ reabsorption. Although TRPM6 has been identified as the 
apical entry mechanism of transcellular Mg2+ transport, the identity of proteins and 
(hormonal) factors that regulate and coordinate the essential steps in transcellular 
Mg2+ transport, including cytosolic Mg2+ diffusion and basolateral extrusion, are still 
elusive. Therefore, the aim of this thesis was to increase the knowledge of renal 
Mg2+ handling at the molecular, cellular and body level in health and disease. 
This chapter discusses the research presented in this thesis, which significantly 
attributed to our understanding of active transcellular Mg2+ reabsorption in general 
and in particular of TRPM6. 
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of TRPM6 (4). In addition, these results correspond with the pore properties of 
TRPM4, which also has a more complex pore structure, but are in contrast with the 
members of the TRPV family in which a single amino acid determines the pore 
permeation properties (5, 6). Interestingly, the permeation rank order of divalent 
cations for TRPM6 is: Ba2+ > Ni2+ > Mg2+ > Zn2+ ≥ Ca2+ whereas for TRPM7 this 
is: Ba2+ > Ni2+ > Zn2+ > Mg2+ > Ca2+. Compared to the permeation profile of 
TRPM7, the selectivity for Mg2+ conductance is higher for TRPM6 (chapter 2). 
Although the putative pore-formig regions of both proteins are highly homologous, 
differences are found at positions Y1022, G1028, C1034, S1035 and Q1036 and 
P1037 for TRPM6 corresponding to F1045, Y1051, A1057, N1058, D1059, and S1060 
in TRPM7, respectively (figure 1). 
Further investigation is needed to unveil the role of these individual amino acids in 
constituting the difference in selectivity for Mg2+ between TRPM6 and TRPM7.
In addition to individual differences between TRPM6 and TRPM7, the identification 
of molecular pore determinants of TRPM6 and TRPM7 is even more complex 
Structural analysis of the TRPM6 pore
At present, little is known about the structure and the specific amino acids that 
determine the specific conductive properties of TRP and more specifically TRPM 
pores. To identify the molecular pore determinants responsible for the Mg2+ 
permeability of TRPM6, the putative pore-forming region of this channel was 
modeled based on the crystal structure of the K+ channel KcsA (3). The putative 
pore-forming region of TRPM6 contains three negatively charged amino acid 
residues, i.e. E1024, E1029 and D1031, which are potential Mg2+ binding sites 
determining the conductive properties of this channel (figure 1). The latter two are 
present in the putative selectivity filter which stretches from G1028 to C1033. 
Interestingly, E1024 is conserved in TRPM1, TRPM3 and TRPM7 and E1029 in 
TRPM5 and TRPM7. D1031 is fully conserved throughout all members of the TRPM 
subfamily. To evaluate the functional role of these negatively charged residues all 
were neutralized to alinine. This resulted in non-functional channels except for 
E1029A. Unfortunately, numerous attempts trying to detect the plasma membrane 
localization of HA- and VSV-tagged TRPM6 by biotinylation were unsuccesful. 
Therefore, detection of wild-type HA-tagged TRPM6 channels and the non-functional 
channels at the plasma membrane was unattainable. As a consequence, we were 
unable to determine whether the non-functional channels resulting from the 
mutations described above, are either inserted in the plasma membrane or are 
retained intracellularly. Future studies, using methods with improved TRPM6 plasma 
membrane detection by for example the use of other tags and antibodies should 
address this question. The mutant E1029A displayed dissimilar permeation 
properties as increased pore diameter and reduced ruthenium-red (RR) sensitivity 
compared to wild-type TRPM6. Substitution of I1030 by methionine to resemble the 
pore of TRPM4 and V1032 by alanine resulted in functional TRPM6 channels with 
distinctive pore properties. The I1030M mutant displayed a decreased pore 
diameter and reduced RR sensitivity compared to wild-type TRPM6. The V1032 
mutant showed decreased current amplitudes, but no change in pore diameter or 
RR sensitivity. 
Taken together, these data indicated that several amino acids together in the 
putative pore region 1028GEIDVC1033 determine the Mg2+ selectivity of TRPM6 
(figure 1), which is in accordance with a report of Li and colleagues who 
demonstrated that E1024 and E1029 residues are essential for the Mg2+ permeability 
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Figure 1.  Alignment of the putative pore-forming region of all eight members  
of the TRPM subfamily
 
The highly conserved hydrophobic amino acids are highlighted with a diagonal pattern, the 
 conserved aspartate (D) is shown in a vertical pattern, and the conserved residues with polar  
or charged groups are shown in a horizontal pattern (adapted from (5, 7)). Asterisks denote the 
amino acid residues mutated described in chapter 2.
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TRPM7 and trafficking was not affected, detailed patch clamp analysis is required 
to investigate the P1070R pore properties in detail. In addition to studying pore 
mutants by patch clamp analysis, future crystallographic structure assays of the 
TRPM6 pore allow a detailed study of the pore structure of TRPM6. 
Tissue distribution of  TRPM6  
To characterize the distribution of the epithelial Mg2+ channels TRPM6 and TRPM7, 
we studied the expression profile of these channels in various mouse tissues. We 
demonstrated that TRPM6 mRNA is predominantly expressed in kidney, lung, 
cecum and colon, whereas TRPM7 showed a ubiquitous mRNA expression pattern 
(chapter 3). The omnipresent expression pattern of TRPM7 is in line with its essential 
role in cell viability and maintaining cellular Mg2+ homeostasis (10-12). The 
expression pattern of TRPM6 is in accordance with the observed disturbance of 
Mg2+ (re)absorption in HSH patients and its physiological function to maintain a 
proper body Mg2+ balance (13, 14). Moreover, by Northern blot analysis of human 
tissues, Walder et al. demonstrated that TRPM6 mRNA was abundantly expressed 
in kidney and colon (13). In addition, Northern blot analysis of mouse tissues 
revealed that full-length TRPM6 is predominantly expressed in kidney and to a 
lesser extent in lung (13). Moreover, Fonfria and colleagues reported that TRPM6 
mRNA in human is principally expressed in kidney, intestine, brain and pituitary 
gland (10). Although Fonfria et al. detemined the TRPM6 mRNA expression levels 
by two different techniques (SYBR green and TaqMan), the values were not 
corrected for the mRNA expression levels of a housekeeping gene but for the 
amount of total mRNA used, rendering the results less reliable. Moreover, the 
expression of TRPM6 mRNA in human brain was not confirmed by the study of 
Walder and colleagues, who did not detect TRPM6 mRNA expression in both 
human and mouse brain (13). Thus, in human and mouse, TRPM6 is predominantly 
expressed in kidney and intestine. 
In kidney, TRPM6 protein was demonstrated to be specifically expressed in DCT 
(15). In contrast, Schlingmann and colleagues showed by reverse transcriptase 
PCR (RT-PCR) that TRPM6 mRNA in rat kidney is not only expressed in DCT but 
also in the proximal convoluted tubule, connecting tubule, cortical collecting duct, 
outer medullary collecting duct, and inner medullary collecting duct. A possible 
explanation for this discrepancy could be the result of cross contamination of these 
because different pore properties were described for TRPM6, TRPM7 and TRPM6/
TRPM7 heteromeric channels (8). Moreover, TRPM7 is expressed in every cell type 
and therefore possibly contributes to TRPM6/TRPM7 tetramer formation and 
observed channel properties in cells transiently overexpressing TRPM6. 
It can be speculated that the selectivity filter for Mg2+ in TRPM6 consists of a ring 
of 8 negatively charged residues in a tetrameric pore molecule (figure 2). 
Consequently, mutations in the selectivity filter of TRPM6 could result in defective 
channels and the identification of such mutations in hypomagnesemic patients can 
further unveil the molecular determinants of Mg2+ permeability. The mutation 
P1017R, which results in a dominant-negative inhibition of TRPM6 channel activity, 
was the first identification of a mutation in the putative pore-forming region upstream 
of the selectivity filter in a patient with hypomagnesemia with secondary 
hypocalcemia (HSH) (9). Although heterotetrameric assembly of this mutant with 
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Figure 2. The predicted structural organization of TRPM6 and TRPM7
 
(A) TRPM6 and TRPM7 belong to the largest TRP channels consisting of around 2000 amino 
acids including very large cytosolic amino- and carboxyl-termini, and an atypical α-kinase 
domain. The gate and selectivity filter are formed by the four 2 transmembrane domains 
 (TM5-pore loop-TM6) facing the centre of the channel. Cations are selected for permeation by the 
extracellularly facing pore loop, held in place by the TM5 and TM6 α-helices. (B) Top view of a 
schematic representation of the tetrameric organization of the TRPM6/7 pore. The pore-forming 
regions of four TRPM6/7 monomers join to constitute a single pore. The individual  transmembrane 
domains are indicated by numbers 1 to 6. 
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investigation. Since a simultaneous disturbance of the Mg2+ and Ca2+ balance is 
often observed in various electrolyte disorders (chapter 1), the interrelationship 
between 17ß-E2, Ca2+ and the Mg2+ balance requires further investigation to reveal 
whether TRPM6 expression is primarily regulated by 17ß-E2 or is a secondary effect 
of changes in the Ca2+ balance induced by 17ß-E2. Interestingly, Mg2+ homeostasis 
and 17ß-E2 have been linked in menstrual migraine, pregnancy,  pre-eclampsia, 
and menopause (23-25). This raises the question whether in males, who express 
lower concentrations of 17ß-E2, the Mg2+ reabsorption is differentially regulated 
(26). Moreover, it would be interesting to study the role of androgens and estrogens 
in male and female Mg2+ homeostasis and in particular its effect on TRPM6 
mediated transcellular Mg2+ transport in more detail. 
Transepithelial transport of Mg2+ and Ca2+ in intestine
In chapter 3 was demonstrated that the epithelial Ca2+ channel TRPV6, which 
constitutes the luminal Ca2+ entry mechanism in active Ca2+ absorption (27, 28), is 
predominantly expressed in duodenum and colon. Since in mouse intestine, TRPM6 
is predominantly expressed in cecum and colon with very low expression levels in 
duodenum and jejunum, it is likely that Mg2+ is exclusively actively absorbed in the 
distal part of the intestinal tract, including cecum and colon, whereas Ca2+ is 
transcellularly absorbed in both the proximal (duodenum) and distal (colon) part of 
the intestinal tract. This is supported by the fact that 45Ca2+ absorption studies, 
which measure the rate of Ca2+ absorption in the proximal intestine, showed that 
dietary Mg2+ content did not compete with the rate of Ca2+ absorption (chapter 3). 
Possibly, differences of the intestinal epithelium and the intestinal mucosa of 
different parts of the intestinal tract affect or create an environment favoring the 
absorption of Mg2+ or Ca2+ divalents. This could explain the partial overlap of 
active Mg2+ and Ca2+ absorption. 
Regulation of TRPM6 by dietary Mg2+ and coupling of the Mg2+ and Ca2+ balance
Disturbances in the Mg2+ balance are often accompanied with disturbances in the 
Ca2+ balance (29). Mutual disturbances of the Mg2+ and Ca2+ balance are for 
example observed in HSH and Gitelman syndrome. However, the concurrence of 
these symptoms in these disorders is  not well understood. As described in chapters 
3 and 4, dietary Mg2+ restriction in mice resulted in hypomagnesemia, renal Mg2+ and 
Ca2+ conservation, and increased expression of TRPM6 in kidney. In contrast, the 
segments with DCT during isolation. In addition, Schlingmann et al. revealed with 
RT-PCR that TRPM6 mRNA is expressed in all intestinal segments of rat. However, 
RT-PCR is not quantitative and might not represent physiological expression levels 
(14). Therefore, based on our results of quantitative PCR in mouse, we suggest that 
cecum and colon, which comprise the distal part of the intestine, are the dominant 
intestinal segments important for transcellular Mg2+ absorption. By Northern blot 
analysis of human tissues Walder et al. also demonstrated TRPM6 mRNA expression 
in colon but not in the small intestine (13). Interestingly, over 60% of the total 
intestinal TRPM6 mRNA expression of mouse resides in cecum and suggests that 
this segment is most important for transcellular Mg2+ absorption (chapter 3). 
Although the explanation for the high cecum TRPM6 expression levels remains 
obscure, the fermentation processes and the breakdown of cellulose by bacteria in 
the cecum possibly generate a favorable environment for transcellular Mg2+ 
absorption. Detailed analysis of TRPM6 expression levels in the human intestinal 
tract is necessary to conclude which intestinal segments are (most) important for 
transcellular Mg2+ absorption. Preliminary results indicate that in human, TRPM6 is 
predominantly expressed in colon (data not shown). 
The role of TRPM6 in lung remains elusive and further research, first determining in 
which cells and tissues the Mg2+ channel is specifically expressed, is needed to 
ascertain the function of TRPM6 in this organ. We and Walder et al. demonstrated 
that TRPM6 mRNA is expressed in lung tissue of mouse (13). However, expression 
of TRPM6 mRNA was not detected in human lung tissue (10, 13). It was  suggested 
that low dietary Mg2+ intake may be involved in the etiology of asthma and chronic 
obstructive airways disease (16). 
Regulation of TRPM6 in kidney by 17ß-estradiol
In chapter 3 it was demonstrated that 17ß-estradiol (17ß-E2), which has been 
implicated in maintenance of the Ca2+ balance (17-19), positively regulates renal 
TRPM6 mRNA expression levels. In addition it was shown that 1,25-dihydroxyvitamin 
D3 (1,25(OH)2D3) and parathyroid hormone (PTH) did not alter renal TRPM6 mRNA 
expression levels. Although the calciotropic hormones 1,25(OH)2D3 and PTH (20, 21) 
did not modify the renal expression levels of TRPM6 and TRPM7, these hormones 
have been suggested to influence Mg2+ homeostasis (2, 14, 22). However, the role 
of 1,25(OH)2D3 and PTH in regulation of the systemic Mg2+ balance needs further 
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could be an explanation for the renal Mg2+ wasting in these mice, the question 
remains what triggered the downregulation of TRPM6 protein expression. It was 
demonstrated that TRPV5-/- mice show impaired Ca2+ reabsorption, hypercalciuria, 
hypervitaminosis D, and intestinal hyperabsorption of Ca2+ (39). Moreover, it was 
shown that the hypervitaminosis D mediates the compensatory Ca2+ hyperabsorption 
in TRPV5-/- mice (40). Possibly, the high vitamin D levels present in TRPV5-/- mice, 
which result in hyperabsorption of Ca2+, also lead to hyperabsorption of Mg2+. 
Consequently, downregulation of renal TRPM6 expression levels in TRPV5-/- mice 
could be a secondary effect in response to an increased filtered load of Mg2+ 
resulting from the concomitant hyperabsorption of Mg2+ with Ca2+. Thus, if 
hypervitaminosis D induces hyperabsorption of Mg2+, the hypermagnesuria and 
downregulation of renal TRPM6 expresion in TRPV5-/- mice might be explained. 
Interestingly, we showed that 1α-hydroxylase knockout (1α-OHase–/–) and TRPV5/1α-
hydroxylase double knockout (TRPV5–/– /1α-OHase–/–) mice (40, 41), which have 
undetectable levels of 1,25(OH)2D3, display hypomagnesuria. This indicated that 
the lack of TRPV5 does not primarily cause hypermagnesuria and renal 
downregulation of TRPM6 in TRPV5-/- mice. In addition to wild-type mice, the Mg2+ 
and Ca2+ balance of TRPV5-/- mice fed a Mg2+-deficient, Mg2+-normal and a 
Mg2+-enriched diet was studied (chapter 4). TRPV5-/- mice responded similarly as 
wild-type mice to the three different dietary Mg2+ regimes, as described previously. 
Dietary Mg2+ restriction resulted in hypomagnesemia, renal Mg2+ and Ca2+ 
conservation, and increased expression of TRPM6 in kidney. Moreover, the 
Mg2+-enriched diet increased renal Mg2+ and Ca2+ excretion and TRPM6 
expression levels in colon. In addition, dietary Mg2+ content did not alter TRPM7 
mRNA expression levels in kidney and intestine. Moreover, dietary Mg2+ content did 
not influence serum Ca2+ levels.
Elucidation of the gene defect of isolated recessive renal hypomagnesemia (IRH)
The role of epidermal growth factor (EGF) as a magnesiotropic hormone was 
discovered by careful analysis of a Dutch family with two daughters suffering from 
IRH, which is characterized by hypomagnesemia, convulsions from the first year of 
life, and moderate mental retardation. Remarkably, other biochemical abnormalities 
were not identified, especially no disturbance in urinary Ca2+ excretion. Previously, 
the Mg2+ balance in these two affected daughters was extensively studied as 
reported in 1987 (42). Twenty years later, improvement of linkage and DNA analysis 
Mg2+-enriched diet increased urinary Mg2+ and Ca2+ excretion and TRPM6 expression 
levels in colon. These different dietary Mg2+ regimes did not alter TRPM7 mRNA 
expression levels in kidney and intestine supporting the role of TRPM7  in cellular Mg2+ 
homeostasis. Dietary Mg2+ content did not influence serum Ca2+ levels. Dietary Mg2+ 
content influences Ca2+ excretion at the level of the intestine or kidney possibly via 
hormones. In addition, the involvement of the Ca2+/Mg2+-sensing receptor (CaSR) 
and transport of Mg2+ and Ca2+ by claudin-16 and/or claudin-19 need further attention 
since all three proteins are involved in maintenance of both the total body Mg2+ and 
Ca2+ balance (30-34). The exact mechanism resulting in the altered Ca2+ balance in 
response to dietary Mg2+ restriction or supplementation, remains unresolved. 
The upregulation of TRPM6 in kidney during dietary Mg2+ restriction supports a 
mechanism actively regulating the expression level of this channel to maximally 
facilitate Mg2+ reabsorption during Mg2+ deficiency. This emphasizes the gatekeeper 
function of TRPM6 in transepithelial Mg2+ transport. Remarkably, TRPM6 mRNA 
levels in colon are upregulated by the Mg2+-enriched diet, but not after dietary 
Mg2+ restriction. The molecular details resulting in the differential upregulation of 
TRPM6 expression in kidney and intestine in response to Mg2+ restriction and a 
Mg2+-enriched diet, respectively, need to be elucidated. It is possible that the 
CaSR, which is present in kidney and colon (35-37), fulfills an opposite role in the 
regulation of renal and intestinal TRPM6 expression levels upon alternating dietary 
Mg2+ content. In analogy, a Ca2+-enriched diet increased duodenal mRNA 
expression levels of the epithelial Ca2+ channel TRPV6 of 25-hydroxyvitamin D3-1α-
hydroxylase (1α-Ohase) knockout mice, which have undetectable levels of 
1,25(OH)2D3 (38). Thus, in the absence of 1,25(OH)2D3 regulating intestinal Ca2+ 
absorption, TRPV6 mRNA expression levels increase during high dietary Ca2+ 
intake. Since a similar effect of TRPM6 expression was observed in response to 
high dietary Mg2+ content in wild-type mice, this suggests that no hormone, like 
1,25(OH)2D3 regulating Ca2+ absorption, exists for Mg2+. 
Hypermagesuria in TRPV5 knockout mice
In chapter 4 the Mg2+ and Ca2+ balance of TRPV5 knockout (TRPV5-/-) mice  was 
studied. Surprisingly, TRPV5-/- mice displayed renal Mg2+ wasting, decreased renal 
TRPM6 mRNA and protein abundance together with normal serum Mg2+ levels. 
Although the observed reduced renal expression levels of TRPM6 in TRPV5-/- mice 
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48). The identified P1070L mutation resides in the intracellular tail of pro-EGF and 
results in aberrant secretion of EGF to the basolateral compartment, but not in 
disturbed secretion to the luminal space as studied in polarized MDCK cells. Based 
on the fact that pro-EGF-P1070L is efficiently secreted to the luminal space, we 
suggested that disturbed basolateral sorting of pro-EGF-P1070L results from 
missorting and is not due to affected pro-EGF processing or aberrant processing 
by proteases. In the literature, several basolateral sorting motifs have been 
described, including the PXXP motif, in which X is an arbitrary amino acid (49-51). 
In addition, pro-EGF contains a cytoplasmic arginine-arginine (RR) motif. 
Interestingly, both the PXXP and RR motifs have been identified as cellular kinase 
binding motifs and could be involved in the apical function of pro-EGF (52). We 
hypothesized that the P1070L mutation disrupts the basolateral sorting motif 
1067PKNP1070 resulting in improper basolateral sorting of pro-EGF. Impaired 
basolateral sorting was demonstrated functionally by patch clamp analysis 
measuring the stimulatory effect on TRPM6 of the separately collected apical and 
basolateral pre-conditioned media of MDCK cells stably expressing either wild-type 
or mutant pro-EGF. Additional biochemical experiments are necessary to resolve 
the biochemical processing of mutant EGF in detail. In addition, experiments are 
required to elucidate all residues which constitute the basolateral sorting motif of 
pro-EGF. Interestingly, in the salivary gland, pro-EGF appears to be processed 
intracellularly to the mature 6 kDa EGF which is stored as a high molecular weight 
complex within secretory granules (53-55). Therefore, it is expected that patients 
with IRH display normal excretion of EGF in the saliva. Furthermore, the role of EGF 
in intestinal Mg2+ absorption needs to be investigated since TRPM6 is also 
abundantly expressed in human colon (unpublished observations). 
Additional role of EGF in ion reabsorption: EGF and transcellular phosphate 
transport
In addition to the role of EGF as a magnesiotropic hormone, EGF has previously 
been reported to stimulate phosphate transport in the proximal convoluted tubule 
(PCT) via basolateral receptors (56). It is possible that the basolaterally released 
form of EGF, which enters the interstitium, can bind the basolaterally localized 
EGFRs of the PCT, because the PCT is in the immediate vicinity of the DCT. 
Therefore, phosphaturia in patients with IRH might be expected. However, the 
values of phosphate reabsorption of the patients with IRH were between 85 and 
resulted in the discovery of the candidate gene EGF, encoding pro-EGF, and 
subsequent identification of a mutation in this gene. The identified mutation 
substitutes a proline at position 1070 for a leucine (P1070L) and is located in the 
intracellular domain of the protein. Through the elucidation of the gene defect in IRH 
we could demonstrate that EGF is a novel autocrine/paracrine magnesiotropic 
hormone, which regulates Mg2+ reabsorption by regulation of TRPM6 activity via 
EGF receptor (EGFR) binding (chapter 5). In addition, disruption of basolateral 
sorting and release of EGF by a point mutation or inhibition of the EGFR results in 
reduced activity of TRPM6 and renal Mg2+ wasting. Thus, stimulation of basolateral 
EGFR by EGF is required for baseline TRPM6 activity necessary to maintain Mg2+ 
homeostasis. This is supported by the fact that the hypomagnesemia observed in 
the two sisters with IRH (serum Mg2+ 0.53-0.66 mM) is less severe than the 
hypomagnesemia reported in patients with hypomagnesemia with secondary 
hypocalcemia (serum Mg2+ as low as 0.08 mM), in which TRPM6 itself is affected 
and non-functional (13-15, 42). The identification of autocrine/paracrine regulation 
of TRPM6 activity by EGF and thereby of active Mg2+ reabsorption could open new 
leads to develop therapeutic possibilities to control renal Mg2+ handling. In addition, 
this discovery might help to elucidate the mechanisms and epidemiological 
phenomena of hypomagnesemia in the general population and its correlation with 
diseases such as cardiovascular diseases, diabetes and hypertension. 
Impaired basolateral sorting of pro-EGF results in renal Mg2+ wasting
Pro-EGF is a type I membrane protein, which in kidney is abundantly expressed at 
the apical and at a low level at the basolateral membrane of DCT cells (43, 44). 
Pro-EGF is cleaved by an unidentified protease to release the mature active 53 
amino acid EGF in the luminal and basolateral compartments. A possible candidate 
for the EGF sheddase is ADAM17, which is a transmembrane protein and belongs 
to the superfamily of zinc proteases. ADAM17 can cleave peptides of many EGF 
family members including TGF-α, amphiregulin, betacellulin, epiregulin, and 
HB-EGF (45, 46). The function of apically expressed pro-EGF remains elusive since 
expression of the EGFR is restricted to the basolateral membrane. To date there is 
no evidence for a luminal effect of EGF, but it has been suggested that apically 
released EGF is involved in maintenance of epithelial surface integrity, because 
EGF constantly baths the epithelial surfaces of the urinary tract or that apically 
expressed pro-EGF might function as a receptor that is involved in ion transport (47, 
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of the EGFR signaling pathway, which stimulates TRPM6 activity, could provide new 
clues for therapies to overcome the side effect of hypomagnesemia during 
cetuximab treatment. Surprisingly, thus far hypomagnesemia has not been reported 
for cancer patients treated with erlotinib (alias tarceva) or gefitinib (alias iressa), 
which are specific EGFR tyrosine kinase inhibitors (65). The mechanism by which 
these drugs circumvent the side effect hypomagnesemia is elusive and more 
detailed research is needed to investigate whether patients treated with these drugs 
have no or mild hypomagnesemia. The EGFR belongs to the erythroblastoma viral 
gene product, v-erbB (ErbB) family of proteins, which comprises four receptors 
(ErbB1-4, also known as HER1-4). After ligand binding, the EGFR (or ErbB1) forms 
homodimers, as well as three functional heterodimers (66). Possibly, cetuximab 
completely prevents homo- and heterodimerization completely abolishing EGFR 
activity, whereas erlotinib and gefitinib only prevent EGFR tyrosine kinase activity 
but not dimerization. Thus, in the presence of erlotinib and gefitinib the EGFR in 
kidney could still be phosphorylated by for instance its dimerization partner ErbB2 
and subsequently recruit its unique set of signaling proteins, which stimulate 
TRPM6 activity thereby preventing hypomagnesemia. Because erlotinib and 
gefitinib are effectively used to treat cancer without the development of the side 
effect of hypomagnesemia, these drugs probably target mainly EGFR homodimers 
(66). Although ErbB2 is present in kidney, its basolateral localization in DCT and of 
the other ErbB members needs to be determined (67). 
Molecular mechanism of TRPM6 activation by EGFR signaling
Studying the signaling pathways of the EGFR, which stimulate TRPM6 activity, the 
Src family of tyrosine kinases and the Rho GTPase Rac1 pathways have been 
identified as possible routes of TRPM6 activation (chapter 6). It was demonstrated 
that the EGF-mediated stimulation of TRPM6 occurs via signaling through Src 
kinases and Rac1, which increased the cell surface abundance of TRPM6. 
However, it is unknown whether TRPM6 activity is directly gated by Src. Moreover, 
the effect of both pathways simultaneously stimulating TRPM6 activity can not be 
excluded. Patch clamp analysis demonstrated that the stimulatory effect of EGF is 
specific for TRPM6 because EGF did not increase the activity of its closest 
homologue TRPM7. This supports the role of EGF in specifically maintaining total 
body Mg2+ homeostasis rather than the cellular Mg2+ balance. However, the 
effect of EGF on heterotetramers of TRPM6 and TRPM7 needs further investigation 
97%, and the patients display a tubular transport maximum for phosphate of ~1.2 
mmol/min/100 ml GFR, which is in the normal range (42). 
The relationship between EGF and 17ß-E2
EGF and 17ß-E2 have been described in this thesis to stimulate TRPM6 activity and 
TRPM6 mRNA abundance, respectively. Interestingly, a coupling between estrogen 
and pro-EGF expression has been described (57-59). Mice treated for four weeks 
with 17ß-E2 showed a 2-fold increase in pro-EGF mRNA expression in the uterus 
(60). It was speculated that estrogens stimulate processing of the pro-EGF 
precursor. Moreover, no EGF immunoreactivity was observed in the uterus of OVX 
mice compared to OVX mice supplemented with 17ß-E2 (58). The administration of 
17ß-E2 to OVX mice was also shown to increase the level of uterine EGFR 
expression, increasing the number of EGF-binding sites (61). Furthermore, evidence 
was provided that exogenous EGF can mimic estrogen function in the stimulation of 
female genital-tract growth and differentiation and that EGF can interact with the 
estrogen receptor (57, 59). Taken together, these results suggest that estrogen is 
positively involved in the upregulation of EGF and EGFR in uterus and that EGF can 
mimic the effect of estrogen. However, the effect of 17ß-E2 positively stimulating the 
expression of EGF and the EGFR reported for the uterus needs to be established 
for the kidney. Moreover, the relationship between EGF and 17ß-E2 regarding Mg2+ 
homeostasis needs to be determined. Interestingly, it was demonstrated that the 
excretion of EGF by women taking oral contraceptives was significantly greater than 
in females who did not use contraceptives (62). The effect of gender differences 
with respect to levels of EGF and 17ß-E2 in relation to regulation of the Mg2+ 
balance require additional research. Nevertheless, the relationship between EGF 
and estrogen is striking and should receive further attention with respect to their 
coupled interaction regarding TRPM6 regulation and Mg2+ homeostasis. 
EGFR inhibition and hypomagnesemia
In chapter 5 we demonstrated that, in accordance with other studies, several 
colorectal cancer patients treated with cetuximab, which is an antagonist of the 
human EGFR, develop hypomagnesemia due to renal Mg2+ wasting (63, 64). These 
results emphasize the significance of EGF in maintenance of a proper Mg2+ 
balance. Importantly, cetuximab abolished EGF-stimulated TRPM6 activity 
underlining the involvement of the EGFR in hypomagnesemia. Detailed elucidation 
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demonstrated in schizophrenia (74-76). Interestingly, decreased levels of EGF were 
observed in serum, prefrontal cortex and striatum of schizophrenic patients (77). 
However, decrease of serum EGF levels in schizophrenia patients was not confirmed 
by another group (78). Two groups reported that the EGF nucleotide polymorphism, 
A61G, is associated with schizophrenia (79, 80), but this association was not 
confirmed by two other studies (81, 82). Recently, it was demonstrated that this 
polymorphism is not associated with the risk of schizophrenia but with with the age 
of onset of the disease in male patients (82). In addition, a relationship between 
EGF and schizophrenia was found by studies performing genome-wide linkage 
analysis, which were used to map the complex genetic disorder schizophrenia in 
order to pinpoint susceptibility genes. Multiple linkage regions have been identified 
in schizophrenia and interestingly, linkage with a region on chromosome 4, which 
harbours the EGF gene and a single polymorphic marker pinpointing EGF have 
been reported (83, 84). Taken together, these data suggest that EGF might be a 
susceptibility gene for schizophrenia. Sequencing of this gene in families with 
schizophrenia, which show linkage to a region on chromosome 4 harbouring the 
EGF gene, should substantiate our hypothesis. 
Missing links in active transcellular Mg2+ transport
The research presented in this thesis contributed to the understanding of molecular 
mechanisms that regulate active Mg2+ (re)absorption. However, a comprehensive 
model of active transepithelial Mg2+ transport is still lacking because the identity of 
proteins coordinating essential steps in transepithelial Mg2+ transport including 
cytosolic Mg2+ diffusion and basolateral extrusion are still unknown (figure 3). 
An interesting candidate for cytosolic Mg2+ transport is parvalbumin, a member of 
the family of cytoplasmic Ca2+-binding proteins, which has been suggested to 
function in renal Mg2+ handling and is specifically expressed in DCT (85). However, 
parvalbumin is not expressed in the entire DCT but only in the first segment DCT1, 
whereas TRPM6 is expressed in DCT1 and DCT2 (15). Possibly, parvalbumin 
mediates cytosolic transport for Mg2+, comparable to the function of calbindin-D28k, 
which transports cytosolic Ca2+ (21). Moreover, parvalbumin knockout mice display 
a disturbed contraction-relaxation cycle of fast twitch muscles, which supports a 
role of parvalbumin in renal Mg2+ handling (86). However, parvalbumin knockout 
mice did not show a disturbance of the Mg2+ balance (87). At present no candidate 
gene has been identified for the basolateral extrusion mechanism for Mg2+. 
since TRPM6, TRPM7 and TRPM6/7 channels display different properties (8). 
Moreover, it is not clear how stimulation of the EGFR by EGF can result in specific 
stimulation of TRPM6 channel activity. Possibly, small differences between TRPM6 
and TRPM7 allow specialized auxiliary proteins, which might be activated after 
stimulation of the EGFR, to specifically bind and regulate TRPM6 activity. To date, 
no regulatory proteins have been described that modify the biophysical, 
pharmacological, and expression properties of TRPM6 by direct interactions as 
has been described for the epithelial Ca2+ channels TRPV5 and TRPV6 (68). As 
described above, Src kinase is a downstream signaling molecule of the EGFR. 
Furthermore, this kinase is a non-receptor protein tyrosine kinase, which is known 
to be directly activated after a steroid stimulation, and is rapidly activated by 
co-stimulation of 17ß-E2 and EGF (69, 70). Subsequently, activated Src kinase 
phosphorylates a wide variety of substrate proteins, which finally induce gene 
transcription (71, 72). In contrast, androgens are able to activate Src without the 
EGF stimulation (73). It is tempting to speculate that estrogens, androgens and 
EGF cooperate together in a concerted action to tightly regulate active Mg2+ 
reabsorption by controlling EGFR signaling pathways and thereby regulate the 
activity and transcription/translation of TRPM6.
EGF and schizophrenia
The identification of a mutation in the EGF gene raised the question whether this 
mutation has an effect on mental development since the two previously described 
IRH patients are mentally retarded. Moreover, in our family with IRH, one unaffected, 
EGF P1070L-carrier sister suffers from schizophrenia and two brothers and one 
sister of the carrier mother are known with cluster A (diagnostic and statistical 
manual of mental disorders, fourth edition, text revision) personality disorders. 
Schizophrenia or cluster A personality disorders has not been diagnosed for the two 
affected sisters. EGF functions as a neurotrophic, survival and maintenance factor 
for selective neurons in the central nervous system (CNS). EGF is present in the 
developing nervous system and, based on the various studies reporting that EGF 
has neurotrophic and neuromodulatory effects on developing dopaminergic 
neurons both in vitro and in vivo,  it is suggested that dopaminergic dysfunction 
might play a role in the etiopathology of schizophrenia [77-86]. Moreover, EGF is 
expressed in brainstem, cerebral cortex, hippocampus, basal hypothalamus, 
striatum and thalamus which are all brain regions where changes have been 
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Our understanding of molecular mechanisms regulating the Mg2+ balance primarily 
arose from the elucidation of the genetic basis of rare monogenic Mg2+ human 
disorders (chapter 1 and 5). The identification of additional genes, by studying 
disorders with unexplained forms of hereditary Mg2+ disturbance, could reveal the 
missing links in the molecular mechanism of transcellular Mg2+ transport. Other 
approaches that were applied to identify mammalian Mg2+ transporters include 
homology searches with prokaryotic Mg2+ transport proteins and genomics to 
identify genes that are upregulated by low extracellular Mg2+ concentrations in cell 
lines or in mouse kidney. This resulted in the identification of hsaMrs2p, NIPA1 (alias 
SPG6), MagT1, SLC41A1, SLC41A2, and ACDP2 (89-94). Although it has been 
demonstrated that these newly identified proteins transport Mg2+, their physiologic 
function remains to be determined. However, the ubiquitously expression pattern of 
these proteins does not support a specialized role in epithelial Mg2+ transport in 
kidney and intestine. Irrespective of the approach used, the identification of new 
genes involved in body Mg2+ homeostasis will increase our knowledge about Mg2+ 
homeostasis and might explain other Mg2+ wasting disorders. In addition, increased 
insight into Mg2+ homeostasis could provide clues to make therapeutic intervention 
possible in the treatment of hypomagnesemia. 
Conclusions
The overall aim of the research presented in this thesis was to elucidate the 
molecular mechanisms of active Mg2+ (re)absorption, and therefore the maintenance 
of the Mg2+ balance in health and disease. This thesis described the identification 
of factors regulating TRPM6 and the discovery of EGF as an autocrine/paracrine 
hormone essential for maintenance of the body Mg2+ balance by regulating renal 
Mg2+ handling. Herewith, a major step is taken towards elucidation of the 
mechanisms which regulate Mg2+ homeostasis. Future studies directed to disclose 
the molecular mechanisms and (hormonal) factors that regulate transepithelial 
Mg2+ transport will certainly contribute to a better understanding of Mg2+ 
homeostasis. Increased knowledge of molecular and cellular aspects of Mg2+ 
homeostasis may lead to a better treatment of patients with Mg2+ deficiencies that 
is directed towards correcting the underlying functional defect(s). This will be of 
great benefit to patients because of the adverse symptoms resulting from 
Cell lines cultured on special media, e.g. with Mg2+ concentrations up to 100 mM 
can be used to identify responsive genes via a proteomics approach (88). 
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Figure 3. Schematic representation of active trancellular Mg2+ transport in DCT
 
(A) Active and transcellular Mg2+ transport is carried out as a three-step process. Driven by the 
transmembrane voltage, Mg2+ leaves the pro-urine compartment and enters the cell through the 
epithelial Mg2+ channel TRPM6. Subsequently, Mg2+ diffuses, possibly bound to Mg2+ -binding 
proteins (?), to the basolateral plasma membrane. At the basolateral plasma  membrane, Mg2+ is 
extruded into the interstitium by a hypothetical Na+/Mg2+-exchanger protein and/or a plasma 
membrane Mg2+-ATPase (?) against both electrical and concentration gradients. Importantly, 
Mg2+ entry into the cells appears to be the rate-limiting step. TRPM6 is positively regulated by i) 
17ß-estradiol (17ß-E2), which binds the estrogen receptor (ER); ii) low Mg2+ levels in pro-urine 
and/or blood and iii) EGF, which binds the EGF receptor (EGFR). The functioning of the Na+,Cl- 
cotransporter (NCC), the Ca2+ sensing receptor (CaSR), the g-subunit of the Na+,K+-ATPase and 
the renal Cl--channel CLC-Kb are also important for active Mg2+ reabsorption.  
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Introductie
Magnesium (Mg2+) is een belangrijk tweewaardig positief geladen ion dat een 
cruciale rol speelt in een breed scala van verschillende biologische processen. 
Ondanks het feit dat Mg2+ het op een na meest voorkomende intracellulaire kation 
is en een noodzakelijke rol vervult in het functioneren van meer dan driehonderd 
enzymen, zijn de moleculaire mechanismen die de Mg2+ balans reguleren nog niet 
volledig opgehelderd. In het behoud van de Mg2+ balans spelen de nieren een 
essentiële rol. De Mg2+ concentratie in het bloed wordt nauwkeurig gereguleerd 
doordat de uitscheiding van Mg2+ in de urine wordt aangepast aan de opname van 
Mg2+ in het spijsverteringsstelsel. Het grootste deel van het door de nieren 
gefiltreerde Mg2+ wordt geresorbeerd in de proximale tubulus en het dikke 
opstijgende been van de lis van Henle door middel van passief paracellulair 
transport. Het nauwkeurig aanpassen van de Mg2+ excretie vindt plaats in het 
distaal convoluut, een deel van de distale tubulus, waar Mg2+ wordt geresorbeerd 
via een actief transcellulair transportproces. De eerste stap van het transcellulaire 
transport is de aanvoer van Mg2+ vanuit de gevormde voorurine door het apicale 
plasmamembraan van de epitheelcel. Vervolgens bereikt het Mg2+ door middel van 
diffusie de basolaterale plasmamembraan, waar het actief wordt getransporteerd 
naar het bloed. Genetisch onderzoek naar aandoeningen met erfelijk verlaagde 
bloed Mg2+ concentraties is belangrijk in het verkrijgen van meer inzicht in de 
moleculaire en cellulaire mechanismen die ten grondslag liggen aan het Mg2+ 
transport. De kennis over actief Mg2+ transport is sterk toegenomen door de 
ontdekking van het epitheliale Mg2+ kanaal TRPM6, na bestudering van patiënten 
met hypomagnesiëmie met secundaire hypocalcemie (HSH) en de ontdekking van 
een met TRPM6 overeenstemmend Mg2+ kanaal, genaamd TRPM7. TRPM6 vormt 
de poortwachter van transcellulair Mg2+ transport in nier en darm en is essentieel 
voor het behoud van de Mg2+ balans in het lichaam. Het TRPM7 eiwit is in de 
meeste weefsels aanwezig en speelt een belangrijke rol in het constant houden van 
de cellulaire Mg2+ concentratie. Omdat TRPM6 de toegangspoort vormt voor Mg2+ 
in nierepitheelcellen, is het een ideaal doelwit voor de hormonale regulatie van het 
proces van actieve Mg2+ resorptie. Ondanks dat TRPM6 is geïdentificeerd als het 
apicale instroommechanisme van Mg2+, zijn de identiteit van de eiwitten en 
(hormonale) factoren die de vervolgstappen van het transcellulaire Mg2+ transport 
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door de nieren, terwijl een Mg2+ verrijkt dieet leidde tot een verhoogde uitscheiding 
van Mg2+ en Ca2+ in de urine. Onthouding van Mg2+ in het dieet zorgde voor een 
toename van het TRPM6 expressieniveau in de nier en een Mg2+ verrijkt dieet 
resulteerde in een toegenomen expressie van TRPM6 in colonweefsel. 
De expressieniveaus van TRPM7 in nier en colon bleven onveranderd na inname 
van de verschillende Mg2+ diëten. Bovendien werd in ratten aangetoond dat het 
steroïdhormoon 17ß-oestradiol het renale TRPM6 expressieniveau verhoogt. 
Daarentegen hadden de calciotrope hormonen 1,25-dihydroxyvitamine D3 en het 
parathormoon geen invloed op het expressieniveau van TRPM6 in de nier. 
TRPM6 downregulatie en hypermagnesuria in TRPV5 knock-outmuizen
Uit voorgaande studies met TRPV5 knock-outmuizen is gebleken dat deze muizen 
een sterk verhoogde hoeveelheid Ca2+ uitscheiden via de urine. Ten gevolge van 
deze verhoogde Ca2+ uitscheiding is bij deze muizen het vitamine D gehalte 
verhoogd waardoor extra Ca2+ wordt geabsorbeerd in de darm om dit verlies aan 
te vullen. Een uitvoerige analyse van de Mg2+ balans in TRPV5 knock-outmuizen 
heeft aan het licht gebracht dat deze dieren ook een verhoogde hoeveelheid Mg2+ 
uitscheiden via de urine in combinatie met een verlaagde expressie van TRPM6 in 
de nier (hoofdstuk 4). Nadat TRPV5 knock-outmuizen op een Mg2+ arm dieet waren 
geplaatst werd een verhoogde expressie van TRPM6 in de nier en een sterk 
verminderde uitscheiding van Mg2+ en Ca2+ ionen in de urine waargenomen. 
Daarentegen resulteerde een Mg2+ verrijkt dieet in een verhoogde expressie 
van TRPM6 in colon en een toename van de excretie van Mg2+ and Ca2+ ionen 
in de urine. Bij 25-hydroxyvitamine D3-1α-hydroxylase (1α-OHase) knock-outmuizen 
en TRPV5/1α-OHase dubbel knock-outmuizen, waarbij de vorming van 
1,25-dihydroxyvitamine D3 is uitgeschakeld, werd een verlaagde excretie van Mg2+ 
in de urine geconstateerd. Hieruit werd geconcludeerd dat de verhoogde excretie 
van Mg2+ in de urine en de verlaagde expressie van TRPM6 in de nier van TRPV5 
knock-outmuizen niet direct wordt veroorzaakt doordat het eiwit TRPV5 ontbreekt 
bij deze muizen. 
Epidermale Groeifactor (EGF) is essentieel voor de Mg2+ homeostase
De ontdekking van een mutatie (C3209T) in het gen dat codeert voor epidermale 
groeifactor (EGF), in een familie met geïsoleerd recessief renaal Mg2+ verlies, heeft 
geleid tot de vondst dat het auto-en paracriene hormoon EGF een essentiële rol 
reguleren en coördineren, zoals  intracellulaire Mg2+ diffusie en basolaterale 
uitscheiding, nog onbekend. Daarom was het doel van het onderzoek beschreven 
in dit proefschrift het vergroten van de kennis over de handhaving van de Mg2+ 
balans door de nier op het moleculaire-, cellulaire- en lichaamsniveau. Deze 
samenvatting geeft een bondig overzicht van dit onderzoek dat een significante 
bijdrage heeft geleverd aan het begrip van de regulatie van TRPM6 en daarmee aan 
het proces van actieve transcellulaire Mg2+ resorptie. 
Structuur en functionele analyse van de porie-eigenschappen van TRPM6 
Tussen het vijfde en zesde transmembraandomein van TRPM6 ligt de porie 
waardoor Mg2+ vanuit het lumen de cel in getransporteerd kan worden. Door de 
aminozuursequentie van deze porie te vergelijken met die van de overige leden van 
dezelfde TRPM subfamilie, is een potentieel selectiviteitsfilter voor Mg2+ 
geïdentificeerd zoals beschreven in hoofdstuk 2, bestaande uit de aminozuren 
1028GEIDVC1033. De twee negatief geladen aminozuren E1024 en D1031, die 
geconserveerd zijn in de meeste leden van de TRPM subfamilie, zijn belangrijke 
determinanten voor kationpermeatie van TRPM6 omdat neutralisatie van beide 
aminozuren in een alanine residu resulteerde in niet-functionele ionkanalen. 
Neutralisatie van het geconserveerde aminozuur E1029 vormde kanalen met een 
verhoogde geleiding voor barium- en zink-ionen, een verminderde rutheniumrood 
gevoeligheid en een grotere poriediameter in vergelijking tot het ongemuteerde 
wild-type TRPM6. Bij vervanging van het aminozuur I1030 door methionine ontstonden 
kanalen met een verminderde permeabiliteit voor nikkel-ionen, een afgenomen 
gevoeligheid voor rutheniumrood blokkade en een kleinere poriediameter. Uit de 
hierboven beschreven resultaten werd geconcludeerd dat de aminozuren E1024, 
I1030 en D1031 belangrijk zijn voor het functioneren van TRPM6 en dat subtiele 
aminozuurvariaties in de porie resulteren in veranderingen van de permeatie-
eigenschappen van het kanaal. 
TRPM6 expressie wordt gereguleerd door Mg2+ in het dieet en oestrogenen
In hoofdstuk 3 werd aangetoond dat TRPM6 met name tot expressie komt in nier-, 
long-, caecum- en colonweefsel, terwijl TRPM7 in de meeste weefsels voorkomt. 
Deze analyse bewees bovendien dat de actieve Mg2+ resorptie plaatsvindt in het 
distale deel van de muizendarm. Bovendien toonden Mg2+ dieetstudies aan dat 
Mg2+ deprivatie leidt tot hypomagnesiëmie en conservering van Mg2+ en Ca2+ 
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homeostase kan leiden tot een betere behandeling van patiënten met Mg2+ 
deficiënties die erop gericht is de onderliggende functionele defect(en) te verhelpen. 
Aangezien hypomagnesiëmie gepaard gaat met ernstige symptomen zoals tetanus, 
spierzwakte en hartritmestoornissen, zal een verbeterde behandeling deze patiënten 
ten goede komen. Bovendien kan deze kennis helpen om tot nu toe onopgehelderde 
aandoeningen met Mg2+ verlies en de associatie van hypo magnesiëmie met 
algemeen voorkomende chronische aandoeningen zoals hart- en vaatziekten en 
diabetes te verklaren en daarvoor nieuwe therapieën te ontwikkelen.
vervult in de Mg2+ homeostase (hoofdstuk 5). De bovengenoemde mutatie 
resulteert in de aminozuur substitutie P1070L en in een verstoorde lokalisatie van 
het pro-EGF eiwit waardoor deze niet in de basolaterale plasmamembraan 
terechtkomt. Hierdoor kan de basolateraal gelokaliseerde epidermale 
groeifactorreceptor (EGFR) niet worden gestimuleerd, hetgeen uiteindelijk leidt tot 
een verminderde activiteit van het epitheliale Mg2+ kanaal TRPM6. De verminderde 
activiteit van TRPM6 zorgt voor een afname van Mg2+ resorptie en heeft zodoende 
Mg2+ verlies via de urine tot gevolg. Het belang van EGF in het constant houden 
van de Mg2+ balans wordt onderstreept door het feit dat patiënten met 
colorectaalkanker die behandeld werden met het medicijn cetuximab, een antagonist 
van de EGFR, een verlaagde bloed Mg2+ concentratie ontwikkelden. 
Stimulatie van TRPM6 activiteit door EGFR activatie
Stimulatie van de EGFR door EGF resulteerde in een toegenomen activiteit van 
TRPM6 via de stimulatie van zowel de Src familie van tyrosinekinases als het kleine 
Rho GTPase, Rac1 (hoofdstuk 6). Hierbij zorgde de activatie van de laatst genoemde 
effector voor een toegenomen mobiliteit van TRPM6 in de cel. Bovendien werd 
aangetoond dat een dominant negatieve vorm van Rac1 (T17N) niet alleen de 
basale activiteit van TRPM6 reduceerde, maar ook het stimulerende effect van EGF 
op de TRPM6 activiteit blokkeerde. Daarentegen bleek dat de constitutieve actieve 
vorm van Rac1 (G12V), de TRPM6 activiteit juist stimuleerde. De toegenomen 
activiteit van TRPM6 na stimulatie van de EGFR met EGF bleek het resultaat te zijn 
van een toegenomen expressie van TRPM6 op de plasmamembraan. Deze 
verhoogde activatie van TRPM6 door EGF is specifiek omdat EGF niet de activiteit 
van het homologe Mg2+ kanaal TRPM7 stimuleerde. Bovendien werd aangetoond 
dat het carboxy-uiteinde van TRPM6, waarin zich een α-kinase domein bevindt, 
geen rol speelt in de stimulatie van TRPM6 door EGF. 
Conclusies en toekomstperspectieven 
Dit proefschrift beschrijft het onderzoek waarin werd getracht de moleculaire 
mechanismen en (hormonale) factoren die transepitheliaal Mg2+ transport reguleren 
op te helderen. Tijdens deze studie zijn verschillende factoren ontdekt die TRPM6 
reguleren. Hierbij werd ontdekt  dat EGF een essentiële functie vervult in de Mg2+ 
homeostase. Hiermee is verdere vooruitgang geboekt in de opheldering van de 
mechanismen die de Mg2+ balans reguleren. De toenemende kennis van de Mg2+ 
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GS Gitelman syndrome
HCO3- bicarbonate
HEK293 cells human embryonic kidney cells
HHC1 hypocalciuric hypercalcemia familial type 1
HHHM hypomagnesemia, hypertension and hypercholesterolemia, mitochondrial
HHN hypomagnesemia, hypercalciuria, and nephrocalcinosis
HPRT hypoxanthine-guanine phosphoribosyl transfers 
aBS antenatal Bartter syndrome
HSH hypomagnesemia with secondary hypocalcemia
IC50 concentration required to induce 50% of the maximum effect
IDH isolated dominant hypomagnesemia
IDHH isolated dominant hypomagnesemia associated with hypocalciuria
IOD integrated optical density
IRH isolated recessive renal hypomagnesemia
K+ potassium ion
KCNJ1 gene encoding the renal outer medullary K+ channel
kDa kilo dalton
M mitochondrially inherited
MagNuM Mg2+ nucleotide-regulated metal ion current
MDCK cells madin darby canine kidney cells
Mg2+ magnesium ion
Mg2+·ATP Mg2+ bound to ATP
MIC Mg2+-inhibited cation current
M-MLV-RT moloney-murine leukaemia virus-reverse transcriptase
mRNA messenger ribonucleic acid
mTAL medullary thick ascending limb of Henle’s loop
MTTI gene encoding the mitochondrially encoded tRNA isoleucine
Na+ sodium ion
NaCl sodium chloride
NCC Na+,Cl- cotransporter
NKCC2 Na+, K+, Cl- cotransporter 2 
NSHPT neonatal severe hyperparathyroidism
OMIM online mendelian inheritance in man
PAGE  polyacrylamide gelelectrophoresis
PBS phosphate-buffered saline
List of abbreviations
1,25(OH)2D3 1,25-dihydroxy-vitamin-D3 / calcitriol
1a-OHase 25-hydroxyvitamin-D3-1α-hydroxylase
45Ca2+ radioactive calcium isotope
ANOVA analysis of variance
ADH autosomal dominant hypoparathyroidism 
ATP adenosine 5’-triphosphate
ATPase adenosine 5’-triphosphatase
bp base pairs
BS Bartter syndrome
BSND gene encoding Barttin, the b subunit of CLC-Ka and CLC-Kb 
Ca2+ calcium ion
CaSR Ca2+, Mg2+-sensing receptor
cBS classic Bartter syndrome
CCD cortical collecting duct
CD collecting duct
cDNA copy DNA
Cl- chloride ion
CLC-Kb Cl- channel Kb
CLCNKB gene encoding the Cl- channel Kb
CLDN16 gene encoding claudin-16 (= paracellin-1)
CLDN19 gene encoding claudin-19
CNT connecting tubule
cM centi-Morgan
cRNA copy RNA
DCT distal convoluted tubule
DMEM dulbecco’s modified eagle medium
DMSO dimethylsulphoxide
EGF gene encoding pro-EGF
EGF epidermal growth factor
EGFR epidermal growth factor receptor
ELISA enzyme-linked immunosorbent assay
ERBB erythroblastoma viral gene product, v-erbB
FHH familial hypocalciuric hypercalcemia
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PCLN-1 gene encoding claudin-16 or paracellin-1
PCR polymerase chain reaction
PCT proximal convoluted tubule
PLP periodate-lysine-paraformaldehyde
PMSF phenylmethylsulphonylfluoride
PST proximal straight tubule
PVDF polyvinylidine difluoride
PT proximal tubule
PTH parathyroid hormone
ROMK renal outer medullary K+ channel
RT-PCR reverse-transcriptase polymerase chain reaction
SDS sodium dodecyl sulphate
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEM standard error of the mean
SLC12A1 solute carrier family 12 (Cl- cotransporter family), member 1, encodes NKCC2
SLC12A3 solute carrier family 12 (Cl- cotransporter family), member 3, encodes NCC
TAL thick ascending limb of Henle’s loop
TM transmembrane segment
TRP transient receptor potential channel
TRPA transient receptor potential channel subfamily ankyrin
TRPC transient receptor potential channel subfamily canonical
TRPM transient receptor potential channel subfamily melastatin
TRPM6 transient receptor potential channel subfamily M, member 6
TRPM7 transient receptor potential channel subfamily M, member 7
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TRPV transient receptor potential channel subfamily vanilloid
TRPV5 transient receptor potential channel subfamily V, member 5
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UTR untranslated region
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in het geloof in het kandidaat-gen dat ik presenteerde. Zonder jouw steun lag dit gen 
misschien nog steeds op de plank te wachten om geïdentificeerd te worden.
Prof. dr. Sabine Tejpar van de afdeling Interne Geneeskunde van de Katholieke 
Universiteit Leuven wil ik bedanken voor haar essentiële bijdrage aan het onderzoek 
naar de rol van EGF beschreven in dit proefschrift. 
Natuurlijk wil ik ook de patiënten bedanken voor hun waardevolle medewerking aan 
het onderzoek waardoor het inzicht in de regulatie van de magnesiumbalans weer 
groter is geworden.
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Sabine en Anjo, het vertrouwen dat jullie mij hebben gegeven tijdens mijn stage die 
ik onder jullie supervisie bij Schering-Plough heb gelopen hebben er in grote mate 
toe bijgedragen dat ik wilde gaan promoveren. Anjo, ik ben blij dat je de afdeling 
Fysiologie nog hebt teruggebeld ;). Met veel plezier denk ik nog altijd terug aan mijn 
periode bij jullie en de kansen die jullie hebben geboden. Bedankt daarvoor!
Degenen die een cruciale rol hebben gespeeld in het ontstaan van mijn eerste artikel 
zijn de mensen van het Centraal DierenLaboratorium. Met name Henk, Gerrie en 
Jeroen, ontzettend  bedankt voor julie goede zorgen voor de dieren, behulpzaamheid 
en jullie vakbekwaamheid tijdens het uitvoeren van de experimenten. Maar bovenal 
was het gewoon altijd erg gezelllig, bedankt!
Qing, when I arrived at the department of Physiology you were the first ‘resident’ of 
unit 4 I met. Together with Kirsten we developed a strong friendship and we had 
many interesting talks and discussions. Remembering your jokes and singing still 
makes me laugh. I really treasure the time with you in U4!
Kirsten, wat een geluk dat ik jou als collega mocht verwelkomen in unit 4. Vanaf het 
eerste uur was je mijn labmaatje en ik heb veel aan je steun, humor en luisterend 
oor gehad gedurende de 4 onderzoeksjaren. Nu zie ik je niet meer als collega maar 
als goede vriendin. Ik vind het fantastisch dat ik je paranimf mag zijn!
Mijn paranimfen, Helma en Rob. Helma, jou leerde ik kennen tijdens mijn stage bij 
Moleculaire Dierfysiologie en sindsdien zijn we vrienden en hebben we al veel 
mogen lachen. Was ik al vereerd dat ik jouw paranimf mocht zijn, nu valt mij een 
nog grotere eer ten deel nu jij mijn paranimf wilt zijn. Rob, vanaf de tijd dat wij 
samen hebben gewerkt aan het EGF-project waaraan je een belangrijke bijdrage 
hebt geleverd, zijn we goede vrienden geworden. Het was een mooie en spannende 
tijd en het enthousiasme vloog er aan alle kanten af, bedankt daarvoor! Gelukkig 
vinden we genoeg ontspanning met knallen in de sportschool en met onze beste 
vriend master chief.
Dirk, Farida, Martijn en Michel, jullie ken ik nu al enige jaren en samen hebben we 
in Nijmegen mooie dingen meegemaakt. Bedankt voor alle ontspanning tussen het 
harde werken door! Ik hoop dat we nog lang zulke goede vrienden zullen blijven!
I would like to thank all my colleagues of the department of Physiology. Altogether 
you created a unique atmosphere that was both professional and very social. 
I enjoyed the coffee breaks and working with all you guys! In het bijzonder wil ik nog 
een aantal mensen bedanken die nauw bij mijn onderzoek betrokken zijn geweest.
Annemiete, bedankt voor het overdragen van je kennis en ervaring op het gebied 
van de immunohistochemie en dierexperimenten. 
Dennis, wat hebben wij hard gewerkt aan het EGF-project, jouw inzet hierbij was 
enorm. Menig weekend hebben we besteed aan het invriezen van stabiele cellijnen 
en hoe vaak moest je niet op het einde van de dag nog experimenten afmaken. 
Je enthousiasme, kritische blik en werkhouding zijn voor mij zeer waardevol 
geweest. Het heeft mijn werk in ieder geval een stuk makkelijker gemaakt. Je mag 
me altijd als referent opgeven ;). 
De patch-clampers, Stéphanie, thanks for your thoughts regarding the research and 
your fast and accurate patching. Catalin, thanks for your collaboration in the study 
to elucidate the molecular determinants of permeation through TRPM6. Jenny, 
bedankt voor je last minute patchwerk voor de rebuttal waardoor alles toch nog is 
goed gekomen. 
Angelien, bedankt voor het meedenken en het uitvoeren van de whole genome 
linkage analyse. 
Gang, it was nice to share a unit with you and to work both on TRPM6 and I always 
enjoyed your speeches in public! Henrik (alias E.G.), I remember the time I gave you 
the ‘L’ but unfortunately for me times have changed. But you know how it works, 
when you’re pushed.... Bob, je bent mijn magnesium maat en ik kan niet wachten 
om weer samen met jou de alpen en de aprês-ski kroegen te bedwingen. Weet dat 
als je weer eens wordt gebeld door een onbekend nummer ik het echt niet altijd ben 
hoor. Mcsponzio, je bent een man zonder overhemden maar je hield het toch altijd 
weer het langste vol in het vrijdagnachtcafé. Mijn hotel heeft voor jou altijd een 
kamer vrij en een ‘extra’ sleutel is ook geregeld! Todd, I enjoyed all the discussions 
we had and admire your hard work combined with a good sense of humour. 
Thanks for making the working environment more fun!
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Tot slot mijn familie, Mam, Rogier & Maaike en Erlijn. Zonder de hechte band die we 
samen hebben waarin iedereen de steun en vrijheid krijgt om zichzelf te ontwikkelen 
zou het promoveren zeker niet gelukt zijn. Bedankt daarvoor!
Lieve Anne, mooi dat je er bent!
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